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Zusammenfassung 
 
Aviäre Influenza A Viren (AIV), wie alle Influenza Viren, und das Virus der Bornaschen 
Krankheit (BDV) sind Negativstrang RNA-Viren, die ihr Genom im Kern der infizierten Zelle 
replizieren und transkribieren. Influenza A Viren infizieren Säuger und Vögel und AIV haben 
weltweit zu enormen Verlusten und Schäden in der Geflügelindustrie geführt. Außerdem 
stellen sie eine ständige Bedrohung der menschlichen Gesundheit dar. So wurde 1997 das 
aviäre Influenza A Virus vom Subtyp H5N1 direkt von Vögeln auf den Menschen übertragen 
und führte zum Tod von 6 von 18 infizierten Menschen in HongKong. BDV kann eine 
Vielzahl von Warmblütern infizieren und führt zu einer persistenten Infektion des zentralen 
Nervensystems des infizierten Tieres, welche eine neuropathologische Erkrankung auslösen 
kann.  
Reverse Genetik-Systeme haben sich als nützliche Werkzeuge für die Analyse des viralen 
Replikationzyklus, der regulatorischen Funktion viraler Proteine und molekularer 
Pathogenitätsmechanismen erwiesen. Wissenschaftler haben sehr viel an reversen Genetik-
Systemen für humane Influenza Viren gearbeitet, aber kaum für AIV. BDV ist immer noch 
eine mysteriöses Virus, zu dem es noch viele ungeklärte Fragen gibt. In dieser Studie habe ich 
versucht ein reverses Genetik-System für das aviäre Influenza Virus 
A/Goose/Guangdong/1/96 (H5N1) und BDV zu etablieren.  
In dem ersten Teil meiner Arbeit wurden zur Erstellung eines reversen Genetik-System acht 
Pol I-Plasmide konstruiert, welche die kompletten cDNAs der acht Genomsegmente von 
A/Goose/Guangdong/1/96 (H5N1) enthalten. Da bei Arbeiten mit Influneza Viren vom 
Subtyp H5N1 die biologische Sicherheit berücksichtigt werden muß habe ich versucht 
Reassortante Viren zu generieren, welche als genetischen Hintergrund jeweils sieben 
Gensegmente des aviären Influenza Virus A/FPV/Rostock/34 (H7N1) (FPV, Laborstamm) 
und eins von A/Goose/Guangdong/1/96 (H5N1) enthalten. Hierdurch sollten meine neuen 
Plasmide funktionell getestet werden. Mindestens fünf Plasmide waren funktionsfähig, wie 
sich sowohl durch direkte (CAT-Analyse) als auch indirekte Untersuchungen (Erzeugung 
eines Reassortanten Virus) zeigen ließ.  
Das Reassortante Virus GD1NSFPV, welches das NS-Segment von 
A/Goose/Guangdong/1/96 (H5N1) und die übrigen Segmente von FPV enthält, unterscheidet 
sich in seinen Vermehrungseigenschaften signifikant von dem Wild Typ FPV. Zur 
Untersuchung worin dieser Unterschied begründet liegt, habe ich die virale Induktion der 
Raf/MEK/ERK-Signalkaskade durch beide Viren analysiert, da diese zelluläre Kaskade für 
die Bildung infektiöser Viren wichtig ist. Da das NS1-Protein ein wichtiger 
Pathogenizitätsfaktor der viralen Replikation ist habe ich auch das NS1-Protein beider Viren 
näher untersucht. Die Ergebnisse zeigten keine großen Unterschiede in der Aktivierung der 
Raf/MEK/ERK-Kaskade, was darauf hindeutet, daß hierin kein wichtiger Grund für die 
unterschiedlichen Wachstumseigenschaften der beiden Viren liegen kann. Mit der Hilfe von 
zwei Proteindomänen übt das NS1-Protein seine proviralen Funktionen aus. Teilweise durch 
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Bindung freier RNA (dsRNA/mRNA), wodurch die Aktivierung zellulärer 
Verteidigungsmechanismen verhindert wird und die Translationseffizienz zellulärer mRNA 
zum Vorteil der Virusvermehrung reduziert wird. Die Aminosäuresequenz des NS1-Proteins 
von GD1NSFPV unterschiedet sich von der des FPV-NS1 speziell in der RNA-Bindungs- und 
in der Effekor-Domäne. Darüber hinaus resultieren dieses Unterschiede in einer Änderung der 
Hydrophilizität beider Proteine. Außerdem zeigte es sich, daß das reassortante GD1NSFPV 
Virus deutlich effizienter die zelluläre Interferonexpression unterdrückt, welche ein wichtiger 
initialer Schritt in der Etablierung der zellulären Immunität darstellt. Trotzdem muß der 
eigentliche Grund für die unterschiedlichen Vermehrungseigenschaften noch genauer 
bestimmt werden. Die Studien zur Pathogenität der Reassortante GD1NSFPV werden 
zukünftig durch Tierexperimente in China untersucht.  
Im zweiten Teil meiner Arbeit habe ich, auf Grundlage neuer Daten (die Existenz eines „A“-
Nukleotids am äußerten 3´-Ende der genomischen Einzelstrang-RNA von BDV und einem 
„U“-Nukleotid am 5 -´Ende), neue Pol I-Expressionskonstrukte erstellt, die ein Reportergen 
(CAT) expremieren. Die Pol I-Transkripte beginnen mit einer „Hammerhead“ 
Ribozymsequenz (HHR), die mit einem „A“ startet, da die RNA-Polymerase I normalerweise 
nicht „U“ als erstes Nukleotid einbaut. Ich konnte zeigen, daß die HHR-Versionen die 
Transkripte in cis schneiden und so neue 5´-Enden generieren, die mit dem genomischen „U“ 
als erstes Nukleotid beginnen, und das die korrekten 3´-Enden der Transkripte durch ein 
Hepatitis Delta Virus-Ribozym (HDV) erzeugt werden, welches ebenfalls in cis schneidet. 
Darüber hinaus konnte ich zeigen, daß die korrekten Enden auch in vivo durch die beiden 
Ribozyme erzeugt werden, und das die BDV-Polymerase das antigenomische Mini-Transkript 
in einem BDV-abhängigen System repliziert und transkribiert. Weiterhin zeigen RPA-
Ergebnisse, daß das putative Polyadenylierungssignal in der 3´-Nichtkodierenden-Region 
(NCR) wirklich von der viralen Polymerase genutzt wird. Zusätzlich konnte ich zeigen, daß 
das von dem Pol I-Expressionkonstrukt erzeugte Mini-Genom in einem plasmidbasierten 
reversen Genetik-System funktionell ist und dabei publizierte Daten bestätigen die zeigen, 
daß dieser Prozeß von einem empfindlichen Verhältnis zwischen BDV-Proteinen N und P 
abhängt.  
Da AIV vom H5N1-Subtyp von großer Bedeutung für die Geflügelwirtschaft sind wird meine 
Arbeit helfen einen Grundlage für zukünftige Arbeiten über die Pathogenese dieser Viren zu 
legen und könnte zu neuen Antigenen für die Vakzinierung führen. Speziell die Analyse der 
Unterschiede in der Pathogenität zwischen der Reassortante GD1NSFPV und dem Wild Typ 
FPV werden helfen die besondere Rolle von NS1 für den viralen Replikationszyklus zu 
beleuchten. 
Obwohl zwei reverse Genetik-Systeme während des Abschlusses meiner Arbeiten publiziert 
worden unterscheiden sich meine Mini-Genome in der spezifischen Nukleotidsequenz der cis-
aktiven NCRs. Da diese von besonderer Bedeutung für die Replikation und Transkription des 
BDV-Genoms sind, war es wichtig zu zeigen, daß die vorhergesagten NCRs funktionell sind. 
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Meine Arbeit könnte somit die Basis für verbesserte reverse Genetik-Systeme für beide Viren 
(AIV und BDV) sein und helfen den Charakter dieser Viren besser zu verstehen.  
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Summary 
 
Both, avian influenza virus (AIV) and the Borna disease virus (BDV), are negative-strand 
RNA viruses, that replicate and transcribe their genomes in the nucleus of infected cells. 
Influenza A viruses can infect mammals and all species of birds and AIV have caused 
enormous losses and heavy shocks to avian industries worldwide. These viruses are also 
potential threats to human health. Specifically, the avian H5N1 influenza virus was directly 
transmitted from birds to humans and led to the death of 6 of 18 infected people in Hongkong 
in 1997. BDV can infect a variety of warm-blooded animals and cause a persistent infection 
in the central nervous system of infected animals, which can lead to neuropathological 
disease.  
Reverse genetic systems have proved that they are a very useful tools to analyze the viral life 
cycle, the regulatory function of viral proteins and molecular mechanisms of viral 
pathogenicity. Scientists have done a lot of research on reverse genetic systems for human 
influenza virus, but less on AIV. BDV is still a mysterious virus, about which there are many 
open questions that are not answered. In this study I tried to establish a reverse genetic system 
for the avian influenza virus A/Goose/Guangdong/1/96 (H5N1) and for BDV, respectively. 
In the first part of my work, eight Pol I plasmids including the complete cDNAs of the eight 
segments of the A/Goose/Guangdong/1/96 (H5N1) have been constructed to establish a 
reverse genetic system for the A/Goose/Guangdong/1/96 (H5N1). As the biological safety has 
to be considered, I tried to rescue reassortant viruses using the genes of the strain 
A/FPV/Rostock/34 (H7N1) (FPV) as a genetic background with only one gene of 
A/Goose/Guangdong/1/96 (H5N1) in order to test that every plasmid with a complete cDNA 
of the strain A/Goose/Guangdong/1/96 (H5N1) virus is functional. At least five plasmids were 
proved to be functional either by a direct (CAT-assay) or indirect (generation of a reassortant 
virus) method.  
The rescued reassortant GD1NSFPV virus, that carries the A/Goose/Guangdong/1/96 (H5N1) 
NS gene and the other 7 genes of FPV, differs in its growth characteristics significantly from 
the wild type virus FPV. In order to analyze why the reassortant GD1NSFPV is different from 
the wild type FPV, I investigated the induction of the Raf/MEK/ERK cascade with both 
viruses, as this cascade is important for the formation of infectious virus. Also I compared the 
NS1 protein of both viruses, as it is a major viral factor for the pathogenicity and replication 
efficiency of influenza A viruses. The results showed that there are no big differences in the 
activation Raf/MEK/ERK cascade between both viruses, which therefore can not be an 
important reason for the different growth characteristics of both viruses. With the help of two 
protein domains, the NS1 protein exerts its proviral functions in part by binding free RNA 
(dsRNA/mRNA) thereby preventing the activation of cellular defense mechanisms and 
reducing the translation efficiency of cellular mRNAs for the benefit of viral replication. The 
amino acids sequence of the NS1 protein of GD1NSFPV differs from that of FPV, specially 
in the RNA binding domain and in the effector domain. Moreover the differences in the RNA 
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binding domain and the effector domain of both NS1 proteins result in a difference of 
hydrophilicity of both proteins. Furthermore the reassortant GDNS1FPV virus more 
effectively prevented the cellular interferon expression, which is an important initial step to 
establish cellular/innate immunity. Nevertheless the key element that leads to the different 
growth characteristics of both viruses remains to be determined. The studies about the 
pathogenicity of the reassortant GD1NSFPV virus will be performed by animal experiments 
in future work in China. 
In the second part, according to new data for the BDV genomic 5'- and 3'-ends (the existence 
of an additional "A" residue at the extreme 3'-end of the single-strand genomic RNA of BDV 
and a "U" residue probably to be found at the 5'-end), I have generated Pol I expression 
constructs expressing a reporter transcript (CAT gene). They start with a hammerhead 
ribozyme sequence beginning with an "A" residue, because the RNA polymerase I normally 
does not incorporate an "U" as the first residue. I could show that the hammerhead ribozyme 
cleaves the transcript in vitro in cis to generate a new 5’-end that starts with the genomic "U" 
residue, and that the correct 3’-end of the transcript is generated by a hepatitis delta virus 
(HDV) ribozyme that also cleaves the transcript in cis. Moreover I was able to show that the 
correct 3'- and 5'-ends of the mini-genome were also generated by the two ribozymes in vivo, 
and that the BDV polymerase can use the antigenomic mini-transcript for replication and 
transcription in a BDV-dependent system. Furthermore the RPA results indicate that the 
putative polyadenylation signal in the 3’-non coding region (NCR) is indeed used by the viral 
polymerase. I also showed that the mini- transcript generated by the Pol I expression construct 
is functional in a plasmid-based reverse genetic system, and I could confirm published results 
demonstrating that this process depends on the delicate ratio of the viral N and P proteins. 
As AIVs of the H5N1 type are of major important for poultry production, my work will help 
to provide the basis for future work on the pathogenicity of these viruses and could lead to 
designed immunogens for vaccination. Specially an analysis of the differences in the 
pathogenicity between the reassortant GDNS1FPV and the wild type FPV will help to 
elucidate the specific role of the viral NS1 protein for the viral replication cycle. 
Even though two reverse genetic systems for BDV have been published during the completion 
of my work on an according system, my mini-genome differs in the specific nucleotide 
sequence of the cis-active NCRs. As these are important for BDV-genome replication and 
transcription, it was important to show that the predicted NCR-sequences are functional. My 
work could therefore be a basis for improved reverse genetic systems for both viruses and 
might help us to understand the character of these viruses.  
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1  
Introduction 
 
1. Avian influenza and influenza A virus 
1.1 Avian influenza 
Avian influenza (AI) is an infectious disease caused by type A influenza virus. This disease 
can affect all species of birds and the symptoms of this disease can vary from a mild disease 
with little or no mortality to a highly fatal epidemic depending on the virus strains and host 
species. The highly pathogenic avian influenza (HPAI) has been classified as a " list A " 
disease by the O.I.E (Office International des Epizooties, the World Organization for Animal 
Health). 
 
1.1.1 History  
Avian influenza was firstly described in 1878 by Perroncito et al. as a serious disease of 
chicken in Italy, at that time this disease was called "fowl plague". The causative agent of this 
disease was isolated from a chicken in 1902, marking the first documented isolation of 
influenza virus (92). The first human influenza virus was isolated in 1933 (204). It was 
determined in 1955 that fowl plague virus is actually an influenza A virus (2). Only type A 
influenza viruses are known to cause natural infections of birds and this type also is the most 
common type leading to serious epidemics in humans, type B and C do not affect domestic 
animals. Influenza A viruses are divided into different subtypes based on the antigenic nature 
of their hemagglutinin (HA) and neuraminidase (NA) glycoprotein (116). Up to now 15 
subtypes of HA (H1-H15) and 9 subtypes of NA (N1-N9) have been identified. But it is 
possible that all 15 HA and 9 NA subtypes of influenza A viruses can combine new viruses to 
infect avian species naturally.  
 
1.1.2 Current situation 
Since the first AI was reported in Italy in 1878, up to now many occurrences of AI were 
described in different areas of the USA (1983 - 1984, 1986, 1995), Mexico (1994-1995), 
England (1963, 1979, 1991), Germany (1979,1995 - 1996, 1998), Australia (1992, 1995, 
1997), Ireland (1983 - 1984, 1997), Italy (1994, 1999), Iran (1998), China (1994), South 
Africa (1995), Pakistan (1994-1995, 1999), Hongkong (1997, 1999) (2). AI has caused 
enormous losses and heavy shocks to avian industries worldwide, and it still threats and 
destroys seriously the avian industries of the world. A low pathogenic avian influenza (LPAI) 
H7N2 has caused the infection of more than 4.7 million chickens and turkeys and about 4 
million were destroyed in Virginia poultry farms in 2002 (148). An epidemic of HPAI H7N7 
happened in the Netherlands, Belgium and Germany in 2003, it caused that more than 20 
million chickens, expected to cost hundreds of millions of dollars, had to be slaughtered (1, 
57). At the same time it also infected more than 80 people and one veterinarian died (57, 229). 
Introduction  
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Therefore, AI is a constant threat to the poultry industry, and avian influenza viruses  are also 
potential threats to human health. 
Aquatic birds are believed to be the natural host and reservoir of influenza A virus, they play 
a key role in spreading virus and leading to the infection of other birds and other species. 
Avian influenza viruses in wild aquatic birds are spread to susceptible birds through 
inhalation of viral particles in nasal and respiratory secretions and from contact with the feces 
of infected birds. Influenza A viruses infecting poultry can be divided into two groups on the 
basis of their pathogenicity: highly pathogenic avian influenza (HPAI) and low pathogenic 
avian influenza (LPAI). The highly virulent viruses cause mortality in poultry as high as 
100%. To date, all highly pathogenic isolates have been influenza A viruses of subtypes H5 
and H7, although not all viruses of these subtypes can cause HPAI. Until the end of 20 
century, 17 outbreaks of HPAI were reported in different countries and areas (2). Other AI 
viruses cause LPAI, the clinical signs are much less evident or absent and mortality is much 
lower. Sometimes environmental conditions or secondary infections may cause exacerbation 
of LPAI infection and result in more serious disease.  
The HA glycoprotein on the surface of influenza A virus is synthesized as a precursor 
polypeptide (HA0) (30), which plays a central role in the pathogenicity of AIVs (207). In 
order to activate membrane fusion function and virus infectivity, the precursor HA0 must be 
cleaved into the disulfide linked subunits HA1 and HA2 (107, 120), so HA0 cleavage is 
regarded as a major determinant of pathogenicity. There are special molecular differences in 
the HA glycoprotein between HPAI and LPAI viruses. HA proteins of LPAI virus have a 
single arginine at the cleavage site (17). These viruses are limited to HA cleavage by extra 
cellular proteases and the viral replication is restricted in the host. HPAI viruses possess 
multiple basic amino acids at their HA cleavage sites and appear to be cleavable by an 
ubiquitous protease (17). These viruses are able to replicate in most tissues throughout the 
bird and cause death (181).  
During the epidemic of avian influenza in the past time, the outbreaks of H5 and H7 HPAI 
have caused enormous losses to poultry industries worldwide. In 1983-1984 a epidemic of 
H5N2 HPAI occurred in Pennsylvania in United States (29) and resulted in the destruction of 
more than 17 million birds. It took more than 2 years to eradicate the disease by quarantine 
and slaughter, at a direct cost of more than $60 million and an indirect cost to the industry of 
more than $250 million. In 1994 another outbreak of H5N2 HPAI occurred in Mexico (94, 
215), 18 million birds had to be slaughtered and it was eradicated from chickens by 
quarantine and use of inactivated vaccine, at the cost of more than $100 million. Avian 
influenza viruses (AIV) affect not only the poultry industries, but also are potential threats to 
the human health. Up to now three different subtypes of AIV have been detected in humans. 
In 1996, in England a H7N7 virus of avian origin was isolated from the eye of a woman with 
conjunctivitis who kept ducks (6). The most serious cases occurred in 1997 in Hongkong, 18 
people were infected by a H5N1 virus of avian origin and 6 of them died (203). H9N2 viruses 
of avian origin were isolated from humans in China in 1999 (75, 78). Subsequently two 
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independent isolates of H9N2 virus of avian origin were obtained from two people who 
recovered from flu- like-illness in Hongkong (156). In February 2003, the same subtype 
H5N1, as in 1997 in Hongkong, was isolated from two members of one family in Hongkong. 
One of them died and other members of the same family were affected. Recently HPAI H7N7 
broke out in Netherlands on March 2003 and spread to Belgium and Germany. It has caused 
the death of one veterinarian and 82 farmworkers and slaughtermen were affected by this 
avian flu virus (57, 229). Affected people have shown symptoms ranging from conjunctivitis 
to mild flu (57). It should be noticed that this virus can spread from human to human in a 
limited fashion, because the wife and child of one infected man were also infected, who had 
no direct contact with poultry (57).  
Normally pigs play very important role as "mixing vessel" for the transmission of influenza 
virus between birds and humans (27). Since they are susceptible to infection with both avian 
and human influenza A virus, and are often involved in interspecies transmission, facilitated 
by regular close contact with human and birds. AIV HAs have receptor specificity for 2, 3-
galactose sialic acid and human influenza virus for 2, 6-galactose sialic acid that are 
predominantly found in the according host, whereas pigs have both 2, 3- and 2, 6-galactose 
sialic acid linkages in the cell lining of the trachea. This can lead to modification of the 
receptor binding specifcities by mutation of avian influenza viruses from 2, 3 to 2, 6 linkage 
(98, 99) , that is the native linkage in humans (39). This provides a potential link from birds to 
human. But the avian influenza viruses can also overcome the species barrier and be 
transmitted to humans from birds directly without any intermediate (pig), for example H5N1 
in Hongkong, H9N2 in China and H7N7 in Netherlands as mentioned above. Last not least 
reassortant viruses can form, that are able to replicate in humans but carry avian influenza HA 
proteins. This can lead to pandemic outbreaks.  
 
1.1.3 Clinical symptoms 
The main symptoms of HPAI in poultry are depression, loss of appetite, cessation of egg 
laying, nervous signs, swelling and blue discoloration of combs due to disturbance of blood 
circulation, ruffled feathers, severe respiratory signs and diarrhea. Sudden death can occur 
without any previous signs. Death occurs as early as 24 hours after the first signs of disease, 
and frequently with 48 hours, or can be delayed for as long as a week. The mortality rate can 
reach up to 100% depending on the species, age, the virus type involved and environmental 
factors. The clinical symptoms of LPAI consist of mild respiratory disease, depression and 
drop in egg production in laying birds.  
 
1.2 Influenza A virus  
1.2.1 Morphology and genome structure of influenza A virus 
The virions of  influenza A virus can exhibit a variety of shapes and sizes, ranging from 
spherical particles with a diameter about 100 nm to elongated filamentous forms of the virus. 
The virion is made up of a lipid envelope derived from the plasma memberane of host cells 
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(69) and nine viral structure proteins (Table 1 and Figure 1). The HA and NA glycoproteins 
are attached to the lipid envelope by short sequence of hydrophobic amino acids. The HA is 
responsible for binding of the virus to cell surface receptors (sialic acid) and for membrane 
fusion during virus entry into hosts cells. The function of the NA is to cleave sialic acid from 
the virus and host cells at the end of virus life cycle in order to allow mature virions to be 
released. Within the lipid envelope lies the integral membrane matrix protein M2, which is an 
ion channel that modulates the pH of intracellular compartments (35, 214). The viral matrix 
protein M1 is thought to play an important role in the process of assembly and budding. 
Perhaps M1 interacts with ribonucleoproteins (RNPs) (96, 139), the exact mechanism is still 
not known. The NS2 protein was originally designated as nonstructural protein. NS2 acts as 
nuclear transport factor (127, 149) and has been proved to be a minor component of virions 
(130, 133, 172). NS1 is an another nonstructural protein, which is a regulator of both mRNA 
splicing and translation and also modulates the interferon responses to viral infection (186, 
236, 256). M1 and NS1 mRNAs are collinear transcripts, M2 and NS2 are coded by spliced 
transcript of their genome segments. An alternative reading frame of PB1 encodes PB1-F2 
protein, which is transported into mitochondrion and can induce apoptosis. This protein is not 
essential in infected cells and not strongly conserved for some animal influenza viruses (31). 
The role of this protein in viral propagation is not known.  
 
Table 1. Influenza A virus proteins and functions (stem A/PR/8/34, H1N1) 
(modified from S. Ludwig et al., 1999) 
 
Segment vRNA(nt) Protein AA Functions 
1 2341 PB2 759 subunit of  RDRP; "Cap-snatching" 
2 2341 PB1 
PB1-F2 
757 
87 
catalytic subunit of  RDRP 
not known  
3 2233 PA 716 subunit of  RDRP 
4 1778 HA 566 surface-glycoprotein;  
receptor binding; membrane fusion 
5 1565 NP 498 nucleoprotein; encapsidation of v/cRNA 
6 1413 NA 454 surface-glycoprotein; neuraminidase;  
receptor disruption, virus releasing 
7 1027 M1 
M2 
252 
97 
matrix protein; 
ion channel activity;  
protecting HA-conformation 
8 890 NS1 
 
 
NEP/NS2 
230 
 
 
121 
post-transcription regulator; inhibition of (i) 
pre-mRMA splicing, (ii) polyadenylation 
(iii) PKR-activation 
nuclear export factor 
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Avian influenza virus (AIV) is a type A influenza virus belonging to the family 
Orthomyxoviridae. The family Orthomyxoviridae also includes influenza type B and C 
viruses. The type A, B, C is based upon the antigenic character of the viral M protein and the 
nucleoprotein (NP). Influenza A virus is a negative-sense RNA virus with a segment genome. 
The genome length is approximately 13.6 kb and the genome contains 8 segments encoding 
11 proteins. In contrast to positive strand RNA viruses, the naked RNAs are not infectious. 
Only viral RNAs molecules encapsidated by the NP and the three subunits of the viral 
polymerase (PB1, PB2, PA) form RNPs, which are able to initiate viral replication and 
transcription (116). 
A striking feature of influenza viruses is that the surface proteins are constantly changed due 
to mutations of the according genes. This is a result of the high mutation frequency of the 
RNA-dependent RNA-polymerases (RDRP). As the RDRP posses no proofreading function, 
the mutation frequency for influenza A virus genes for any single nucleotide appears to be 
about 10-3 -10-4 per replication compared to10-8 -10-11 for eukaryotic genes.  
 
1.2.2 Propagation and genome replication of influenza A virus  
The propagation cycle of the influenza A virus takes about eight hours. At the beginning the 
glycoprotein HA of influenza virions binds the cell surface receptor containing 2, 3- or 2, 6-
galactose sialic acid linkages (adsorption), then endocytosis occurs (Figure 2). The release of 
the viral genome (uncoating) takes place in acid environment of the endocytotic vesicle. 
Firstly, low pH triggers conformational changes in the HA, which leads to exposure of 
lipophilic "fusion domain" of the HA2 that triggers fusion of the viral envelope and the 
vesicle membrane (penetration). Further the ion channel protein M2 is actived by the low pH 
to permit the flow of ions from the endosome to the virion interior, which leads to the 
reduction of the pH in the virions resulting in the dissocation of M1 from the RNPs 
(uncoating). All four proteins that are in the RNP (NP, PB1, PB2 and PA) contain nuclear 
localization signal (NLS) and the RNPs are actively transported into the cell nucleus through 
the nuclear pore complex (NPC) (Figure 2). In the late phase of propagation cycle newly 
formed RNPs are transported from the cell nucleus to the cytoplasm through the NPC (116). 
M1 and NEP/NS2 play an important role in exporting the RNPs and preventing the RNPs to 
be reimported into the nucleus (115, 116, 130).  
After the RNPs are transported into the nucleus of the infected cell, the viral genome is 
transcribed and replicated by the RDRP. The RDRP of influenza A virus consists of three 
subunits: PB1, PB2 and PA. The NP encapsidates cRNAs and vRNAs, which is necessary for 
them to be recognized as templates for the viral polymerase. The vRNA with the four proteins 
together form the biologically active RNPs (116). Influenza v/cRNAs have short noncoding 
regions (NCRs) at their 5'-terminus (13 nt) and 3'-terminus (12 nt), which are highly 
conserved (116). It is known that the influenza vRNA promoter structure consists of the 5' - 
and 3'-terminal sequences of the RNA. The NCR sequences are partly complementary, thus 
base pairing can happen and short double stranded RNA (dsRNA) can be formed. The unique 
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conformation ("corkscrew" model) appears to be the core element in vRNA recognition by  
the viral polymerase (58). The cRNAs are synthesized on the basis of vRNAs as templates, 
then cRNAs act as templates for the synthesis of new vRNAs. Since the RDRP can not 
synthesize Cap structures (m7GpppNm), the PB2 subunit splices 5' Cap structure from the 
cellular mRNAs (Cap snatching), which serve as primers for the initiation of viral mRNA 
synthesis. (164, 165). Polyadenylation of the mRNAs occurs at a site 15 to 22 nucleotides 
before the 5´ end of the vRNA segment. Termination occurs apparently as a result of 
stuttering or reiterative copying of the stretch of U residues, thereby adding a poly(A) tail to 
the 3´ ends of the viral mRNAs (166, 178, 255).  
NS1 is a multifunctional protein, which regulates the mRNA splicing and translation and 
plays a key role in the pathogenesis of influenza A virus (115, 130, 236). For example, 
functional cellular mRNAs are present in the cytoplasma, the synthesis of cellular proteins is 
practically switched off approximately after three hours of viral infection. At the same time 
viral proteins are efficiently translated. Although the details of "host cell shut off" are not 
completely understood, it is sure that the NS1 plays a special role. It inhibits splicing and 
polyadenlation of the cellular pre-mRNAs and keeps the cellular mRNAs in the nucleus (61, 
128, 142). At the same time it binds to double stranded RNA (dsRNA) (80) and prevents the 
activation of the NF-kB pathway (236). It also blocks the dsRNA-dependent protein kinase 
PKR (15, 81, 129). PKR is activated by dsRNA, the activated PKR phosphorylates the a-
subunit of the eukaryotic translation initiation fator elF2, resulting in the inhibition of viral 
mRNA translation, and assists in the production of the autocrine and paracrine acting IFN that 
initiates innate immunity and establishes an antiviral state (5, 64, 65). Thereby fighting the 
innate immune response of the cell, which is the first line of defense against pathogens. 
NA, M2 and the HA precursor (HA0) are transported via the rER to the cell membrane in a 
signal recognition particle (SRP)-dependent manner (97). Posttranslational processing will 
take place upon the export, for example, the proteolytic cleavage of HA0 into two subunits 
HA1 and HA2, which are linked by a single disulphide bond. This cleavage is necessary for 
the virus to be infectious. Due to the newly generated N-terminus of HA2, the fusion peptide is 
available to trigger the fusion of viral membrane and cellular membrane (116). Normally 
different cellular proteases are able to cleave the HA0, but it depends on the amino acid (AA) 
sequence at the HA0 cleavage site. The highly pathogenic H5 and H7 subtypes can be cleaved 
by ubiquitous proteases due to possessing the multiple basic AAs at HA0 cleavage sites. 
These viruses are able to replicate throughout the avian organism and damage vital organs and 
tissues which results in disease and death. The avian H5N1 virus, which in 1997 led to the 
death of 6 people of 18 infected humans, has the multiple basic AAs at HA0 cleavage sites 
(212). In contrast to the subtypes with a monobasic AA at the HA0 cleavage sites (H1, 2, 3, 4, 
6, 8, 9, 10, 11, 12, 13, 14, 15), these viruses are limited to cleavage by host proteases and 
restricted to replication in the host.  
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The mature glycoprotein HA and NA and the nonglycosylated M2 are transferred to the 
cellular membrane as a trimer (HA) and/or as tetramers (NA, M2). In the nucleus M1 and 
NEP bind to the RNPs and are exported into the cytoplasma through the NPC. For the further 
maturation (assembly) the M1 retains the RNPs in the cytoplasm. Finally new mature viral 
particles pinche off from the plasma membrane (budding), but the mechanism of budding is 
not well understood. The virions enwrap themselves with the cellular membrane by budding, 
at the same time they also carry membrane components, for example proteins which contain 
the receptor determinant. As the ripe virions carry cellular membrane receptors, they can 
agglutinate with themselves and aggregate to a cluster. The enzymatic activity of the 
neuraminidase is needed to release the virions from the cell surface, because NA cleaves sialic 
acid from virus and cell surface glycoconjugates (receptors) (115, 116).  
 
 
 
Figure 1: Schematic diagram of the influenza virion. Spherical Influenza A virus particle 
has a diameter of approximately 100 nm. The eight viral RNA segments were isolated in a 
urea polyacrylamide gel electrophoresis and detected by silver staining (left). The 
corresponding gene products and their accepted localization in the virion are right indicated. 
NS1 is not a component of mature virions (Adapted from S. Pleschka and S. Ludwig). 
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Figure 2: Propagation cycle of influenza virus. The virus binds to the cellular receptor 
determinant through the receptor-binding site in the HA molecules and enters the cell by 
receptor-mediated endocytosis. After the fusion between the viral membrane and the vesicle 
membrane the RNPs are released into the cytoplasma. The RNPs are then transported into the 
nucleus, where vRNA transcription and replication takes place. The viral mRNAs are 
transported into the cytoplasma and translated into viral proteins. The viral glycoproteins are 
transported to the cell surface through the exocytotic transport pathway. They are modified by 
various posttranslational processing. The replicative proteins move back into the nucleus and 
continue genome replication. In the late phase of the infection newly synthesized RNPs are 
exported from the nucleus and packed into the virions, which are finally released from the cell 
surface by budding (adapted form S. Pleschka). 
 
1.2.3 The relation between human flu epidemics and AIV 
Influenza  type A, B, C viruses all can infect human beings, but only influenza type A viruses 
have caused catastrophic pandemics. The pandemic in 1918 to 1919 was particularly severe, 
between 20 to 40 million people in the world were killed. In the USA about 0.5% of the 
population died, half the population perished in Alaska and the Pacific islands (102).  
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Influenza A viruses are renowned for their capacity to cause epidemics on a nearly annual 
basis due to the continuously evolving nature of the surface glycoproteins, referred to as 
antigenic drift. This is due to the high error rate of the RDRP that lacks a proofreading 
function. Antigen shift describes that in unpredictable intervals viruses with completely 
different surface antigens are introduced into new hosts, as a result of genetic reassortment 
that can occur in mixed infection with different strains (243). The consequence of this 
reassortment is the appearance of a new virus subtypes containing a novel HA or NA that is 
immunologically distinct from those of the previous circulating strain (s). There is no 
immunprotection in the population, and therefore these viruses can cause global pandemics. 
Phylogenetic evidence suggests that an influenza virus (H1N1) containing eight gene 
segments from avian influenza virus was transmitted to human and pigs before 1918 and 
replaced the 1900 strain (H3N8) (242). This virus was probably carried from North America 
to Europe by American troops and caused the catastrophic spanish pandemic.  
In 1957 an avian influenza virus from wild ducks provided three genes for the Asian influenza 
pandemic virus (H2N2) which kept five other genes from the circulating human strain (104). 
Similarly, the H3N2 virus that caused the "Hong Kong" pandemic of 1968 was a reassortant 
virus that derived its HA and PB1 genes from an avian influenza virus and the remaining gene 
segments from the circulating H2N2 virus (40, 104) (Figure 3).  
In 1997 the avian H5N1 influenza virus infected humans directly and resulted in the death of 
six people of 18 infected people (203). Recently HPAI H7N7 broke out in Netherland and led 
to death of one man from more than 80 infected people, even more alarming is the apparent 
human-to-human spread of the virus (57). All facts provided evidence for the role of avian 
influenza viruses in the emergence of human pathogenic strains (48).  
As mentioned before pigs are thought to provide the "mixing vessel" for AIV and human 
influenza virus where genetic reassortment may occur. Early on it was speculated that the 
transmission of virus from pigs to humans resulted in the 1918 pandemic (87, 226). Therefore 
it should be given more concern where waterfowl, swines and humans have close contact, for 
example, in south China, that emphasizes the need for persistent influenza surveillance.  
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Figure 3: Postulated evolution of the influenza A viruses currently circulating in 
humans.  Seroarcheology suggests that H2N2 and H3N8 influenza viruses circulated in 
humans in 1889 and 1900, respectively. Phylogenetic evidence suggests that an influenza 
virus possessing eight gene segments from avian influenza reservoirs was transmitted to 
humans and pigs before 1918 and replaced the 1900 strain. This virus was probably carried 
from North America to Europe by American troops and caused the catastrophic influenza 
pandemic of 1918. In 1957 the Asian pandemic virus acquired three genes (PB1, HA, and 
NA) from the avian influenza gene pool in wild ducks by genetic ressortment and kept five 
other genes from the circulating human strain. After the Asian strain appeared, the H1N1 
strains disappeared from humans. In 1968 the Hong Kong pandemic virus acquired two genes 
(PB1 and HA) from the duck reservoir by reassortment and kept six genes from the virus 
circulating in humans. After the appearance of the Hong Kong strain, the H2N2 Asian strains 
were no longer detectable in humans. In 1977 the Russian H1N1 influenza virus that had 
circulated in humans in 1950 reappeared and spread in children and young adults. This virus 
probably escaped from a laboratory and has continued to cocirculate with the H3N2 influenza 
viruses in human population (adapted from Field Virology, 2001). 
 
2. Borna disease  
Borna disease (BD) is an infectious and fatal progressive Polioencephalitis that is caused by 
Borna disease virus (BDV). 200 years ago BD was documented in central Europe and 
primarily affected horses and sheep (140, 182). This name of the disease originated from the 
town of Borna in Saxonia, Germany, where a serious epidemic occurred between 1894 and 
1896 (182). More sporadic occurrence of equine BD has been described in different areas of 
Germany, Switzerland (140), Liechtenstein (25) and in Austria (246). The mode of 
transmission is still unknown, but it is assumed to be through salival, nasal or conjunctival 
secretions (176). Rodents are suspected carriers of the virus, but the true host reservoir of 
BDV has not yet been identified (176, 206). BDV was firstly isolated in Giessen by Zwick et 
al. in 1927 (258).  
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2.1 Host range and clinical symptoms  
Horses and sheep have been regarded as the main natural hosts of BDV. Other warm-blooded 
animals are also but rarely naturally infected, for example other Equidae, cattle, goats, rabbits 
and zoo animals (83, 175, 182). Seroepidemiological surveys suggest that BDV can infect 
humans and is associated with mental disorders (73, 125). Some reports indicated that BDV 
was isolated from humans and proved that the RNA of BDV can be detected from human 
samples (16). The published sequences of human strains show high homology with the 
sequences of strains used in the according laboratory. It is considerable whether these are 
contaminations of the laboratory strains or natural infections (162, 176, 206). 
BDV causes a persistent infection in a variety of warm-blooded animals and different cell 
lines. The incubation period of natural BDV infection varies from 2 weeks to several months 
(174). Clinical symptoms in naturally and experimentally infected animals are not uniform, 
they depend on the host species and the virus strain. BDV infection in horses can result in 
acute or subacute symptoms with meningoencephalitis. Typical clinical signs of BD in horses 
involve simultaneous or consecutive changes in behavior, sensibility, mobility and in the 
function of autonomic nervous system (52). 
 
2.2 BDV 
BDV is an enveloped nonsegmented negative-strand RNA virus. BDV transcribes and 
replicates its genome in the nucleus of infected cells and uses the splicing machinery to 
regulate the expression of viral proteins (20, 41, 100, 194). According to its unique genetic 
and biologic features, BDV is the prototypic member of the family Bornaviridae, within the 
order Mononegavirales (50, 192). BDV is a highly neurotropic virus that persist in the central 
nervous system of infected animals (182). The virions of BDV are spherical with a diameter 
ranging from 70 to 130 nm (111). The length of the BDV genome is about 8900 nt, and can 
code for 10 possible proteins. At least six viral proteins can be found in the BDV-infected 
cell: the nucleoprotein (N), the phosphoprotein (P), a polypeptide of 10 kDa (p10/X), the 
matrix protein (M), the membrane glycoprotein (G) and the RNA-dependent RNA 
polymerase (L). Six open reading frames (ORFs) were identified in the BDV genome 
sequence (Figure 4). ORF I codes for N, ORF II for P, ORFx1 for P10/X, ORF III for M, 
ORF IV for G and ORF V for L. All these viral proteins have been detected with the help of 
specific antibodies (50, 192). RNA transcripts encoding BDV proteins are initiated at three 
transcriptional start sites (S1-S3) and terminated at four transcriptional termination sites (T1-
T4) (Figure 4). RNA from the first transcription unit (S1 -T1) codes for the nucleoprotein N. 
Because there are two AUGs for initiation of the translation in the same ORF, two isoforms of 
the BDV N protein (p38 and p40) are found in BDV-infected cells (167). p38 is shorter than 
p40 about 13 amino  acids (AA). A nuclear localization signal (NLS) for N protein has been 
characterized to the 13 N-terminal amino acid residues, with the motif 4KRR6 playing an 
essential role (109). Recently Perez et al. have proved that only p40 is strictly required for 
virus polymerase activity by a reverse genetic system (157).  
Introduction  
  
12  
RNA transcripts from the second transcriptional unit (S2 - T2) are bicistronic and code for the 
BDV protein p10/X (10 kDa) and the phosphoprotein P (24 kDa). The ORFx1 encoding the 
p10/X-protein overlaps N-terminal with ORF II, encoding P (Figure 4).  
The translation of p10/X takes place most likely through leaky ribosome scanning. Regarding 
the genome localization of the p10/X-gene, the p10/X-protein is comparable with the C-
proteins, which are found in representatives of the Mononegavirales replicating in the 
cytoplasm (e.g. Sendai, Measles, Vesicular Stomatitis virus (VSV)) (13, 70, 117, 118, 205). It 
could be demonstrated that the C-proteins of Sendai virus and VSV could have modulating 
effects on viral RNA synthesis in vitro and in vivo (23, 44, 91, 117, 220). p10/X colocalizes 
with N and P in the nucleus of the BDV-infected cells, that indicates an association of the 
p10/X-proteins with the viral RNP. Sequence analyses and functional investigations show that 
this protein contains a nuclear export signal in the N-terminal region (250), which could 
indicates a function as a genomic export factor. 
BDV-P is phosphorylated predominantly by protein kinase C (PKC) and to a lesser extent by 
casein kinase II (200, 224). Viral phosphoproteins that serve as typically transcription factors 
are modulated in their functional activities through phosphorylation.  
RNA transcripts originating from the third transcription start site (S3) can be terminated at the 
third termination site (T3) or the fourth (T4). Initiation of transcription at S3 predominantly 
results in the 2.8 kb RNA transcript. When transcription is terminated at T4, a 7.1 kb RNA is 
synthesized (Figure 4). In both cases, the RNA transcripts contain two introns (intron 1 and 2) 
(43, 194). These transcripts can code for M, G and L. 
ORF III codes for the matrix protein, which is argued for that it exists as a nonglycosylated 
(16 kDa) or as a glycosylated (18 kDa) protein (108, 113, 209). Kraus et al. did not find any 
proof that matrix protein is a glycosylated protein. There are no consensus amino acid 
sequences (N-X-S/T) for putative attachment of N glycosidic carbohydrates within matrix 
protein (21, 108). The supposed N-glycosylation sites are N74-I-Y and L-N88-S-L-S (108). 
When the supposed N-glycosylation sites were introduced N74-I-T76 and L-N88-S-T90-S, no 
carbohydrate attachment could be observed (113). This suggests that the matrix protein is a 
typical nonglycosylated protein associated at the inner surface of the viral membrane, as 
homologous proteins of other members of the order Mononegavirales (113). The matrix 
protein is thought to be a mediator between the nucleocapsid and the lipid-containing 
envelope, stabilizing the virus shape (114). Other groups suggests that matrix protein is a 
glycosylated protein that exists as a stable tetramer, with a relative molecular mass of 18 kDa 
(108, 209, 210). It  can be recognized by neutralizing antibodies, which arise in the chronic 
phase of the disease of the  experimentally infected rats (82, 208). It remains to be determined 
which form the matrix protein exists. 
All S3-transcripts, which contain the intron 2, can code for the G (ORF IV) (Figure 4). In 
order to achieve an efficient translation of the G, intron 1 between the splice donor site 1 
(SD1) and the splice acceptor site 1 (SA1) must be removed through splicing (193, 194). This 
only surface membrane glycoprotein of BDV is synthesized as a polypeptide with a molecular 
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mass of 57 kDa and N-glycosylated to a precursor glycoprotein of about 94 kDa (72, 175, 
193). The precursor glycoprotein (gp94) is processed by the cellular protease furin into the C-
terminal membrane-anchored subunit GP-C (gp43) and the identified N-terminal subunit GP-
N (gp51) in BDV-infected cells (105), that is highly glycosylated. GP-N seems to be 
responsible for receptor binding as shown by pseudotype method of vesicular stomatitis virus 
containing a BDV GP/VSV-G chimeric glycoprotein (158). GP is obviously involved in the 
surface fusion between viral and cellular membrane after proteolytic activation of GP, which 
results in release of the viral genome into the cytoplasma (71, 173). 
ORF V codes for an approximately 190 kDa protein (p190), the RDRP (L = RDRP), that can 
only be synthesized after splicing of intron 1 (SD1-SA1) and 2 (SD2-SA2) (192, 233). 
Translational initiation from the second AUG on the same ORF can generate a shorter form of 
the polymerase with approximately 180 kDa (p180) (192). Which form of the polymerase is 
actually active in infected cells, is at present not well-known. Within the coding region of the 
L-protein, a second alternative splice acceptor site (SA3) was recently described (42, 225). 
Alternative splicing of intron 2 gives rise to two new ORFs with coding capacities for a 8,9 
kDa and a 165 kDa protein. Whether these two proteins are really formed in BDV infected 
cells and whether they have essential functions for the viral reproduction remains to be 
determined. Additionally to this "new" ORFs, a smaller one was recently described, which 
codes for a P'-protein with approximately 16 kDa (110). As p38/p40 (N-ORF) and p180/p190 
(L-ORF), P' can be translated through a second start codon in the P-ORF. (Figure 4). Up to 
now it is also not known for P' whether it is necessary for the BDV reproduction. Another 
ORF (ORF VI) generated by splicing of intron 2 has been shown by Pleschka et al (192), but 
it remains to be investigated whether the ORF VI product is indeed synthesized during BDV 
infection.   
There is still a lot of work to be done on functional studies of BDV proteins. A complexation 
between P and N could be proven by immunoprecip itation experiments with specific serums 
against P or N in infected cells. Two-hybrid analyses confirmed interactions between P and N 
(95, 201). Here it could be further proved that P is able to bind specifically not only N, but 
also p10/X. In contrast, N and p10/X can not form complexes in the two-hybrid system (201). 
However, the interaction of N with p10/X could also be shown by cotransfection studies in 
eucaryotic cells (134). The colocalization of N, P and p10/X in the nucleus of infected cells 
(201, 245, 250) could refer to p10/X as a component of the functional replication complexes. 
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Figure 4: BDV genome organization 
Consensus transcription map of four different BDV genomes: Position of transcription start 
sites (S1-S3) and termination sites (T1-T4) are indicated. Transcription orientation is marked 
by arrows. Locations and nucleotide sequences flanking splice donor (SD1,SD2) and acceptor 
sites (SA1-SA3) are given. ORFs are individually marked on the various viral transcripts. 
Letters N, X, P, P´, M, G and L indicate translation products that have been identified in 
infected cells by immunohistochemical methods. The putative products of ORF6 remains to 
be visualized. Due to the absence of a functional SA3 site in strain No/98, this consensus 
transcription map does not include SD2-SA3 spliced viral mRNAs and their predicted 
translation products (adapted from S. Pleschka et al., 2001). 
 
It is accepted that per cell approximately 1-10 infectious virus particles are formed in 48 h, 
depending on the infected cell lines (26). Electron microscopy studies of negatively stained 
cell free infectious BDV particles have shown that the virions are spherical with the diameter 
approximately 100 nm (111, 257) and these virions will be set free after budding from the cell 
surface. In what extent the replication cycle of BDV is similar to influenza viruses, is not 
well-known. It is accepted that BDV is an enveloped, nuclear replicating, negative-strand 
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RNA virus with an fusion-active glycoprotein and that the virions are set free at the cell 
surface by budding (111, 257). But the life cycle of BDV and the regulation among the 
proteins are still waiting to be determined. 
There are many open questions about BDV that are not answered yet, so the establishment of 
reverse genetic system for BDV is urgent and important. Reverse genetic systems for other 
viruses have proved that they are a very useful tool to analyze the viral life cycle, the 
regulatory function of viral proteins and molecular mechanisms of viral pathogenicity. 
Nevertheless the knowledge of the genetics of BDV is very limited and the development of a 
reverse genetic system for BDV is very tedious. In my study, I tried to establish a helper virus 
dependent reverse genetic system for BDV. 
 
3. The progress of reverse genetic systems for negative-strand RNA 
viruses 
The negative-strand RNA viruses are a large group of viruses that comprises some important 
human pathogens, including influenza, measles, mumps, rabies, respiratory syncytial, Ebola 
and Hanta viruses. In contrast to the positive strand RNA viruses, the genomic RNA of 
negative-strand RNA viruses is not infectious, and infectious virus particles must deliver their 
own RDRP into the infected cell to start the first round of virus specific mRNA synthesis. 
This means that the translation of their RNAs is possible by cellular ribosomes only after 
transcription of the viral genome by the RDRP. For genetic manipulation of the viral RNA-
genome this has to be cloned as DNA from which it will then be expressed as RNA. This step 
from RNA to DNA to RNA explains the term "reverse genetics". The DNA derived RNA 
genome can only be replicated and transcribed by the viral RDRP. 
 
3.1 Influenza virus  
In 1989 the first system was developed for influenza viruses. In this approach the purified 
polymerase and nucleoprotein (NP) were mixed with in vitro synthesised vRNA to assemble 
the functional RNP complexes. The biologically active RNP was then transfected into the 
cells infected by influenza virus (132) (Figure 5). With the help of this reverse genetic system, 
it became possible to generate negative-strand RNA viruses containing the vRNA derived 
from cloned cDNAs. This means that these viruses can carry changed or additional genetic 
information (144). Site specifically mutated influenza viruses were firstly generated by Enami 
et al. (55). In this system, helper virus provides in trans the viral proteins required for 
amplification of the synthetic RNP complex. Different strategies can be used to select an 
reassortant virus containing a synthetic gene from helper viruses, for example antibody 
growth restriction (8, 56, 93, 183), temperature sensitivity (122, 251), host range restriction 
(55, 211), or drug resistance (28). Up to now selection systems have been established for six 
of the eight influenza A viral segments, these are PB2 (211), HA (56), NP (122), NA (55), M 
(28) and NS (56), and for the HA and NA segments of influenza B virus (8, 183). But the 
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application of this technology was limited and complex due to the demand for a strong 
selection system and technical expertise. 
The second impetus for reverse genetics of influenza virus was the establishment of RNA 
polymerase I system for the intracellular synthesis of influenza virus RNA (146). RNA 
polymerase I is a cellular enzyme in nucleus that transcribes ribosomal RNA which lacks both 
5’ cap and 3’ poly(A) tail. Transfection of cells with a plasmid containing cloned cDNA of 
influenza virus gene, flanked by RNA polymerase I promoter and terminator sequences, 
followed by influenza virus infection, resulted in the production of wild type and recombinant 
viruses carrying a reporter gene. Pleschka et al. successfully improved this system to generate 
clonal recombinant influenza virus in 1996 with synthetic NA (150) and HA. This system was 
also used to establish reverse genetics system for Thogoto viruses (six RNA segments, 
Orthomyxoviridae) (230, 241) which replicates in nucleus and other viruses, for example, 
Uukuniemi virus (3 RNA segments, Bunyaviridae) (59) which replicates in the cytoplasm. 
With both systems the RNP transfection method and RNA polymerase I system, transfectants 
must be selected from a vast background of helper virus, which requires a strong selection 
system and complicates the generation of growth defective viruses. Another drawback is that 
the efficiencies of virus generation are low. 
Based on the system of Pleschka et al., a completely plasmid-based system was developed in 
1999 by Neumann et al. and Fodor et al. (60, 145). This system is able to generate the 
influenza A virus entirely from cloned cDNA and can be used to introduce mutations into any 
gene segment. In this approach, the eight cDNAs were inserted between a human RNA 
polymerase I promoter and the mouse RNA polymerase I terminator or a hepatitis delta virus 
ribozyme respectively. Fodor et al. used the hepatitis delta virus ribozyme instead of the RNA 
polymerase I terminator in order to generate vRNA possessing the precise 3’ end sequence. 
The expression of the four RNP-complex proteins was driven by the human cytomegalovirus 
promoter or the HMG-promoter respectively. Transfection of twelve plasmids into 106 293T 
cells led to virus recovery of more than 1´  103 PFU of virus per ml of posttransfectional 
supernatant. The efficiency could be increased to 5 ´ 107 PFU after transfection of 17 
plasmids (Figure 6). This highly efficient system was attributed to the high transfection 
efficiency of 293T cells, which led to a pool of cells that receive the full complement of 
constructs required to initiate virus replication. 
An eight plasmid system, designated RNA polymerase I/II system, was developed by in 2000 
(89). A cDNA encoding a viral segment was cloned in the negative-sense orientation between 
RNA polymerase I promoter and terminator sequence, and this cassette was in turn cloned in 
the positive-sense oriention between RNA polymerase II promoter (CMV) and a 
polyadenylation sequence. Transcription by RNA polymerase I yields negative-sense vRNA, 
whereas transcription by RNA polymerase II results in positive-sense mRNA synthesis. Thus 
the vRNA and mRNA are generated from the same template, circumventing the need for 
protein expression constructs (Figure 7). They also established the unidirectional RNA 
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polymerase I-polymerase II transcription system for the generation of influenza A virus from 
eight plasmids (90). In this approach, cotransfection of eight RNA pol I-pol II tandem 
promoter plasmids containing the cDNA of A/WSN/33 (H1N1) resulted in the generation of 
infectious influenza A virus, albeit with a lower yield than the bidirectional system. These two 
reverse genetics systems reduce the number of plasmids required for the recovery of influenza 
A viruses and allow the generation of reassortant viruses. Because both protein expression 
and vRNA synthesis are achieved from the same template, this system does not allow 
generation of virus like particles lacking or containing lethal mutations in one or more viral 
segments. 
The RNA polymerase I system allows to introduce any desired mutation into the genome of 
influenza virus. This ability to manipulate the viral genome without technical limitation has 
profound implications on the study of the viral life cycle, functional regulation of viral 
proteins and molecular mechanisms of viral pathogenicity. Perhaps this system can also be 
used to create an live-attenuated influenza virus vaccine. 
 
3.2 Nonsegmented negative-strand RNA-viruses (NNS viruses)  
As the negative-strand RNA-viruses with segmented genome, the nonsegmented negative-
strand RNA-viruses (NNS viruses) in the order Mononegavirales package their own RDRP 
together with the nonsegmented genome in virions. This way replication/transcription is 
initiated in the infected cell. The naked genome is not infectious and not able to begin the 
reproduction cycle. Most NNS viruses have been generated from antigenomic, positive-sense 
cRNA (177). At the beginning of the establishment of reverse genetic systems for NNS 
viruses, a synthetic Sendai virus- like RNA, containing the positive-sense coding region of the 
chloramphenicol acetyltransferase (CAT) gene replacing the coding region of the Sendai virus 
genome, was transcribed from a cDNA in vitro. When introduced into cells infected with 
Sendai virus, this RNA construct was transcribed, replicated, and packaged into infectious 
virions (152). Here a virus- like RNA, which codes for CAT reporter gene, could be assembled 
by the viral RDRP transcomplementation. Schnell et al. (196) established an approach to 
generate rabies virus from cloned cDNA for the first time for negative-stranded RNA viruses. 
Plasmids encoding the viral nucleocapsid protein (N) and the polymerase protein (L and P) 
under the control of T7 polymerase promoters were transfected into cells previously infected 
with recombinant vaccinia virus expressing the T7 polymerase protein. In addition to these 
plasmids, a plasmid encoding a full- length antigenomic viral RNA under the control of a T7 
promoter and hepatitis delta ribozyme was also transfected into the cells. After transcription 
of RNAs from the T7 promoter and translation of the encoded proteins, nucleocapsid proteins 
assemble with the antigenomic RNAs and polymerase proteins, then replicate these RNPs to 
form RNPs containing genomic RNAs. After transcription of mRNA from the genomic RNP 
and translation, infectious virus is assembled (Figure 8).  
An effective DNA transfection system has also been developed for another Rhabdoviridae, 
vesicular stomatitis virus (VSV) (119, 247). Reverse genetic systems have also been 
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developed for paramyxoviruses. For example for measles virus, a cell line constitutively 
expressing T7 polymerase and the measles N and P proteins has been used for the rescue of 
infectious virus from full- length clones (171). Vaccinia virus based systems have allowed the 
rescue of respiratory syncytial viruses (RSV) (37) and of Sendai viruses (68, 103).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. RNP transfection. For generating recombinant influenza virus, RNPs are 
reconstituted by in vitro purified viral polymerase subunits and NP and an in vitro T7-
transcript. These reconstituted RNPs are transfected into cells, then these cells are infected by 
helper virus. A part of the newly formed virions contain the synthetic genomic segment. This 
method needs a selection system, that allows only the recombinant viruses to propagate. 
 
Recently T7 polymerase system and Pol I system for BDV have been reported (157, 195), but 
up to now infectious BDV is not rescued by a reverse genetic system. BDV replicates its 
genome in the nucleus of the infected cell. Since the T7 polymerase works in the cytoplasm, it 
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might not be successful for the rescue of BDV by T7 polymerase system. A T7 generated 
minigenome that was replicated and transcribed by transiently expressed influenza virus 
proteins (RNPs) was not packaged into a helpervirus after infection of new cells with the 
supernatant of transfected cells. In contrast a PolI generated minigenome was (Pleschka, 
unpublished data). On the other hand BDV causes a very slow and persisting infection. This 
means that perhaps its genome replication requires a very exact and tuned system. In my 
study, I tried to establish a helper virus dependnet reverse genetic system for BDV analoge to 
the successful system for influenza viruses. 
 
Synthesis of influenza virus entirely from cloned cDNAs 
 
Figure 6: Synthesis of influenza virus entirely from cloned cDNAs. Plasmids containing 
the RNA polymerase I promoter, a cDNA for each of the eight viral RNA segments, and the 
RNA polymerase terminator are transfected into cells together with four plasmids for the 
expression of viral proteins required for vRNA replication and transcription (PB1, PB2, PA, 
and NP). This system (12 plasmids) yields more than 1 x107 infectious viruses per milliliter of 
supernatant from transfected cells. Cotransfection of cells with nine plasmids for expression 
of all viral structural proteins increases the efficiency of virus production and also permits 
production virus particles lacking genes or possessing genes containing some mutations. 
(adapted from Neumann, et al., 2001) 
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The RNA polymerase I/II system for the generation of influenza virus 
 
 
Figure 7. The RNA polymerase I/II system for the generation of influenza virus. Cells are 
transfected with plasmids that contain a cDNA encoding a viral RNA flanked by RNA 
polymerase I promoter and terminator sequence in a negative-sense orientation. This cassette 
is then inserted between RNA polymerase II promoter and terminator sequence in a positive-
sense orientation. Transfection of these plasmids results in influenza vRNA sysnthesis by 
cellular RNA polymerase I and in mRNA sysnthesis by cellular RNA polymerase II. (adapted 
from Neumann, et al., 2001) 
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Figure 8. Reverse genetic systems for the rescue of infectious nonsegmented negative-
strand RNA viruses from cDNA. Transcriptionally competent viral RNPs are made by 
cellular expression of the viral proteins N, P and L. This can be achieved by a variety of 
methods, including vaccinia virus-driven T7 expression and T7 complementing cell lines 
constitutively expressing T7 polymerase and viral proteins. The full- length viral RNA can be 
provided by transfecting plasmids expressing antigenomic or genomic RNA or by directly 
transfecting naked RNA (plus-sense or minus-sense). The intracellularly assembled RNPs are 
transcribed and replicated by the viral polymerae complex (N, P and L proteins) generating 
infectious viruses.  
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Materials and methods  
 
1. Materials  
1.1 Chemicals and reagents 
Acetic acid         Roth, Germany 
Acrylamide        Bio-Rad, USA 
Acrylamide/bisacrylamide 30, 30%, 37.5:1    Roth, Germany 
Acrylamide/bisacrylamide 40, 40%, 19:1    Roth, Germany 
Agarose ultra pure        Roth, Germany 
Ammonium persulfate (APS)     Serva, Germany 
Ampicillin        ICN, USA 
Agar high-gel strength      Serva, Germany  
Boric acid         Roth, Germany 
Bromophenol blue       Merck, Germany 
Chloroform        Roth, Germany 
Coomassie brilliant blue R 250     Merck, Germany 
Dimethylsulfoxid (DMSO)      Sigma, USA 
1,4-Diazabicyclo [2,2,2]octane (DABCO)    Merck, Germany 
DEAE Dextran (Mw, 500,000)     Pharmacia  Biotech, 
         Denmark 
Di-Sodium hydrogen phosphate anhydrous (Na2HPO4)  Merck, Germany 
Ethanol (absolute)        Roth, Germany 
Ethidium bromide        Roche, Germany 
Ethylenediamine tetraacetic acid (EDTA)     Fluka, USA 
Extract of yeast powder      Merck, Germany 
Formamide        Fluka, USA 
Glycerol        Sigma, USA 
Glycogen         Roche, Germany  
Isoamyl alcohol        Roth, Germany 
Isopropanol         Roth, Germany 
Magnesium chloride (MgCl2)      Merck, Germany 
Mowiol 40 - 88       Aldrich, Germany 
Methanol        Roth, Germany 
N-2-hydroxyethylpiperazine (HEPES)     Sigma, USA 
Oxoid Agar        Oxoid, England 
Peptone from meat trypsin-digested     Merck, Germany 
Potassium chloride (KCl)      Roth, Germany  
Potassium dihydrogen phosphate (KH2PO4)    Roth, Germany  
Roti-phenol         Roth, Germany 
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Roti-phenol/ chloroform      Roth, Germany 
Sodium acetic acid (NaAc)      Roth, Germany 
Sodium chloride (NaCl)      Roth, Germany 
Sodium dodecyl sulfate (SDS)     Merck, Germany 
Sodium hydroxide (NaOH)      Merck, Germany 
Sodium borohydride NaBH4)     Roth, Germany 
Sodium hydrogen carbonate (NaHCO3)    Fluka, USA 
Sodium citric acid        Roth, Germany 
Silver nitrate        Merck, Germany 
Tris base        Roth, Germany 
N,N,N',N'-Tetramethyl-ethylene diamine (TEMED)   Serva, Germany 
Urea         BRL, USA 
ß-mercraptoethanol (MetOH)     Roth, Germany 
Xylene cyanole       Sigma, USA 
 
1.2 Enzymes and enzyme inhibitor 
Klenow frament of DNA polymerase I     NEB, England  
Restriction endonucleases       NEB, England  
RQ1 RNase free DNase (1U/µl)      Promega, USA 
Taq DNA polymerase (5U/µl)      Promega, USA 
RNase inhibitor (RNasin, 40U/µl)     Promega, USA 
T7 RNA Polymerase       Ambion, USA 
 
1.3 Nucleotides and reaction buffer 
DNA ladder mix       PEQLAB, Germany 
10x restriction enzyme buffer 1, 2, 3 and 4    NEB, England 
10x RQ1 DNase buffer      Promega, USA 
10x Taq polymerase buffer      Promega, USA 
Tris-HCl buffer for flash cat assay (pH 7.4)    Stratagene, Germany 
Bio-Rad protein assay buffer      Bio-Rad, USA 
Cell lysis buffer        Promega, USA  
 
1.4 Kits 
QIAGEN plasmid maxi kit      QIAGEN, Germany 
QIAGEN plasmid midi kit      QIAGEN, Germany 
QIAGEN RNA/DNA mini kit     QIAGEN, Germany 
QIAprep spin miniprep kit      QIAGEN, Germany 
TOPO TA cloning kit       Invitrogen, USA 
Rapid DNA ligation kit      Roche, Germany  
Rapid DNA ligation kit      NEB, England  
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Expand high fidelity PCR system     Roche, Germany  
High pure PCR product purification kit    Roche, Germany 
Flash CAT Non-Radioactive CAT Assay Kit   Stratagene, USA  
MAXIscriptTM (In vitro Transcription Kit)    Ambion, USA 
RPAIIITM (Ribonuclease Protection Assay Kit)   Ambion, USA 
BrightStarTM BioDetectTM (Nonistopic Detection Kit)  Ambion, USA 
 
1.5 Materials for cell culture  
Dulbecco's Modified Eagle's medium (DMEM)   Invitrogen, USA 
Fetal calf serum (FCS)      PAN, Germany 
Opti-MEM        Invitrogen, USA 
100x penicillin-streptomycin solution    PAA, Austria 
1x trypsin-EDTA (0.5 g/L trypsin, 0.2 g/L EDTA)   PAA, Austria 
Tissue culture dish       Greiner, Germany  
Tissue culture flask       NUNC, USA 
Bovine Albumin       ICN, USA  
 
1.6 E. coli strains, virus strains and cell lines 
XL1-Blue       Stratagene, Germany 
REB (rat embryo brain cells)  kindly provided by Dr. M. Flüß 
BDV-H1766     kindly provided by PD Dr. J. A 
Richt 
The following three cell lines were kindly provided by HDoz Dr. S. Pleschka: 
293T (Human embryonic kidney cells)  
Vero (African green monkey kidney cells)    
MDCK (Madin-Darby canine kidney cells)    
 
1.7 Plasmids  
pcDNA3.1      Invitrogen, USA  
pSV2 CAT      Stratagene, USA  
pCAGGS T7       kindly provided by Dr. E. Muehlberger 
Philipps-Unversity Marburg, Marburg 
pCITC Luci                                                     kindly provided by Dr. N. Tautz  
 Justus-Liebig -Universtiy, Giessen 
p125-luci (IFN-ß promoter)               kindly provided by Prof. Dr. S Ludwig 
 Heinrich Heine-University, Duesseldorf 
The following plasmids were constructed by Wenjun Ma in Harbin Veterinary Research 
Institute, Chinese Academy of Agricultural Science, China: 
pCI-NP (A/Goose/Guangdong/1/96 (H5N1)) 
pCI-HA (A/Goose/Guangdong/1/96 (H5N1)) 
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pCI-NA (A/Goose/Guangdong/1/96 (H5N1)) 
pCI-M (A/Goose/Guangdong/1/96 (H5N1)) 
pCI-NS (A/Goose/Guangdong/1/96 (H5N1)) 
The following plasmids were kindly provided by HDoz Dr. S. Pleschka:  
pHMG-PA (A/WSN/33(H1N1)) 
pHMG-PB1 (A/WSN/33(H1N1)) 
pHMG-PB2(A/WSN/33(H1N1)) 
pHMG-NP(A/WSN/33(H1N1)) 
pPolI-CAT-RT(-)     
pAM500 GFP    
The following eight plasmids were kindly provided by Dr. R. Wagner Philipps-Unversity 
Marburg: 
pPolI-PB1 (A/FPV/Rostock/34 (H7N1)) 
pPolI-PB2 (A/FPV/Rostock/34 (H7N1)) 
pPolI-PA (A/FPV/Rostock/34 (H7N1)) 
pPolI-NP (A/FPV/Rostock/34 (H7N1)) 
pPolI-HA (A/FPV/Rostock/34 (H7N1)) 
pPolI-NA (A/FPV/Rostock/34 (H7N1)) 
pPolI-M (A/FPV/Rostock/34 (H7N1)) 
pPolI-NS (A/FPV/Rostock/34 (H7N1)) 
The following three plasmids were kindly provided by Dr. M. Perez The Scripps Research 
Institue, Department of Neuropharmacology, La Jolla, USA: 
pCAGGS-N (BDV) 
pCAGGS-P (BDV) 
pCAGGS-L (BDV) 
 
1.8 Antisera and monoclonal antibodies 
Biotin-SP-conjugated attinipure sheep anti-Mouse IgG Dianova, Germany 
Peroxidase-conjugated Streptavidin    Dianova, Germany 
Furescein (FITC) conjugated goat anti-mouse IgG  Sigma, USA   
Monoclonal Bo18/p40     kindly provided by PD 
Dr. J. A. Richt 
1.9 DNA oligonucleotides 
DNA oligonucleotides were ordered from MWG-Biotech, Germany and Bao biological 
technique company, China. 
T7 clone Fw: 5'- GCG CCG TCT CTA ACA ACA AAC CAA TCA CCA TTC TTC 
TAA CAA AAT GAA CAC ACG CAA TGA ACA CGA TTA ACA 
TCG -3' 
T7 clone Bw: 5'- CGC GTG GCC ATT ATT ACG CGA ACG CGA AGT CCG AC -
3' 
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HH-Ribo Fw1: 5'- GCG CTC TAG AAC CAG AGG GCC CCG G -3' 
HH-Ribo Bw1: 5'- GCG CAA GCT TCG TCT CTA ACG CAA CAG ACT CCT TAC 
GGA GTT TCG GCC TTT CGG CCT CAT CAG TGT TGC GTT 
AAC AAC TAA TAA CCC GGC GGC CC -3' 
HH-Ribo Bw2:  5'- GCG CAA GCT TCG TCT CTA ACG CAA CAG ACT CCT TAC 
GGA GTT TCG GCC TTT CGG CCT CAT CAG TGT TGC GTT 
AAC TAA TAA CCC GGC GGC CC -3' 
HH-Ribo Bw3: 5'- GCG CAA GCT TCG TCT CTA ACG CAA CAG ACT CCT TAC 
GGA GTT TCG GCC TTT CGG CCT CAT CAG TGT TGC GTT 
AAT AAC CCG GCG GCC C -3' 
CAT29-52 Fw: 5'- CCG TTG ATA TAT CCC AAT CGC ATC -3' 
CAT612-589 Bw: 5'- CAT TCT GCC GAC ATG GAA GCC ATC -3' 
NS-NCR SapI Fw: 5'- GCG GGC TCT TCC ATT AGT AGA AAC AAG GGT G -3' 
NS-NCR SapI Bw: 5'- GGG CGC TCT TCA GCC AGC AAA AGC AGG G -3' 
Seq pBD Fw: 5'- GAC TCA CTA TAG GCT AG -3' 
Seq pBD Bw: 5'- GTG TCC GTG TCG CGC G -3' 
PA H5N1-Fw: 5'- CCA GCA AAA GCA GGT ACT GAT -3' 
PA H5N1-Bw: 5'- TTA GTA GAA ACA AGG TAC TT -3' 
PB1 H5N1-Fw: 5'-CCA GCA AAA GCA GGC AAA CAA -3' 
PB1 H5N1-Bw: 5'- TTA GTA GAA ACA AGG CAT T -3' 
PB2 H5N1-Fw: 5'- CCA GCA AAA GCA GGT CAA T -3' 
PB2 H5N1-Bw: 5'- TTA GTA GAA ACA AGG TCG T -3' 
NP H5N1-Fw: 5'- CGC GGG ATC CGC TCT TCT GCC AGC AAA AGC AGG GTA 
CCT AAT CAC TCA C -3' 
NP H5N1-Bw: 5'- CGC GGG GCC CGC TCT TCC ATT AGT AGA AAC AAG GGT 
GGA ATT CTT TAA TTG TCG TAC TCC TC -3' 
HA H5N1-Fw: 5'- GGC GAA GCT TGC TCT TCT GCC AGC AAA AGC AGG GGT 
ATA ATC TGT CAA AAT GGA GAG AAT AGT GCT TC -3' 
HA H5N1-Bw: 5'- GGC GGG GCC CGC TCT TCC ATT AGT AGA AAC AAG GGT 
GTT TTT AAC TAC AAT CTG AAC TCA CAA ATT TAA ATG 
CAA ATT CTG CAT TG -3' 
NA H5N1-Fw: 5'- GGC GGC TAG CGC TCT TCT GCC AGC AAA AGC AGG AGA 
TTA AAA TGA ATC CAA ATC AGA AGA TAA T -3' 
NA H5N1-Bw: 5'- GGC GGG GCC CGC TCT TCC ATT AGT AGA AAC AAG GAG 
TTT TTT GAA CAA GCT TCT AGG CAA TG -3' 
M H5N1-Fw: 5'- GGC GGG ATC CGC TCT TCT GCC AGC AAA AGC AGG TAC 
CTA TTG AAA AAT G -3' 
M H5N1-Bw: 5'- GGC GGG GCC CGC TCT TCC ATT AGT AGA AAC AAG GTA 
GTT TTT TAC TC -3' 
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NS H5N1-Fw: 5'- GGC GAA GCT TGC TCT TCT GCC AGC AAA AGC AGG GTG 
ACA AAG AC -3' 
NS H5N1-Bw: 5'- GGC GGG GCC CGC TCT TCC ATT AGT AGA AAC AAG GGT 
GTT TTT TAT -3' 
Flu RT-primer: 5'- AGC AAA AGC AGG -3' 
NS-RT Fw: 5'- CCA GCA AAAGCA GGG TGA CA -3' 
NS-RT Bw: 5'- TTA GTA GAA ACA AGG GTG TT -3' 
 
1.10 Other materials 
Deoxynucleosidetriphosphate set (dNTP, 100mM)  Promega, USA 
Eppendorf tube       Eppendorf, Germany 
X-ray film      Kodak X-OMAT, USA 
Syring (5ml, with 25G needle)    Braun, Germany 
Falcon centrifuge tube     Falcon, Germany 
Lipofectamine      Invitrogen, USA 
Lipofectamine 2000      Invitrogen, USA 
Plus Reagent        Invitrogen, USA 
Microtiter plate (96 wells)     Greiner, Germany 
TLC plate      Merck, Germany 
SOC medium       Invitrogen, USA 
 
2. Methods  
 
2.1 DNA cloning and subcloning 
2.1.1 Preparation of competent cells for eletroporation 
Luri-Broth (LB) medium 
0.5% (w/v) Extract of yeast powder 
1% (w/v) Peptone from meat trypsin-digested 
1% (w/v) NaCl 
pH7.5, autoclaved 
 
LB plate 
1.5%(w/v) Agar high-gel strength in LB medium, autoclaved 
 
Washing buffer  
1mM HEPES pH 7.0 
 
Competent cell stock solution 
10% (v/v) glycerol 
autoclaved 
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100 ml of Escherichia coli XL1-Blue was transferred into 10 ml LB medium. Cells were 
grown overnight at 37°C on the incubator shaker with moderate shaking (250 rpm). 10 ml 
culture medium was transferred into 1 L LB medium. Cells were grown for additional 3 - 4 h 
at 37°C until the OD595 reached 0.5-0.8. After cooling on ice for 30 min, cells were 
transferred into four sterile 250 ml centrifugation tubes and pelleted by centrifugation for 10 
min at 10000 rpm, 4°C (Beckmann type 14). Then cells were sequentially resuspended in 500 
ml of chilled 1mM HEPES (pH 7.0), pelleted again by centrifugation and resuspended in 250 
ml of chilled 1mM HEPES (pH 7.0), pelleted by centrifugation again as above. The cells were 
resuspended in 50 ml chilled 10% glycerol in H2O, centrifuged again as above and 
resuspended in 2.5 -3 ml 10% glycerol. Competent cells were aliquoted in 100 ml (per tube) 
on ice. The tube containing the competent cells were placed into nitrogen for freezing, then 
stocked immediately at -70°C.  
 
2.1.2 Electroporation 
Preparation 
Chilled sterile electro cuvette (Bio-Rad, USA)  
1 ml sterile SOC medium in an eppendorf tube 
Thaw competent cells rapidly on ice 
 
Transformation equipment setting  
Ohm: 200 
Capacitance: 25 
Voltage: 2.5 KV 
Time: time Const 
 
10 ng of plasmid DNA or 20 ml of desalted ligation mixture was mixed in 100 ml of rapidly 
thawed competent cells by stirring gently with the pipette tip. Transformation mixture was 
added into the chilled cuvette, and cuvette was dried and placed into the device of the Gene 
Pulser (Bio-RAD, USA). Then two buttons were pushed at the same time until a signal was 
heard (the desired electroporation time is about 4 milliseconds). Immediately SOC medium 
was added into the cuvette and mixed with the cells. The cells and SOC medium were 
removed from the cuvette and given into the eppendorf tube, then incubated on the 
thermomixer comfort (eppendorf, USA) for 30 min at 37°C. If ligation mixture was 
transformed, the cells and SOC medium mixture was centrifuged shortly after incubation, 
then only 100 µl liquid was kept in the eppendorf tube, rest of supernatants were discarded. 
The cell pellet was resuspended in the 100 µl liquid as mentioned and spread onto a pre-
warmed LB plate containing 100 µg/ml ampicillin. The plates were incubated overnight at 
37°C. If the plasmid was transformed, 100 µl of cells and SOC medium mixture (after 
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incubation on thermomixer comfort) was spread onto pre-warmed LB plate containing 100 
µg/ml ampicillin. The centrifugation and resuspension step is not needed. 
 
2.1.3 Preparation of plasmid DNA 
Solution I 
50 mM glucose 
25 mM Tris.Cl (pH 8.0) 
10 mM EDTA (pH 8.0) 
autoclaved for 15 min at 10 lb/sq.  
 
Solution II 
0.2 N NaOH (freshly diluted from a 10 N stock) 
1% SDS 
 
Solution III 
5 M potassium acetate  60 ml 
glacial acetic acid   11.5 ml 
H2O     28.5 ml 
 
Plasmid DNA mini-preparation was normally done according to the following protocol: a 
single bacterial colony was transferred into 5 ml of LB medium containing 100 µg/µl 
ampicillin in a loosely capped 15 ml tube. The tube was incubated overnight at 37°C with 
vigorous shaking. 1.5 ml of culture was poured into a microfuge tube and centrifuged at 6000 
rpm for 4 min at 4°C in a microfuge (Heraeus, Germany). The medium was removed by 
aspiration, leaving the bacterial pellet as dry as possible. The pellet was resuspended in 100 ml 
of solution I by vigorous vortexing, until the pellet was dispersed. Then 200 ml of prepared 
solution II was added, the contents were mixed by inverting the tube rapidly five times. 150 ml 
ice-cold solution III was subsequently added, the tube was vortexed gently for 10 seconds and 
stored on ice for 10 min. The tube was centrifuged at 13,000 rpm for 10 min at 4°C in a 
microfuge (Heraeus, Germany) and the supernatant was transferred to a new tube. The DNA 
was precipitated by adding 2 volumes of isopropanol at room temperature and the contents 
were mixed by vigorously vortexing. The tube was centrifuged at 13,000 rpm for 15 min at 
4°C in a microfuge (Heraeus, Germany). After centrifugation the supernatant was removed by 
gentle aspiration, then the pellet was rinsed with the cooled 500 ml 70% ethanol and 
centrifuged for 2 min at 13,000 rpm. The supernatant was removed as above mentioned, the 
pellet of DNA was dried in the air for 10 min. Then the DNA was redissolved in 50 ml TE 
(pH 8.0) containing DNAase-free pancreatic RNAase (20 µg/ml). 
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Plasmids DNA midi or maxi preparation was preformed using QIAprep plasmid midi or maxi 
kit. The preparations were done according to the manufacturer's protocol. The concentration 
of DNA was calculated by the measurement of the absorbance at two wavelengths, 260 nm 
and 280 nm, in a spectrophotometer (Pharmacia Sweden). Pure DNA should have an OD 
260/280 ratio of approximately 1.8. The amount of DNA can be calculated by the following 
formula, 
µg/ml DNA = OD260 ´ dilution factor ´ 50 
 
2.1.4 Restriction endonuclease digestion 
Digestion of DNA with restriction endonuclease was performed by pipetting DNA 
sample, 10x restriction buffer, restriction enzyme, and distilled and deionized water 
(ddH2O) in a 1.5 ml eppendorf tube. The reaction mixture was incubated at the 
recommended temperature. Normally 1 or 5 U of restriction enzyme was used to 
digest 1 mg DNA. Restriction endonucleases were inactivated by heating 65°C for 15 
min. 
 
2.1.5 Filling recessed 3' termini by Klenow fragment of DNA polymerase I 
After DNA digestion by restriction enzyme was inactivated by heating, 1 µl Klenow fragment 
of DNA polymerase I (5 U/µl) and 1 ml of 1 mM dNTPs were added into a 20 ml of digestion 
reaction. The mixture was incubated for 15 min at 25°C. Klenow fragment can be inactived 
by adding EDTA to a final concentration of 10 mM and heating at 75°C for 20 min. 
 
2.1.6 Dephosphorylation 
In order to prevent self- ligation of the linearized vector DNA during cloning, 
dephosphorylation of 5' termini of vector DNA was performed by using CIP (Alkaline 
Phosphatase, Calf intestinal). DNA sample was mixed with 1 ml CIP (1 U/ml) and 2 ml 10x 
CIP buffer or 10x restriction buffer (NEB) in a 20 ml of reaction. The mixture was incubated 
for 1 h at 37°C. DNA can be purified by gel purification, spin-column purification or phenol 
exaction. CIP can be inactived by heating treatment at 65°C for 20 min. 
 
2.1.7 Phenolization and precipitation of DNA 
Phenolization is normally employed to purify nucleic acid by removing proteins. The volume 
of reaction mixture containing DNA was adjusting to 200 ml with TE or ddH2O. 1 vol of Roti-
phenol/chloroform was added, and mixed by vortexing. After centrifuging at 13000 rpm, 4°C 
for 10 min, the upper aqueous phase was transferred to a new tube and precipitation with 1/10 
vol 3 M NaAc (pH 5.2) and 2 vol of isopropanol. DNA pellet recovered by centrifugation was 
subsequently washed with 1 ml of 70% ethanol, air-dried , and redissolved in ddH2O. 
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2.1.8 Agarose gel electrophoresis 
20000x ethidium bromide stock solution  
10 mg/ml ethidium bromide 
 
6x loading buffer 
0.025% (w/v) bromophenol blue 
30% (v/v) glycerol 
 
50x TAE 
242 g    Tris base 
57.1 ml   glacial acetic acid 
100 ml   0.5 M EDTA (pH 8.0) 
 
0.8-2% agarose gels were routinely used for analyzing DNA. The agarose was melted in 1X 
TAE buffer using a microwave oven (Quelle, Germany), and cooled to about 55oC. Before the 
gel was poured into a casting platform, ethidium bromide was added. DNA samples were 
mixed with appropriate amount of 6x loading buffer before loaded into the wells. Normally, 
the voltage of eletrophoresis was set to 10 V/cm (eletrophoresis apparatus, pharmacia 
Sweden). DNA was visualized by placing gel on a UV light source (Bachofer Germany), and 
picture was photographed directly by a photo system (MWG-BIOTECH Germany).  
 
2.1.9 Preparation of DNA fragments 
DNA bands were excised from gel and subsequently purified with a QIAquick gel extraction 
kit. The preparation was performed according to the manufacturer’s instruction. After 
purification, 5-8 ml DNA was run on agarose gel for analyzing the purified DNA amount for 
ligation.  
 
2.1.10 Ligation 
Ligations were done with a rapid DNA ligation kit (Roche, Germany) or NEB rapid ligation 
kit. The appropriate amount of linearized vector DNA and purified DNA fragment were used. 
The exact operation was performed according to the manufacturer’s instruction. The ligation 
products were purified with high pure PCR product purification kit according to the 
manufacturer’s instruction, before they were used to electroporation.  
 
2.2 Plasmids construction 
2.2.1 Plasmid PCR 
Plasmid DNA was diluted to 10 ng/µl, 2 µl were taken as template. Then the following 
reagents were added. 
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Templates (10 ng/µl)     2 µl 
Forward primer (10 pmol/µl)     5 µl 
Backward primer (10 pmol/µl)   5 µl 
dNTPs mix (10 mM each)     2 µl 
Taq DNA polymerase (5 U/µl, GIBCO)  0.5 µl 
10x PCR buffer (GIBCO)    10 µl 
25 mM MgCl2      6 µl 
ddH2O       69.5 µl 
This mixture was first denatured for 4 min at 94oC followed by cycles as shown below: 
denaturation   2 min   94oC 
annealing   30 s – 50 s  42oC – 60oC (according to primers) 
extension   50 s – 2.5 min  72oC (about 30 s/500bp) 
cycles    25 – 30 
final extension  7 min   72oC 
cool to 4oC 
PCR was performed on the PCR machine (GeneAmp, PCR system 2400, Perkin Elmer). After 
PCR, 10 µl of PCR product was loaded on a appropriate concentration agarose gel for 
analyzing. 
 
2.2.2 RT-PCR 
RNA was prepared from viruses or cells with the Qiagen RNA kits. If the RNA was extracted 
from the DNA transfected cells and RT-PCR was done for identification, it was necessary to 
digest DNA with DNaseI (Roche, Germany 10 U/µl) at 37oC for 30 min to delete the 
transfected DNA contamination. The appropriate amount of RNA was used as template for 
RT. 
 
First - strand synthesis of cDNA  
RNA   2-4 µg 
RT-primer  3 µl (200 ng/µl) 
DEPC H2O was added to 20 µl, and reaction was incubated in PCR machine at 70oC for 10 
min, immediately placed on the ice. Then the fo llowing components were added to the 
annealed primer/template-mix for reverse transcription (RT): 
reverse transcriptase 5x reaction buffer (Invitrogen)   10 µl 
10 mM dNTPs (10mM each, Invitrogen)     1 µl 
RNasin ribonuclease inhibitor (40 U/µl, Promega)   1 µl 
0.1 M DTT (Invitrogen)      5 µl 
Superscript II RNaseH- (200 U/µl, Invitrogen)    0.5 µl       
DEPC H2O         12.5 µl 
The reaction was incubated in PCR machine at 42oC for 90 min, then inactivated at 95oC for 5 
min. 10 µl RT product was used as templa te for PCR (steps were the same as 2.1). 
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2.2.3 pPolI-HHR-CAT2.1#1, #2 and #3 and pPolI-HHR-CAT2.2#1, #2 and #3 
The parent plasmid from which six new clones were made were pPOLI-BDVcCAT2.1SP#10 
and pPOLI-BDVcCAT2.2SP#11, that contain human polymerase I promoter (252 bp), mouse 
polymerase I terminator (175 bp), BDV 5'- NCR and 3'- NCR, and reporter gene CAT. There 
is a hepatitis delta virus (HDV) ribozyme behind 5'-NCR, that cleaves the transcript in cis to 
generate the correct 3'-end.  Plasmid PCR was done with pPOLI-BDVcCAT2.2SP#11 as 
template, (HH-Ribo Fw/ HH-Ribo Bw1, HH-Ribo Bw2 and HH-Ribo Bw3 as primers) PCR 
products were digested by XbaI and HindIII, then cloned into the XbaI and HindIII site of 
pcDNA3.1. New plasmids were named pcDNA3.1HHR#1, #2 and #3, and were sequenced to 
assure that the cloned sequences were correct.  
These plasmids were digested by BsmBI (this site was designed in the three backwards 
primers), then the ends of the fragment were filled in by Klenow enzyme and digested by 
ApaI after filling in. The isolated DNA fragments were cloned into the ApaI and HpaI sites of 
pPOLI-BDVcCAT2.1SP#10 or pPOLI-BDVcCAT2.2SP#11 to generate pPolI-HHR-
CAT2.1#1, #2 and #3 or pPolI-HHR-CAT2.2#1, #2 and #3, and the new plasmids were 
sequenced to determined that the sequences were correct.  
The ribozyme assay (see results) was done to prove that both ribozymes (hammerhead 
ribozyme and HDV ribozme) were functional in vitro, and the three plasmids would then be 
used to transfect BDV infected Vero cells to prove that the BDV polymerase could recognize 
and use the primary RNA transcript ( Pol I- transcript) for transcription and replication. 
 
2.2.4 pcDNA3.1Ribo1p, pcDNA3.1Ribo1s-p, pcDNA3.1Ribo2 and pcDNA3.1Ribo3 
In order to prove that the both ribozymes were functional in vitro, these four plasmids were 
constructed. The inserted fragments were prepared by PshAI digest of pPolI-HH-RCAT#1, #2 
and #3 separately, and by PshAI and SmaI digest of  pPolI-HHR-CAT#1. pcDNA3.1 was 
digested by EcoRV and dephosphorylated using CIP. The inserted fragments were cloned into 
the EcoRV site of pcDNA3.1 under the control of a T7 promoter (HHR ribozyme near T7 
promoter) to generate pcDNA3.1Ribo1p, pcDNA3.1Ribo1s-p, pcDNA3.1Ribo2 and 
pcDNA3.1Ribo3. Then these new plasmids were digested by different restriction enzymes for 
identification.  
 
2.2.5 pPCRII-TOPO-RPA 
Plasmid pPCRII-TOPO-RPA was constructed for in vitro-transcription to generate a probe for 
a RNase protection assay (RPA). Firstly plasmid pPCRII-TOPO-T7 (see method 2.6) and 
pcDNA3.1Rib1 P (see method 2.4) were digested by HindIII and XbaI to generate the vector 
and the inserted fragment respectively, then the inserted fragment was cloned into the HindIII 
and XbaI sites of vector to generate the pPCRII-TOPO-RPA. 
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2.2.6 pPoll-HHR-T7 
For the construction of this plasmid, plasmid PCR was done with pCAGGS T7 as the 
template (T7 clone Fw/ T7 clone Bw as primers) and the PCR product was cloned into 
pPCRII-TOPO vector to generate pPCRII-TOPO-T7. After identification by restriction 
enzyme digest and sequencing, pPCRII-TOPO-T7 was digested by BsmBI and filled in by 
Klenow enzyme, then digested by MscI. The inserted fragment was cloned into the HapI and 
MscI sites of pPOLI-BDVcCAT2.1SP#10 to generate pPOLI-BDVT7. Hammerhead 
ribozyme version 3 (HHR#3) was cut from pcDNA3.1HHR#3 by BsmBI and was also filled 
in by klenow enzyme, then digested by ApaI. The HHR#3 fragment was inserted into the 
HapI and ApaI sites of pPOLI-BDV-T7 to generate pPolI-HHR-T7. 
 
2.2.7 pBD 
pBD was kindly provided by Dr. Kanta Subbarao, influenza Branch, CDC. This plasmid 
includes the CMV promoter, human RNA polymerase I promoter, hepatitis delta virus (HDV) 
ribozyme and two SapI cloned sites.  
 
2.2.8 pBD-PB1, -PB2, -PA 
To construct these plasmids, reverse transcription was firstly performed with viral RNA as 
template (Flu RT-primer as primer), then PCR was done with PB1 H5N1-Fw/Bw, PB2 
H5N1-Fw/Bw and PA H5N1-Fw/Bw as primers respectively. RT-PCR products were treated 
with T4 DNA polymerase (dTTP and dCTP), and pBD was digested by SapI and filled in by 
Klenow enzyme (dTTP and dATP). The treated PCR products were ligated with the linearized 
vector, and transformed into the E coli. cells. The positive plasmids were identified, and 
sequenced to ensure that the complete sequences were correct. pBD-PB1, pBD-PB2 or pBD-
PA was transfected into 293T cells together with the according 3 plasmids of the helper 
plasmid set (pHMG-PB1, -PB2, -PA,-NP) and pPolI-CAT-RT(-). A CAT-assay was 
performed to prove that either one of the three plasmids (pBD-PB1, -PB2, -PA) is functional. 
 
2.2.9 pBD-NP 
To construct pBD-NP, a plasmid PCR was done with pCI-NP as template (NP H5N1-
Fw/Bw), and the PCR product was digested by SapI, then inserted into the SapI site of the 
pBD to generate pBD-NP. pBD-NP was sequenced and transfected into 293T cells with 
pHMG-PB1, -PB2, -PA and pPolI-CAT-RT(-), then CAT assay was made to prove that it is 
functional.  
 
2.2.10 pBD-HA, -NS 
To construct pBD-HA, -NS, a plasmid PCR was done with pCI-HA and pCI-NS as template 
respectively (HA H5N1-Fw/Bw, NS H5N1-Fw/Bw), and the PCR products were digested by 
HindIII/ApaI, then inserted into the HindIII/ApaI sites of pcDNA3.1 to generate pcDNA3.1-
HA and pcDNA3.1-NS. pcDNA3.1-HA and pcDNA3.1-NS were sequenced in order to ensure 
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that the complete sequences were correct, and they were digested by SapI, then inserted into 
the SapI site of pBD to generate pBD-HA and pBD-NS. 
 
2.2.11 pBD-NA, -M 
To construct pBD-NA, -M, a plasmid PCR was done with pCI-NA and pCI-M as template 
respectively (NA H5N1-Fw/Bw, M H5N1-Fw/Bw), and the PCR products were cloned into 
the pPCRII-Topo vector, then sequenced in order to ensure that the complete sequences were 
correct.  They (pPCRII-Topo-NA and pPCRII-Topo-M) were digested by SapI, then inserted 
into the SapI site of pBD to generate pBD-NA and pBD-M. 
 
2.3 Ribozyme assay 
2.3.1 Plasmid linerization 
10 µg of plasmids were digested by appropriate restriction enzyme. After being sure of 
complete digestion through analyzing by gel electrophoresis, plasmids were precipitated by 
adding these chemicals (1/10 volume 3 M NaAc pH5.2, 1-2 volume Isopropanol, 2 µl 
glycogen). After vortexing, this mixture was centrifuged for 15 min at 13000 rpm, 4°C. Then 
pellet was sequentially washed by 70% ethanol and centrifuged again fo r 5 min at 13000 rpm, 
4°C, leaving the pellet as dry as possible. Then the pellet was resuspended in 11 µl of DEPC 
H2O. 1 µl was used for measuring the DNA concentration.  
 
2.3.2 T7 - transcription (in vitro) 
1 µl of linearined DNA was taken as template. Then the following reagents were added. 
DNA      1 µl (1 µg/µl) 
10x transcription buffer (with DTT)  2 µl 
ATP (10 mM)     1 µl 
CTP (10 mM)     1 µl 
GTP (10 mM)     1 µl 
UTP (10 mM)     1 µl 
RNasin (40U/µl)    1 µl 
T7 RNA polymerase (15U/µl)   1µl 
DEPC H2O     11 µl 
The mixture was mixed by pipetting, and incubated for 2 h at 37°C. Then adding 1 µl DNaseI 
(10U/µl) and mixing, the mixture was incubated at 37°C for 30 min. The mixture was 
precipitated as above mentioned (2.3.1), and washed once by 70% ethanol and dried. Finally 
the pellet was resuspended in 30 µl DEPC H2O.  
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2.3.3 Ribozyme reaction 
The following materials were added for ribozyme reaction, then the mixture was incubated at 
at 37°C for 30 min. 
RNA    30 µl 
25 mM MgCl2   20 µl 
RNasin (40U/µl)  1 µl 
 
2.3.4 Running denaturing acrylamide gel 
10x TBE 
TBE is generally used at 1x final concentration for preparing gels and for gel running buffer. 
The following recipe is for 1 L of 10x TBE . 
Tris base   109 g 
Boric acid     55 g 
0.5 M EDTA solution 40ml 
then add ddH2O to 1 L. 
 
Denaturing acrylamide gel mix (5% acrylamide /8 M urea gel) 
Urea (high quality)     7.2 g 
10 x TBE      1.5 ml 
40% acrylamide (acry: bis-acryl = 19:1)  1.9 ml 
add ddH2O to 15 ml. Then stirring at room temperature until the urea is completely dissolved, 
subsequently add: 
10% ammonium persulfate    120 µl 
TEMED      16 µl 
Mix briefly after adding the last two ingredients, which will catalyze polymerization, then 
pour gel immediately. 
 
Loading buffer 
95% Formamide 
0.025% xylene cyanol 
0.025% bromophenol blue 
18 mM EDTA, 0.025% SDS 
Details of attaching gel to the running apparatus (Bio-Rad, USA) according to the 
manufacturer´s instructions. 1x TBE was used as the gel running buffer. Before loading the 
samples, the wells of urea-containing gels were rinsed. 2 µl sample with 8 µl loading buffer 
was incubated at 90°C for 3 min, then shortly centrifuged and loaded in the wells of gel. Gels 
should be run at about 20 V/cm gel length. 
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2.3.5 Silver staining 
After separating the gel from the two glass plates of electrophoresis apparatus, the gel was 
firstly washed in solution I (25% ethanol, 10% acetic acid) for 5 min at room temperature. 
Subsequently washed in solution II (10% ethanol, 0.5% acetic acid) for 5 min, then the gel 
was stained in 1.8 g/L silver nitrate solution (1.8 g silver nitrate dissolved in 1 L H2O) for 20 
min. Meanwhile the reduction solution (3 g NaOH and 40 mg NaBH4 dissolved in 100 ml 
H2O) was prepared. When ready, 0.75 ml formaldehyde was added into the reduction 
solution. The gel was washed with ddH2O for three times, then laid into the reduction solution 
until bands were seen about 2 - 5 min. Immediately the gel was placed in solution of 10% 
acetic acid, then the gel was dried and photographed.  
 
2.4 Indirect Immunofluoresces Assay (IFA) and in situ immunhisto-chemical BDV-
detection 
2.4.1 IFA 
100x Ca2+/Mg2+ solution  
1 g  MgCl2 
1.32 g  CaCl2 
100 ml  dH2O 
autoclaved, then filtered with the 0.2 µm filter column (SARSTEDT, Germany). 
 
10 x PBS 
8 0 g  NaCl 
2 g  KCl 
14.4 g  Na2HPO4 
2.4 g  KH2PO4 
Dissolved in 800 ml of H2O, then adjust the pH to 7.4 with HCl. Finally add H2O to 1 L and 
autoclaved. 
 
1x PBS++ buffer 
500 ml   1x PBS (autoclaved) 
5 ml   100x Ca2+/Mg2+ solution 
 
Cell fixing buffer (100 ml) 
95 ml  PBS++ 
4 ml  Formaldehyde (PFA) 
1 ml  Triton X-100 (t-Octylphenoxypolyethoxyethanol) 
 
Mowiol DABCO 
2.4 g  Mowiol 
6 g  Glycerol 
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6 ml   dH2O 
Mixed by magnetic stirrer over night. Next day 12 ml 0.2 M Tris-HCl (pH 8.5) was added and 
incubated at 50oC for 30 min. The viscous mixture was centrifuged at 6000 rpm at room 
temperature for 15 min, and the supernatant was mixed with  DABCO (final concentration 
2.5%). The solution can be stored at -20oC for several months.  
The confluent cells were trypsinized by trypsin-EDTA, and spilt and reseeded in the wells of 
24 well plate containing sterile glass coverslip (12 mm). After 2-3 days incubation, the cells 
were confluent. The growth medium was removed from the culture vessel, and the cells were 
washed once with PBS++, then the cells were fixed with 1 ml cell fixing buffer for 30 min at 
room temperature. After fixation, the cells were washed twice with PBS++ , subsequently 100 
µl of the first antibody (Bo18 p40 mAB, 1:100 dilution with PBS++/3% BSA) was added (the 
glass coverslip should be covered by the antibody solution) and incubated for 1 h at room 
temperature. After 1 h, the cells were washed once as above, then 100 µl the second antibody 
FITC conjugated goat anti mouse IgG (1:100 dilution with PBS++/3% BSA) was added and 
incubated for 1 h at room temperature. Then the cells were washed twice as above, and once 
with dH2O. The glass coverslip was fixed on the glass carrier with Mowiol, and hardened 
overnight. The analysis was done in next day with a fluorescence microscope.   
 
2.4.2 In situ immunhistochemical BDV-detection 
Substrate solution 
One tablet H2O2 (Sigma, USA) and one tablet Diaminobenzidin tetrahydrochlorid (DAB) 
(3,3'-Diaminobenzidine Tablet Set, Sigma, USA) were dissolved  in 15 ml 1x PBS. 
 
The BDV infected and noninfected cells were grown confluent in the wells of a 24 well plate. 
The growth medium was removed from the culture vessel, and the cells were washed once 
with PBS++, then fixed with 1 ml cell fixing buffer for 30 min at room temperature. After 
fixation, the cells were washed twice with PBS++, subsequently 150 µl of the first antibody 
(Bo18 p40 mAB, 1:100 dilution with PBS++/3% BSA) was added and incubated for 1 h at 
room temperature. After 1 h, the cells were washed once as above, then 150 µl the second 
antibody (biotin anti mouse, Dianova, Germany, 1:100 dilution with PBS++/3% BSA) was 
added and incubated for 45 min at room temperature. Then the cells were washed once as 
above, then 200 ml Streptavidin/HR-Peroxidase-conjungated (Dianova, Germany 1:1000 
dilution with PBS++/3% BSA) was added and incubated for 30 min at room temperature. The 
cells were washed twice with PBS++, 1 ml substrate solution was added for 10-20 min at room 
temperature. The reaction was stopped by washing with dH2O twice. The plate was dried, and 
the analysis was done by a microscope.  
 
 
  
Materials and methods  
  
40  
2.5 Establishment of Vero cell line infected by BDV H1766 
To generate new BDV infected Vero cells, I have tried to infect the new Vero cells with BDV 
directly, but this failed. Therefore I used BDV H1766 to infect primary REB cells (rat embryo 
brain cells that can be easily infected with BDV), and then co-culture the BDV infected REB 
cells together with the new Vero cells. After two passages, the REB cells were dead and the 
Vero cells were infected by BDV H1766. I proved that the new Vero cells were almost 
completely infected by BDV H1766 through in situ immunhistochemical BDV-detection 
(2.4.1) and indirect immuno-fluoresces assay (2.4.2).  
 
2.6 DNA-transfection of eucaryotic cell cultures 
Complete medium 
450 ml   1x DMEM 
50 ml   FCS 
5 ml    Antibiotic (100x penicillin-streptomycin solution) 
 
DMEM/BA/S/P medium (0.5 L) 
492 ml  DMEM 
3 ml  35% Bovine Albumin (ICN) 
5 ml   Antibiotic (100x penicillin-streptomycin solution) 
 
2.6.1 Transfection I; Normal Lipofectamine Reagent  
Adherent cells: The cells in 35 mm dishes should be 70% - 80% confluent for transfection. 
DNA (5 µg) was diluted in 100 µl 1x DMEM (without serum and antibiotics) in a tube (5 ml 
polystyrene Round-Bottom Tube, Falcon), then 10 µl Plus Reagent was added into the 
mixture, mixed by pipetting and incubated at room temperature for 15 min. 7 µl 
Lipofectamine Reagent was diluted into 100 µl 1x DMEM (without serum and antibiotics) in 
a second tube (5 ml polystyrene Round-Bottom Tube, Falcon) and mixed by pipetting. The 
diluted Lipofectamine Reagent was added into the tube containing pre-complexed DNA and 
Plus Reagent, then mixed and incubated for 15 min at room temperature. While complexes 
were forming, the medium on the cells was replaced with 0.8 ml 1x DMEM (without serum 
and antibiotics). The DNA-Plus-Lipofectamine Reagent complexes (total 200 µl volume) 
were added each dishes containing fresh medium. The complexes were mixed into the 
medium gently and incubated at 37oC at 5% CO2 for 6 h. After 6 h, the medium containing 
the complexes was removed and replaced with the complete medium. The cells were 
continually incubated at 37oC at 5% CO2 for 24 - 48 h for assay. If this transfection was to 
rescue viruses, DMEM/BA/S/P medium was used to replace the medium containing DNA-
Plus-Lipofectamine Reagent complexes. 
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2.6.2 Transfection II; Lipofectamine 2000 
Suspension cells: 2-4 h prior to transfection, culture medium was refreshed with new medium 
without antibiotics (DMEM + 10% FCS). DNA (5 µg) was diluted in 50 µl of Opti-MEM I 
reduced serum medium and mixed gently in a tube (5 ml polystyrene Round-Bottom Tube, 
Falcon). Lipofectamine 2000 mixed gently before using, then 10 µl Lifectamine 2000 was 
diluted in 240 µl of Opti-MEM I in a second tube (5 ml polystyrene Round-Bottom Tube, 
Falcon), mixed gently and incubated not longer than 5 min at room temperature. The diluted 
Lipofectamine 2000 was added to the tube containing the diluted DNA, then mixed gently and 
incubated 20-30 min at room temperature to allow the DNA-Lipofectamine 2000 complexes 
to form. During the complexes were formed, the confluent cells (75 cm2 culture flask) were 
firstly washed with 1x PBS, then trypsinized by 5 ml 1x trypsin-EDTA. After digestion, 5 ml 
medium (DMEM + 10% FCS) was added into flask, the mixture was transferred into a 15 ml 
of Falcon centrifuge tube and centrifuged at 1000 rpm in a megafuge (Heraeus, Germany) for 
5 min. The supernatant was removed by aspiration, then the cell pellet was resuspended by 10 
ml medium (DMEM + 10% FCS) and reseeded into fresh 35 mm dishes (1 ml/dish). The 
DNA-Lipofectamine 2000 complexes (total volume 300 µl) were added into the new 35 mm 
dish containing cells and mixed gently. The cells were incubated at 37oC at 5% CO2  for 24 h, 
then the medium containing DNA-Lipofectamine 2000 complexes was replaced with the 
complete medium. The cells were continually incubated at 37oC at 5% CO2 for 24 - 48 h for 
assay. If this transfection was to rescue viruses, DMEM/BA/S/P medium was used to replace 
the medium containing DNA-Lipofectamine 2000 complexes. 
 
2.7 Generation, amplification and purification of wild and reassortant avian 
influenza virus  
293T cells (1 ´ 106) on 35 mm diameter dishes were transfected with 12 plasmids (5 µg 
DNA), with the use of Lipofectamine and plus reagent (Invitrogen, USA) according to the 
transfection I (method 2.6.1). For generating the wild type FPV, 1.2 µl (1µg/µl) of protein 
expression plasmids (pHMG-PB1, pHMG-PB2, pHMG-PA and pHMG-NP) were used for 
transfection and the ratio of pHMG-PB1 : pHMG-PB2 : pHMG-PA : pHMG-NP was 
1:1:0.2:1 (these four plamids were mixed firstly according to this ratio). 3.8 µl (1µg/µl) of the 
RNA polymerase I plasmids were used for transfection. These RNA polymerase I plasmids 
are pPolI-PB1, pPolI-PB2, pPolI-PA, pPolI-NP, pPolI-HA, pPolI-NA, pPolI-M and pPolI-NS 
of the strain A/FPV/Rostock/34 (H7N1), and the ratio was pPolI-PB1 : pPolI-PB2 : pPolI-PA 
: pPolI-NP : pPolI-HA : pPolI-NA : pPolI-M : pPolI-NS =1:1:1:1:2:2:1:1 (these eight 
plasmids were mixed firstly according to this ratio). 
To generate the reassortant virus (GD1NSFPV) of the strain A/FPV/Rostock/34 (H7N1) and 
A/Goose/Guangdong/1/96 (H5N1), only pPolI-NS of the strain A/FPV/Rostock/34 (H7N1) 
was substituted by pBD-NS. The amount of DNA for transfection and the ratio among 
plasmids was not changed. 48 h after transfection, the supernatants were harvested and used 
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to infect confluent MDCK on 6-cm-diameter dishes to amplify progeny viruses.  Then plaque 
purification was done three times for purifying the viruses. Every times a single plaque (in 
agarose gel, method 2.9.1 plaque assay) was picked  and mixed in 500 µl PBS/BA/P/S/Ca/Mg 
solution (see plaque assay recipie). Then the purified viruses were amplified and titrated on 
MDCK cells by plaque assay.  The titrated viruses were stored in -70oC for the following 
experiments. For generating other reassortant viruses, for example GD1MFPV, GD1HAFPV, 
GD1NAFPV and GD1NPFPV and so on, only pPolI-M (pPolI -HA, -NA, -NP) was used to 
instead of the according plamid pPolI-M (pPolI-HA, -NA, -NP). The procedure, that is same 
protocol for generating the reassortant GD1NSFPV, was performed to rescue an reassortant 
virus.    
 
2.8 Chloramphenicol Acetyltransferase (CAT)-Assay 
2.8.1 Preparation of cell extracts  
48 h after transfection (method 2.6.1) , cells were washed twice with 1x PBS, then scraped off 
with 1.5 ml of 1 x PBS and transferred into a microfuge tube. Cells were centrifuged at low 
speed (6000 rpm) in a microcentrifuge (Heraeus, Germany) at 4oC for 5 min and resuspended 
in 100 µl of 0.25 M Tris-HCl buffer (pH 7.4) for flash CAT assay (Stratagene, USA), then 
cell extracts were made by freezing (nitrogen) and thawing (37oC water bath) three times (5 
min/times). The debris was pelleted by spinning for 10 min at 13000 rpm at 4oC in a 
microcentrifuge (Heraeus, Germany), then the supernatant was transferred to a fresh tube and 
the extracts were kept on ice.  
 
2.8.2 Determination of protein amount 
A 5 µl sample from the cell lysate was taken to measure the protein amount, other materials 
were added as followed. 
5 µl  sample  
200 µl  Bio-Rad protein assay buffer 
800 µl  ddH2O 
The concentration of protein was calculated by the measurement of the absorbance at the 
wavelength 595 nm in a DU-70 spectrophotometer (Beckman). According to the indicated 
absorbance, the protein concentration of different samples could be calculated and compared.  
 
2.8.3 CAT-Assay 
For each reaction, mix a predetermined amount of protein with the following prechilled 
reaction components (Flash CAT Non-Radioactive CAT Assay Kit, Stratagene, USA) on ice. 
 
65 µl of cell extracts plus reaction buffer (same amount protein) 
25 µl of 4 mM Acetyl Coenzyme A (Acetyl CoA) 
10 µl of BODIPY CAM substrate 
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The mixture was mixed briefly and incubated at 37oC for 14-16 h. The reaction was 
terminated by adding 500 µl ice-cold ethyl acetate and the samples were vortexed for 20 
seconds. The samples were centrifuged at 13,000 rpm for 3 min, then about 450 µl of 
supernatant was transferred into a fresh tube and the ethyl acetate evaporated in a vacuum 
drier. The yellow residue was dissolved in 10 µl of ethyl acetate, then spotted onto TLC plates 
(20 x 20 cm Silica gel 60, MERCK, Germany) (1.5 cm from the bottom of the TLC plate and 
no less than 1 cm from each sample). To perform TLC, a closed TLC tank (containing a piece 
of Whatmann 3MM filter paper running the vertical height of the tank) was preequilibrated 
with an 87:13 mixture of chloroform-methanol to a depth of 1.0 cm. After samples had been 
applied and air-dried on the plate, chromatography was done until the solvent front was near 
the top of the plate. The TLC plates (were dried in air for several seconds under a hood, then 
analyzed under direct long-wavelength UV light (366 nm) and recorded by standard instant 
photography.  
 
2.9 Plaque-Assay 
MEM/BA (0.5 L) 
100 ml  10x MEM (Gibco) 
10 ml  Antibiotic (100x penicillin-streptomycin solution) 
20 ml   7.5% NaHCO3 
6 ml   35% Bovine Albumin (BA) (ICN) 
354 ml  ddH2O (sterilized) 
 
Viral dilution solution (PBS/BA/P/S/Ca/Mg) 
20 ml  10x PBS 
175 ml  dH2O 
autoclaved, then add the following solutions: 
2 ml  Antibiotic (100x penicillin-streptomycin solution) 
1.2 ml  35% Bovine Albumin (ICN) 
mix completely, add: 
2 ml  100x Ca2+/Mg2+ solution 
mix completely. 
 
Agarose gel solution for plaque assay of influenza virus (50 ml) 
8.5 ml  ddH2O   
25.0 ml 2x MEM/BA 
0.5 ml  1% DEAE Dextran (Mw, 500,000 Pharmacia Biotech) 
15.0 ml 2% Oxoid Agar 
1.0 ml  5% NaHCO3 
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2.9.1 Plaque-Assay 
Virus was exactly diluted with viral dilution solution. The cells (MDCK) were seeded on 3.5 
cm-diameter dishes and grown confluently. The cells were washed once with 1x PBS++, then 
100 µl viral solution was laid on the cells. The cells were incubated at room temperature for 
one hour, and shaken gently. At the same time 2% Oxoid agar was melted and incubated in 
the 42oC water bath. MEM/BA medium was also incubated in the 37oC water bath. After one 
hour, the viral solution was removed from the dishes, 2% Oxoid agar was mixed with 
MEM/BA (and the other solutions). 2 ml mixture was given to every plate. Until the agar 
became solid, the dishes were inversely laid in a 37oC, 5% CO2 humidified incubator 
(Heraeus, Germany). After 2 or 3 days plaques were seen on the dishes. 
 
2.9.2 Analysis of Plaque-Assay  
Preparation of coomassie brilliant blue buffer (100 ml) 
0.25 g   Coomassie brilliant blue R 250 (Merck) 
90 ml   Methanol /H2O (1:1) 
10 ml   acetic acid 
filtered with normal filter paper. 
 
The agar was taken away from the dishes with a spatula. Cells were stained with coomassie 
brilliant blue (1 ml/3.5 cm plate) at room temperature for 5 min, then the plates were washed 
gently with normal water. Plaques were calculated for different dilution and the total amount 
of plaques can be calculated by the following formula: 
PFU/ml = amount of plaques ´ dilution factor ´  volume factor 
volume factor: PFU is related to 1 ml. if a dish was infected with 100 µl viral dilution 
solution, the factor was 10.  
 
2.10 Haemagglutination (HA)-Assay 
2.10.1 Preparation of red blood cells (RBCs) from chicken blood 
Red blood cells should be taken from SPF chickens. If SPF chickens are not available, blood 
may be taken from normal birds (chickens) that are shown to be free from antibodies to avian 
influenza. Firstly about 20 - 30 ml fresh chicken blood (free from antibodies to avian 
influenza) was transferred to a 50 ml sterilized Falcon centrifugation tube containing 10 ml of 
3.7% sodium citric acid. The RBCs was washed with cooled PBS++ and centrifuged at 1500 
rpm at 4oC for 10 min. The supernatant was carefully removed by aspiration, then RBCs 
pellet was washed with PBS++ and centrifuged. This was repeated twice as above mentioned. 
Finally the pellet of RBCs was diluted to 0.5% (v/v) with cooled PBS++ for haemagglutination 
assay.  
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2.10.2 HA-Assay 
50 µl PBS++ was dispensed into each well of a plastic U-bottomed microtitre plate (96 wells), 
then 50 µl virus suspension (cell culture supernatant) was placed in the first well. Twofold 
dilutions of 50 µl volumes of the virus suspension were made across the plate, subsequently 
50 µl of 0.5% chicken RBCs was dispensed to each well. The mixture of every well was 
mixed by tapping the plate gently and then the RBCs were allowed to settle for about 30 min 
at 4oC. 
 
2.10.3 Determination of HA-Units 
HA was determined by tilting the plate and observing the presence or absence of tear-shaped 
streaming of the RBCs. The Haemagglutinating Units (HAU) are : 2x, where X is the number 
of the last well without tear-shaped streaming. 
 
2.11 Luciferase Activity-Assay 
2.11.1 Preparation of passive lysis buffer  
Passive lysis buffer was supplied as a 5x concentrate (Promega, USA). A sufficient quantity 
of the 1x working concentration was prepared by adding 1 volume of 5x passive lysis buffer 
to 4 volumes of distilled water and the mixture was mixed well. 
 
2.11.2 Active lysis of cultured cells 
The transfected cells with plasmids containing the luciferase reporter gene were incubated for 
the appropriate time, the growth medium was removed from the cultured cells by aspiration 
and a sufficient volume of 1x PBS was applied to rinse the bottom of the culture dishes. The 
dishes were swirled briefly to remove detached cells and residual growth medium. A minimal 
volume of 1x lysis reagent was dispensed into the culture dishes (200 µl/35 mm dish), and the 
culture dishes were rocked several times to ensure complete coverage of cells with lysis 
buffer. The attached cells were scraped from the dish, then the cells and all liquid were 
transferred to a microcentrifuge tube. The microcentrifuge tube was vortexed vigorously for 
10-15 seconds, then centrifuged for 15 seconds at 12,000 g at room temperature or for 2 min 
at 4oC. The supernatant was transferred to a new tube, and the cell lysates might be assayed 
directly or stored at -70oC. The assay for measuring was performed according to the 
manufacturer's protocol of Microplate Luminometers machine (Molecular Devices, USA).  
 
2.12 Western Blotting (Semi-dry) 
2.12.1 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
0.5 M Tris pH 6.8 (100 ml) 
6.05 g  Tris-base  
50 ml  dH2O 
adjusted pH to 6.8 with HCl, filled to 100 ml with dH2O. 
1.5 M Tris pH 8.8 (100 ml) 
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18.15 g Tris-base  
50 ml  dH2O 
adjusted pH to 8.8 with HCl, filled to 100 ml with dH2O. 
 
5x SDS-PAGE buffer (5 L) 
5 g  SDS 
30 g  Tris-base 
144 g  Glycine 
dissolved in 5 L dH2O. 
 
Loading buffer (10 ml) 
5 ml   8 M urea solution 
2 ml   120 mM Tris (pH 7.6) 
1 ml   20% (w/v) SDS 
0.5 ml   Methanol 
1.5 ml   Glycerin 
0.05 g   Bromphenol blue 
autoclaved. 
 
Stacking gels: 
30% Acrylamide   0.75 ml 
0.5 M Tris pH 6.8   1.25 ml 
10% SDS    50 µl 
dH2O     2.9 ml 
10% APS    50 µl 
TEMED    3 µl 
 
Resolving gels (10%): 
30% Acrylamide   3.3 ml 
1.5 M Tris pH 8.8   2.5 ml 
10% SDS    100 µl 
dH2O     4 ml 
10% APS    50 µl 
TEMED    5.5 µl 
According to manufacturer's (Bio-Rad, USA) instruction the eletrophoresis apparatus was 
assembled, and the resolving gel was poured into the glass plate sandwich. After the resolving 
gel was polymerized, the stacking gel was poured on top of the resolving gel.  The 150 µl of 
sample (firstly measure the protein concentration, see 2.8.2) with 75 µl loading buffer were 
incubated for 5 min at 95oC and cooled on ice for 1 min, then shortly centrifuged and loaded 
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into wells of gel and Rainbow protein marker (Amersham, Germany) (2 µl Marker + 8 µl 
loading buffer) loaded as control. Gels should be run at about 20 V/cm gel length. 
 
2.12.2 Transfer membrane in "Semi-dry" electroblotter  
Transfer buffer (Semi-dry) 
5.8 g  Tris-base 
2.9 g  Glycine 
0.17 g  SDS 
200 ml  Methanol 
dissolved in 1 L dH2O.  
 
A PVDF-Membrane (Roth, Germany) and six blotting papers (GB004 Scheicher & Schuell, 
Germany) were incubated in 100% Methanol for 2 min, and washed three times (5 min/times) 
in dH2O, then equilibrated in the transfer buffer for 2-3 min. On the layer of 3 blotting papers 
the PVDF-Membrane was laid. The polyacrylamide gel and again 3 blotting papers were then 
placed on the PVDF-Membrane and made a "sandwich" (without any bubbles), and laid in 
"Semi-dry" Electroblotter (Scheicher & Schuell, Germany). The eletrophoresis power was set 
to 0.8 mA/cm2 for transfer. 
 
2.12.3 Antibody-incubation  
10x TBS (Tris Buffer Saline) 
24.2 g    Tris 
80 g   NaCl 
adjusted pH to 6.7 with HCl, filled to 1 L with dH2O. 1x TBS buffer was used for washing 
membrane and diluting antibody. 
1x TBST buffer 
100 ml   10x TBS 
900 ml   dH2O 
0.5 ml   Tween 20 
 
Blocking buffer 
5 g   nonfat dry milk  
100 ml   1x TBST 
1 ml   BSA 
The PVDF-Membrane was washed for 5 min in 1x TBST buffer after the transfer, then the 
membrane was blocked in the blocking buffer overnight. Next day the membrane was washed 
in for 5 min in 1x TBST buffer, then incubated in the first antibody solution (p-ERK 
monoclonal antibody, 1:500 dilution, Santa Cruz) for 1 h at room temperature. After washing 
three times (5 min/once) in 1x TBST buffer, the membrane was incubated with the second 
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antibody solution (horse radish peroxidase conjugated anti mouse monoclonal antibody, 
1:1000 dilution, Santa Cruz) for 1 h at room temperature.  
 
2.12.4 ECL-reaction 
As above washed three times (5 min/once) in 1x TBST buffer and washed once in 1x TBS 
again, the membrane was then incubated for 1 min in ECL (enhanced chemilu-minescence) 
solution (Amerham, Germany) between a glass plate and a clear plastic membrane. After 1 
min, everything was laid into a photo cassette, then a film (Bio Max Film MR1, Kodak) was 
placed on top of the membrane and exposed for 1.5 - 5 min. The film was then developed 
(Protec, Processor-Technology, Germany).  
In order to detect the ERK-2 protein, the attached antibody was striped from membrane by 
incubating with a 1:10 diluted strong stripping solution (Re-Blot Plus Western Blot Recycling 
Kit, Chemicon, Canada) for 30 min at room temperature. Then washed in 1x TBST buffer for 
5 min, the membrane was incubated with the ERK-2 monoclonal antibody (1:1000 dilution, 
Santa Cruz) solution for 1 h at room temperature. Subsequently the membrane was washed 
three times in 1x TBST buffer and washed once in 1x TBS, then incubated for 1 min in ECL 
solution and proceeded as above. 
 
2.13 RNase protection assay (RPA) 
This assay was performed by using three kits from Ambion company: MAXIscriptTM kit (in 
vitro transcription); RPAIIITM kit (ribonuclease protection assay); BrightStarTM BioDetectTM 
kit (Nonistopic detection kit). 
 
2.13.1 Synthesis of the biotin labeled probe  
Firstly, a pool of four nucleotides was prepared according the following procedure: four kinds 
of nucleotides were mixed and the final concentration of every nucleotide is 5 mmol/L. The 
ratio of unlabeled UTP and Biotin-16-UTP (Roche, Germany) is 2:1. (7.5 µl 100mmol/L 
ATP, 7.5 µl 100mmol/L CTP, 7.5 µl 100mmol/L GTP, 5 µl 100mmol/L UTP and 25 µl 
10mmol/L Biotin-16-UTP dissolved in 97.5 µl of RNase-free H2O). 
In order to perform RPA, the biotin labeled experimental probe and the biotin labeled positive 
control probe were synthesized by T7 polymerase in vitro transcription. Firstly, the plasmid 
pPCRII-TOPO-RPA was linearized by BsmBI and purified as mentioned (method 2.3.1), the 
linearized pTRI-actin-Mouse plasmid was provided by MAXIscriptTM kit for generating the 
positive control probe, then T7-transcription in vitro was done and the following reagents 
were added.  
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DNA (1 µg/µl)        1 µl  
10x transcription buffer (with DTT)     2 µl 
BSA (1 mg/ml)        2 µl 
dNTPs (10 mM)       2 µl 
RNasin (40U/ul)       0.5 µl 
(T7, T3, or SP6) Enzyme mix (T7 polymerase 15U/µl)   2µl 
DEPC H2O        10.5 µl 
The mixture was mixed by pipetting, and incubated for 1 h at 37°C. Then adding 1 µl DNaseI 
(10U/µl) and mixing well, the mixture was incubated again at 37°C for 30 min. 1µl of 0.5 M 
EDTA was added to stop reaction, the probe was then purified by on a 6% denaturing 
polyacrylamide gel, from which the according bands were isolated.  
 
2.13.2 Gel purification of probe  
The RNA mixture was mixed with an equal volume of Gel Loading Buffer II (total 42 µl) and 
heated 3 min at 95oC. 12 µl and 32 µl of the mixture (transcription mixture and the Gel 
Loading Buffer II) were loaded separately into two freshly-rinsed wells of a 6% denaturing 
polyacrylamide gel. This gel was run in the eletrophoresis apparatus (Bio-Rad, USA) for 
about 1 h at 120 volts until the bromophenol blue was approaching the bottom of the gel. 
Subsequently the gel was cut into two parts and one part including the 12 µl sample was 
stained by ethidium bromide. After staining, a thin plastic membrane was placed on the top of 
the gel and the band was visualized by UV light, then the position of the probe band, the 
position of the bromophenol blue and the scope of gel could be circled with Marker pen on 
the plastic membrane. When the plastic membrane was placed on the another part of the gel 
(not stained and including the 32 µl sample) according to the position of the bromophenol 
blue and the scope of gel, the probe area of the gel indicated by the circled region on the 
plastic membrane was excised with new scalpel, transferred to an RNase-free microfuge tube, 
and submerged in 350 µl of probe elution buffer (provide by the Ambion MAXIscriptTM in 
vitro transcription kit). This tube containing the gel piece was incubated at 37°C overnight, 
then the gel pieces were removed and the amount of biotin labeled probe was determined by 
the measurement of the absorbance at two wavelengths, 260 nm and 280 nm, in a 
spectrophotometer (Pharmacia Sweden). Pure RNA should have an OD 260/280 ratio of 
approximately 2.0. The amount of RNA can be calculated by the following formula, 
µg/ml RNA = OD260 ´ dilution factor ´ 40 
The labeled probe was stored at -20°C or -70°C. 
 
2.13.3 RNA preparation and purification 
5 µg pPolI-HHR-CAT2.1#3 was transfected into Vero and BDV infected Vero cells 
separately according to method 2.6.1. After three days of transfection, RNA was prepared 
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from the transfected cells with Qiagen RNeasy kit, then RNA was digested by RQ1 to remove 
the DNA contamination. The following reagents were added: 
 
RNA (1µg/µl)     40 µl 
RQ1 10x reaction buffer  20 µl 
RQ1 enzyme (1U/µl)   80 µl  
RNasin (40U/µl)   4 µl 
DEPC H2O    56 µl 
After incubation for 1 h at 37oC, 20 µl of stop buffer (provided by Promega with RQ1 
enzyme) was added and mixed, then incubated for 10 min at 65oC. Phenol/cholorform was 
used to purify the digested RNA sample, then direct PCR (control) was performed by using 
the digested RNA as template and specific CAT primers (CAT29-52 Fw/CAT612-589 Bw). 
When the PCR results were negative, the digested RNA could be used for RPA hybridization. 
If they were positive, the RNA sample has to be digested again by RQ1 as above, until the 
PCR results were negative.  
 
2.13.4 Hybridization and RNase digestion of probe and sample RNA 
This step was performed according to standard hybridization procedure of the instruction 
manual of RPAIIITM Kit of Ambion. 40 µg of digested RNA sample from Vero and BDV-
Vero cells respectively was used for hybridization. 
 
Tube  Sample RNA    Amount probe  RNase dilution 
 1  40 µg BDV-Vero   2400 ng  1:100 
 2  40 µg Vero     2400 ng  1:100 
 3  2 µg Yeast RNA   2400 ng  1:100 
 4  10 µg Mouse liver RNA  600 ng   1:100 
 5  2 µg Yeast RNA   2400 ng  No RNase 
 
Briefly, sample RNA and labeled probe were mixed according to 600 pg probe per 10 µg total 
RNA. Two controls were set up for the experimental probe: 2 µl Yeast RNA was mixed with 
2400 ng of the experimental probe (tube 3, 5). 5 M NH4OAc supplied with the RPAIIITM kit 
was used to adjust the mixture (RNA sample and probe) concentration of NH4OAc to 0.5 M, 
then 2.5 volumes of EtOH was added and mixed thoroughly for co-precipitating the probes 
and sample RNAs. The tubes were placed in -20oC for at least 15 min, then the RNAs were 
pelleted by centrifuging at 13000 rpm in a microcentrifuge for 15 min at 4oC. The supernatant 
was discarded and pellets were washed with 70% EtOH once, then pellets were dried for 5 
min on the bench. Pellets were resuspended in 10 µl hybridization buffer provided by the 
RPAIIITM kit  and the tubes were incubated for 3 - 4 min at 90 - 95oC. The tubes were then 
centrifuged briefly at low speed to collect the liquid at the bottom of the tube, then the tubes 
were incubated overnight at 42oC (16 -18h).  
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After hybridization, 150 µl of the diluted RNase mixture (the 6µl of RNaseA/T1 was added to 
600 µl of RNase Digestion III buffer and mixed very well) was added to every tube except for 
tube #5 (only the 150 µl of the RNase Digestion III buffer without RNaseA/T1 was added). 
This "no" RNase control tube will serve as a control for probe integrity. The tubes were 
incubated for 30 min at 37oC, then 225 µl RNase Inactivation/Precipitation III solution was 
added and vortexed, and these tubes were incubated for at least 15 min at -20oC. 
Subsequently, these tubes were centrifuged at 13000 rpm in a microcentrifuge for 15 min at 
4oC. All supernatant was carefully removed from each tube, pellets were washed with 70% 
EtOH once, then pellets were dried in air for 5 min. 
  
2.13.5 Separation and detection of protected fragments 
After hybridization and RNase digestion, the precipitated sample was resuspended 4 µl 
RNase-free water. 4 µl gel loading buffer provied by the RPAIIITM kit was added to every 
tube and every tube was incubated for 3 min at 90-95°C, then the samples were loaded into 
wells of a 6% denaturing polyacrylamide gel. Gel should be run at about 120 V constant 
voltage for 1 h, then electroblotting from polyacrylamide gel was performed according to the 
protocol provided by nonisotopic detection kit of Ambion. Briefly, a positively charged nylon 
(PCN) membrane (Ambion, Germany) and six blotting papers (GB004 Scheicher & Schuell, 
Germany) were wetted in 0.5x TBE. On the layer of 3 blotting papers the PCN membrane was 
laid. The polyacrylamide gel and again 3 blotting papers were then placed on the PCN 
membrane and made a "sandwich" (without any bubbles), and laid in "Semi-dry" 
Electroblotter (Scheicher & Schuell, Germany). The eletrophoresis power was set to 0.8 
mA/cm2 for transfer. Electroblotting was run for 1 h. Then UV crosslinking was done 
according the manufacturer's recommendation (UV Stratalinker 2000, Stratagene). That is, the 
membrane, which was removed from the sandwich, should be kept wet and exposed under the 
UV of 1.2 millijoules twice, then the protected bands were detected by using BrightStarTM 
BioDetectTM kit (Ambion USA). 
In the detection procedure, all incubations should be done at room temperature with constant, 
gentle agitation in containers that allow free movement of the membrane and the membrane 
must remain wet throughout the procedure. The wash buffer, blocking buffer, Strep-Alkaline 
Phosphatase, the assay buffer and CDP-Star solution are all provided by BrightStarTM 
BioDetectTM kit. 
After UV crosslinking, the membrane was washed with 1x wash buffer twice (5 min in 1 ml 
wash buffer/ cm2 membrane/wash), then the membrane was incubated in blocking buffer 
twice (5 min in 0.5 ml blocking buffer/cm2 membrane/incubation). Subsequently, the 
membrane was incubated in blocking buffer for 30 min (1 ml blocking buffer/cm2  
membrane), then the membrane was incubated in diluted Strep-Alkaline Phosphatase (Strep-
AP) for 30 min (1 µl Strep-AP was added to 10 ml blocking buffer and mixed thoroughly). 
After incubation in diluted Strep-AP, the membrane was incubated in blocking buffer for 15 
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min (0.5 ml blocking buffer/cm2 membrane), then washed in 1x wash buffer twice (15 min in 
1 ml wash buffer/ cm2 membrane/wash). The membrane was incubated in 1x assay buffer 
twice (2 min in 0.5 ml 1x assay buffer/cm2 membrane/incubation), then incubated in 4 ml of 
CDP-Star solution for 5 min. Subsequently, the membrane was laid on a piece of filter paper 
to remove excess CDP-Star, without letting the membrane dry. The membrane was wraped in 
a single layer of plastic and laid into a photo cassette, then a film was placed on the membrane 
and exposed for 1 h at the beginning. The film was developed (Protec, Processor-Technology, 
Germany). An appropriate time was determined for exposures, until an optimal image was 
obtained. 
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Results 
 
1 AIV 
1.1 Testing the expression vector pBD 
The expression vector pBD (kindly provided by Dr. Kanta Subbarao, influenza Branch, CDC, 
USA) includes the human cytomegalovirus (CMV) promoter for mRNA expression, the 
human RNA polymerase I promoter for v/cRNA expression, hepatitis delta virus (HDV) 
ribozyme and two SapI cloning sites (Figure 9). It was important for me to compare the ability 
of CMV promoter and human RNA polymerase I promoter of this vector expressing the 
reporter CAT gene, because this plasmid was to be used to clone the cDNAs of the eight 
RNA-segments of an avian influenza virus (A/Goose/Guangdong/1/96 (H5N1)) to establish a 
reverse genetic system. Therefore the reporter plasmid pBD-CAT was constructed which 
contains the CAT open reading frame in positive sense, flanked by the 3' and 5' noncoding 
regions of the NS-RNA segment of influenza virus A/Goose/Guangdong/1/96 (H5N1) (Figure 
10). At the same time the CMV promoter was partially deleted to construct the plasmid pBD-
CAT(-CMV) (Figure 10) to test the functionality of the Pol I promoter of pBD.  
CAT-assays were performed to test the functionalities of the RNA Pol I and Pol II promoter. 
Although CAT protein was expressed by transfection of pBD-CAT(-CMV), the amount of 
CAT protein was almost equal to the amount of a 1/100 dilution of a sample from pBD-CAT 
transfected cells (Figure 11). This could be due to residual activity of the truncated CMV-
promoter (Figure 10).  
In order to test the functionality of the Pol I promoter, five plasmids were cotransfected into 
293T cells. Four helper plasmids (pHMG- PB1, -PB2, -PA and -NP, which were kindly 
provided by HDoz Dr. S. Pleschka) were used to express the PB1, PB2, PA and NP proteins 
of influenza virus A/PR/8/34 under the control a mouse hydroxymethylglutary-coenzyme A 
reductase promoter (HMG). pPolI-CAT-RT(-), which was also kindly provided by HDoz Dr. 
S. Pleschka, contains CAT open reading in negative polarity flanked by the noncoding regions 
of the NS gene of influenza A/WSN/33 virus (161). The transfection of all five plasmids into 
293T cells led to the expression of CAT protein, as shown in Fig. 12. This indicated that a 
negative-sense RNA synthesized from the pBD-CAT(-CMV) as from the pPolI-CAT-RT(-) 
was reconstituted intracellularly into functional RNPs with the polymerase subunits and the 
NP provided in trans from the helper plasmids. These RNAs were then transcribed by the 
reconstituted viral RNA polymerase into mRNA, which was translated into CAT protein. 
Transfection of only the pBD-CAT plasmid led to a strong CAT-activity due to the active Pol 
II (CMV) promoter (Figure 12). The result of the pBD-CAT(-CMV) with the helper plasmids 
tranfection demonstrated that the Pol I-transcript can only be replicated/transcribed by the 
viral RDRP. The CAT-assay results shown that both promoters were functional (Figure 11 
and 12).  
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Figure 9: Schematic diagram of the vector pBD. The cDNA of each of the eight influenza 
segments was inserted into the SapI sites. The Pol I transcription unit  (Pol I promoter and 
HDV-Rib) is flanked by the Pol II promoter (CMV) of the human cytomegalovirus and a 
polyadenylation signal (T) of the gene encoding the bovine growth hormone. After 
transfection, negative-sense vRNA is synthesized by cellular RNA polymerase I from the Pol 
I promoter. Transcription by Pol II (CMV) yields mRNAs. 
 
 
 
 
 
 
 
 
 
 
Figure 10: Schematic diagram of the pBD-CAT and pBD-CAT(-CMV). The reporter gene 
CAT, flanked by the 3' and 5' noncoding regions of the NS-RNA segment of influenza virus 
A/Goose/Guangdong/1/96 (H5N1), was inserted between the Pol I promoter and HDV-
ribozyme. After tranfection of pBD-CAT, two types of molecules are synthesized (mRNA 
from Pol II promoter and vRNA from Pol I promoter) as indicated. Pol II (CMV) promoter 
was deleted (but not completely as indicated) in order to test the functionality of Pol I 
promoter by CAT-assay. 
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 Figure 11: CAT expression in 293T cells transfected with pBD-CAT or pBD-CAT(-
CMV). Approximately 106 adherent 293T cells were transfected with 5 µg pBD-CAT or 
pBD-CAT(-CMV) using plus reagent and lipofectamine reagent (Invitrogen) according to the 
manufacturer's instruction. Cell extracts were prepared and 50 µl samples were used for CAT-
assay. pBD-CAT transfected 293T cells, cell extracts were diluted as indicated (ud; 1/10; 
1/100) for CAT-assay. pBD-CAT(-CMV) transfected into 293T cells and cell extract were 
used undiluted for CAT-assay. "ud" means undiluted.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: CAT expression in 293T cells tranfected with different plasmids 
combinations. Lane 1, 2, 3: 1.4 mg  of pPolI-CAT-RT(-), cotransfected into 293T cells on 35 
mm diameter dishes together with 3.6 mg of a DNA mixture of pHMG- PB1, -PB2, -PA and -
NP as positive control (the ratio of PB1: PB2: PA: NP always was 1:1:1:2). Lane 4, 5, 6: 1.4 
mg  of pBD-CAT(-CMV) were cotransfected into 293T cells together with 3.6 mg of a DNA 
mixture of pHMG- PB1, -PB2, -PA and -NP. Lane 7, 8, 9: 5 µg of pBD-CAT transfected into 
293T cells. Cell extracts of every transfection was diluted as indicated (ud; 1/10; 1/100) for 
CAT-assay.  
u
d 
1/10 1/100 ud 
pBD-CAT pBD-CAT(-CMV) 
ud        1/10      1/100        ud         1/10      1/100       ud        1/10     1/100   
1          2             3           4             5            6           7            8           9 
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2.1 Construction of pBD-PB1, -PB2, -PA, -NP, -HA, -NA, -M, -NS 
In order to establish a reverse genetic system of an avian influenza virus 
(A/Goose/Guangdong/1/96 (H5N1)), I used the  POLI-POLII system. Therefore I have cloned 
the complete cDNAs of the eight segments of the strain A/Goose/Guangdong/1/96 (H5N1) 
into the expression vector pBD according to the method and materials. The newly constructed 
plasmids are pBD-PB1, -PB2, -PA, -NP, -HA, -NA, -M, -NS. Every plasmid was identified 
by restriction enzymes digest (Figure 13) and was sequenced. The sequence results showed 
that only one nucleotide (G549A) of the NS gene was different compared to the original 
sequence of NS gene (the original sequence refers to sequences of the eight segments of the 
strain A/Goose/Guangdong/1/96 (H5N1) that were sequenced by National Avian Influenza 
center, Harbin Veterinary Research Institute, CAAS, China) and the genebank 
A/Goose/Guangdong/1/96 (H5N1) NS sequence (AF144307), and led to an NS1 protein with 
an AA difference Glu175Lys. There were two nucleotide (G592A, A690G) differences in the 
M gene compared to the original M sequence and A/Goose/Guangdong/1/96 (H5N1) M 
sequences from the genebank (AF144306). This resulted in AA changes Met189IIe and 
His222Arg in the M1 protein. Only one nucleotide (G51A) of the NA gene was different 
compared to the original sequence of the NA gene and A/Goose/Guangdong/1/96 (H5N1) NA 
sequence from the  genebank (AF144304), and led to the AA difference Gly11Arg. There was 
no difference in the complete HA gene. The polymerase genes (PB1, PB2 and PA) and NP 
gene were not completely sequenced, as a functional assay was performed to prove that they 
are correct (Result 1.3).  
 
1.3 Testing the cloned polymerase genes and NP gene  
Unlike positive-strand RNA viruses, the negative-sense viral RNAs of influenza viruses are 
not infectious. Only vRNA molecules encapsidated with the NP and three polymerase 
proteins (PB1, PB2, PA) to form RNPs are able to initiate a viral replication and transcription 
cycle. So pBD-PB1 (pBD-PB2, -PA or -NP) can be cotransfected into 293T cells in 
combination with the functional helper plasmids (pHMG-PB2, pHMG-PA and pHMG-NP, 
pPolI-CAT-RT(-)) (161) respectively, then CAT-assays were done to test the functionality of 
the cloned polymerase genes and the NP gene. For example 1.4 mg pPolI-CAT-RT(-) was 
cotransfected into 293T cells on 35 mm diameter dishes together with 3.6 mg of the four 
helper plasmids (pBD-PB1 (avian influenza), pHMG-PB2, pHMG-PA and pHMG-NP 
(human influenza: A/PR/8/34), the ratio of the four plasmids is pBD-PB1: pHMG-PB2: 
pHMG-PA: pHMG-NP = 1:1:1:2) using lipofectamine and Plus Reagent on adherent cells. 
Furthermore three transfections were done to test functionality of the other avian influenza 
virus three genes (Figure 14). As positive control a transfection (pHMG-PB1, pHMG-PB2, 
pHMG-PA, pHMG-NP and 1.4 mg pPolI-CAT-RT(-)) was done, as a negative control only 
pPolI-CAT-RT(-) was transfected. 48 h after transfection, samples were prepared and CAT-
assays were performed. The results showed that the new plasmids expressing the avian 
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influenza virus polymerase protein and the NP protein are functional (Figure 14). Then the 
four newly constructed plasmids together with pPolI-CAT-RT(-) were cotransfected into 
293T cells and a CAT-assay was performed in order to compare the CAT expression by the 
newly constructed plamids with the helper plasmids expressing the genes of the human 
influenza virus as a positive control. The negative control were done as described above. 
These results showed that the CAT amount expressed by the POLI-POLII system was higher 
compared to system that uses separated promoter: the POLI for vRNA and the PolII for the 
PB1, PB2, PA and NP proteins (Figure 15). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Characterization of pBD-PB1, -PB2, -PA, -NP, -HA, -NA, -M, -NS by 
restriction enzyme digest. Different restriction enzymes were used to digest the constructed 
plasmids for identification. Lane 1: pBD-PB1 was digested by EcoR I, (1603 nt and 5086 nt); 
Lane 2: pBD-PB2 by BamH I, (2006 nt and 4683 nt); Lane 3: pBD-PA by BamH I, (1506 nt 
and 5074 nt); Lane 4: pBD-NP by XbaI (1907 nt and 4006 nt); Lane 5: pBD-HA by NdeI 
(2466 nt and 3661 nt); Lane 6: pBD-NA by HindIII (1851 nt and 3955 nt); Lane 7: pBD-M by 
XbaI (1369 nt and 4006 nt); Lane 8: pBD-NS by XbaI (1232 nt and 4006 nt). All digest 
showed the expected bands. 
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Figure 14: Testing the functionality of the cloned polymerase genes and the NP gene by 
CAT-assay. Different combinations of plasmids were made to transfect 293T cells. 
Independent of the expression vectors used (pHMG or pBD), the ratio of PB1: PB2: PA: NP 
always was 1:1:1:2. These four plamids were mixed according to the ratio. 5 mg DNA in total 
was used for every transfection. 3.6 mg of DNA mixture of the PB1, PB2, PA and NP 
plasmids was cotransfected into 293T cells on 3.5 mm diameter dishes together with 1.4 mg  
of pPolI-CAT-RT(-). 1. pHMG-PA, -PB1, -PB2, -NP + pPolI-CAT-RT(-); 2. pBD-PA, 
pHMG-PB1,-PB2,-NP + pPolI-CAT-RT(-); 3. pBD-PB1, pHMG-PA,-PB2,-NP + pPolI-CAT-
RT(-); 4. pBD-PB2, pHMG-PA,-PB1,-NP + pPolI-CAT-RT(-); 5. pBD-NP, pHMG-PB1,-
PB2, -PA + pPolI-CAT-RT(-); 6. pPolI-CAT-RT(-). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: Comparison of CAT expression in 293T cells transfected with pPolI-CAT-
RT(-) and pHMG expression vectors of the influenza virus A/PR/8/34 genes (PB1, PB2, 
PA and NP), and pBD expression vectors of the avian influenza virus 
A/Goose/Guangdong/1/96 (H5N1) genes (PB1, PB2, PA and NP). The ratio of PB1: PB2: 
PA: NP is 1:1:1:2. 1. pHMG-PB1, -PB2, -PA, -NP + pPolI-CAT-RT(-); 2. pBD-PB1,-PB2, -
PA, -NP + pPolI-CAT-RT(-); 3. pPolI-CAT-RT(-).  
1              2                  3 
1           2            3           4          5          6 
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1.4 Generation of reassortant avian influenza virus  
In order to prove that the eight plasmids encoding the genes of the avian influenza strain 
A/Goose/Guangdong/1/96 (H5N1) are functional, I tried to rescue reassortant viruses using 
the genetic background of the avian influenza strain A/FPV/Rostock/34 (H7N1) (this strain is 
also a pathogenic avian influenza virus that is used regularly in the laboratory) with one gene 
of A/Goose/Guangdong/1/96 (H5N1). Because the plasmids including the genes of the strain 
A/FPV/Rostock/34 (H7N1) (provided by R. Wagner, Marburg) are controlled only by the 
RNA polymerase I promoter, the helper plasmids (pHMG-PA, -PB1, -PB2, -NP) must be 
used to express the polymerase proteins and NP to generate the biological active RNPs 
(Figure 16). To obtain reassortant viruses, 12 plasmids were transfected into confluent 293T 
cells (Figure 16). I have substituted the PB1, PB2, PA, NP, HA, NA, M and NS gene of 
A/FPV/Rostock/34 (H7N1) by the according genes of the A/Goose/Guangdong/1/96 (H5N1) 
respectively to generate a reassortant virus, but only the wild-type A/FPV/Rostock/34 (FPV) 
virus and a reassortant virus (GD1NSFPV) which carries the A/Goose/Guangdong/1/96 
(H5N1) NS gene and the other 7 genes of FPV were successfully rescued. The rescued viruses 
were then purified by three plaque passages on MDCK cells. 
 
1.5 Identification of reassortant virus by RT-PCR  
The reassortant virus obtained in the rescue experiment was analyzed by RT-PCR of the viral 
RNA to confirm that the NS-segment is from A/Goose/Guangdong/1/96 (H5N1). The isolated 
RNAs from the supernatants of cultured cells infected by wild-type and reassortant virus were 
treated by DNaseI to remove residual DNA and purified by phenol/chloroform extraction. 
Half of the RNA was used as a template for RT reaction with Flu RT-primer for the RT of 
influenza viral RNA, the other half was used as a template for direct PCR (control) with a pair 
of NS-specific primers (NS-RT Fw/NS-RT Bw). PCR products were subjected to restriction 
analysis with endonucleases and analyzed by agarose gel electrophoresis.  With the RNA of 
wild-type and reassortant virus, the RT-PCRs  yielded products of about 890 nucleotides. The 
RT-PCR product of the NS-RNA of the reassortant virus was sensitive to HaeIII (after 
digestion, about 523 nt and 367nt bands should be generated), whereas no cleavage occurred 
when the RT-PCR product of wild-type NS-segment of FPV virus digested (Figure 17). 
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Figure 16: Reverse genetics method for the generation of wild and reassortant avian 
influenza viruses. Plasmids containing the RNA plymerase I promoter, a cDNA for each of 
the eight viral RNA segments of the strain A/FPV/Rostock/34 (H7N1), and RNA polymerase 
I terminator are transfected into 293T cells together with plasmids expressing PA, PB1, PB2 
and NP proteins (pHMG-PA, -PB1, -PB2, -NP). To generate the reassortant virus, the NS 
gene of the strain A/FPV/Rostock/34 (H7N1) was substituted by the NS gene of the strain 
A/Goose/Guangdong/1/96 (H5N1).   
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Figure 17: RT-PCR of RNA isolated from wild-type FPV and reassortant virus 
(GD1NSFPV). RT-PCR products were incubated with HaeIII as indicated and separated on 
an agarose gel. Direct PCR was done with the RNA as templates or ddH2O was used as RT-
PCR control. Lane 6: the RNA of wild-type FPV; Lane 7: the RNA of GD1NSFPV; Lane 8: 
RT-PCR control. 
 
1.6 Growth of reassortant virus in cell culture  
It was of great interest to see how both viruses (wild-type FPV and reassortant avian influenza 
virus GD1NSFPV) replicate in cells. Therefore MDCK cells were infected at an MOI of 
0.001 by wild-type FPV and reassortant GD1NSFPV viruses respectively to allow multicycle 
replication, supernatants were monitored for HA titers and plaque assay at different time 
points. The HA titers showed that the reassortant GD1NSFPV growed apparently faster than 
the wild type FPV (Figure18). The studies on the growth characterics were also performed by 
plaque assay on MDCK monolayers. Results obtained by this approach indicated that the 
number of plaque- forming units (PFU) formed by the reassortant GD1NSFPV was more than 
40 fold higher than by the wild-type FPV (Figure 19). Moreover, the plaques formed by the 
reassortant GD1NSFPV were larger than those formed by the wild-type FPV (Figure 20). 
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Figure 18: Growth curves of wild-type FPV and reassortant GD1NSFPV. MDCK 
monolayers were infected at an MOI of 0.001 with wild-type FPV and reassortant 
GD1NSFPV respectively, and supernatants were monitored for HA titers at the time points 
indicated. 
 
 
Figure 19: Growth curves of the wild-type FPV and the reassortant GD1NSFPV. MDCK 
monolayers were infected at an MOI of 0.001 with wild-type FPV and reassortant 
GD1NSFPV, and the supernatants were monitored for plaque assay (PFU) at the time points 
indicated. 
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                         GD1NSFPV       FPV 
Figure 20: Comparison of plaques formed by wild-type FPV and reassortant 
GD1NSFPV. Plaques formed by the reassortant GD1NSFPV virus were larger than those 
formed by the wild-type FPV as indicated.  
 
1.7  Interferon-ß (IFN-ß) induction in cells infected with wild-type FPV and reassortant 
GD1NSFPV 
IFN synthesis is one of the early responses of the host against viral infection. Previous  studies 
shown that an influenza virus with a deletion in the NS1 gene, delNS1 virus, can only 
replicate efficiently in an IFN-deficient system, suggesting that the NS1 protein of influenza 
virus inhibits the IFN system of the host (65, 218). As the reassortant virus that differs from 
the wild-type FPV only by the NS-segment grows to significantly higher titer and forms 
bigger plaques, I investigated the IFN-ß responses through the induction of the IFN-ß reporter 
plasmid in response to infection by both viruses. The results showed that the induction of the 
IFN promoter dependent reporter (luciferase gene is controlled by IFN-ß promoter) by the 
wild-type FPV was much higher (about three folds) than by the reassortant GD1NSFPV 
(Figure 21). 
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Figure 21: The induction of the IFN dependent reporter by the wild-type FPV and 
reassortant GD1NSFPV virus. MDCK cells were transfected with 100 ng of the IFN-ß 
promoter luciferase reporter plamids pIFN-Luci. After 24 h, cells were mock infected or 
infected with the wild-type FPV or the reassortant GD1NSFPV virus at an MOI of 1.  Cell 
extracts were prepared at 4 h postinfection in cell lysis buffer (Promega) and assayed for 
luciferase activity. For a comparison mock values were subtracted, and enzyme activity 
induced by wild-type FPV was set to 100%. Average values determined in four independent 
experiments are shown. 
 
1.8  Investigation of the Raf/MEK/ERK cascade activation between the wild type FPV 
and reassortant GD1NSFPV virus. 
The Raf/MEK/ERK cascade is the prototype of mitogen-activated protein kinase (MAPK) 
cascade and has an important role in cell growth, differentiation and survival (24, 46, 179). 
Growth factor- induced signals are transmitted by consecutive phosphorylation from the 
serine/threonine kinase Raf via the dual-specificity kinase MEK (MAPK kinase/ERK kinase) 
to ERK. Active ERK subsequently translocates to the nucleus to phosphorylate a variety of 
substrates and mediates changes in gene expression (179, 227). A variety of DNA and RNA 
viruses induce signaling via MAPK pathways in infected host cells, suggesting that these 
kinase cascade may play a functional role in virus replication (14, 22, 180). Pleschka et al. 
(163) have proved that this cascade is also activated by influenza virus, and signaling through 
the mitogen cascade seems to be essential for RNP export from the nucleus. As the reassortant 
GD1NSFPV differs from the wild type FPV in growth titer, I investigated whether this 
cascade is differently induced by the infection of wild type or reassortant influenza virus. The 
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results showed that both viruses induce MAPK-signaling, but there were no big difference in 
the activation Raf/MEK/ERK cascade by both viruses (Figure 22). 
 
 
 
 
 
 
 
 
 
 
Figure 22: FPV and GD1NSFPV induce activation of ERK in MDCK cells. MDCK cells 
were mock treated (Control), or infected with FPV or GD1NSFPV at an MOI of 5 and 
incubated for 6, 8, or 10 h as indicated. Cell lysates were separated by sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis and were blotted onto polyvinylidene difluoride 
membrane. The membrane was incubated with the first antibody (pERK monoclonal antibody 
for the detection of activated ERK) and a second antibody (horse radish peroxidase 
conjugated anti mouse monoclonal antibody). ECL was detected by a ECLTM Western 
blotting detection reagents kit (Amerham, Germany). ERK2 Western blots using an anti 
ERK2-antibody were analyzed to confirm equal loading of the kinases. The ECL results were 
visualized on X-ray films.  NP proteins was detected to control virus replication. 
 
1.9  Comparison of NS gene nucleotide and amino acid sequence of the strain 
A/FPV/Rostock/34 (H7N1) and A/Goose/Guangdong/1/96 (H5N1) 
The reassortant GD1NSFPV virus differs from the wild type FPV virus only in the NS-
segment, but the former grows to significantly higher titer and forms bigger plaques than the 
later. So I compared the NS gene nucleotide acid and amino acid (AA) sequences of the strain 
A/FPV/Rostock/34 (H7N1) with the strain A/Goose/Guangdong/1/96 (H5N1). The length of 
NS-segment of both viruses is 890 nt and encodes the NS1 and NS2 proteins due to splicing 
of the mRNA. The NS1 protein encoded by both viruses is 231 amino acids long, and the NS2 
protein encoded by both viruses is 122 amino acids long. NS1 is designated as nonstructural 
because it is synthesized in infected cells, but is not incorporated into virions (116). The NS1 
proteins of influenza A possesses two important functional domains: an RNA-binding domain 
near the amino-terminal end (amino acids 1-73) and an effector domain in the carboxyl half 
the molecule (amino acids 74-231) (147, 168, 169) furthermore the binding domains are 
conserved to different extents among influenza A and B viruses (234). The binding domain 
specifically binds to the RNA poly(A), U6 snRNA and double-stranded (ds) RNA, and the 
activation of PKR kinase is blocked by NS protein binding to dsRNA (see discussion). The 
effector domain of the NS1 protein is required for the inhibition of the nuclear export of the 
poly(A)-containing cellular mRNA and the inhibition of pre-mRNA splicing (128, 234) by 
pERK 
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binding and inhibiting the function of two cellular proteins. These two proteins, that are 
required for the 3’-end processing of the cellular pre-mRNAs, are the 30 kDa subunit of the 
cleavage and polyadenylation specificity factor (CPSF) and the poly(A)-binding protein II 
(PABII) (32, 123, 142). The binding sites for the CPSF and PABII are near the carboxy end of 
the NS1 protein: the CPSF binding site is centered around amino acid 186 and the PABII 
binding site is located in the 223-237 amino acid region (123). Another study demonstrated 
that NS1 protein has a latent nuclear export signal (NES) that is located at the amino end of 
the effector domain (amino acids 134-147). This NES is inhibited by the adjacent 14 AA of 
the effector domain (amino acids 148-161) (124). In addition, the NS1 protein contains two 
nuclear localization signals (NLS) (Figure 23) (76),  it has been proved that NLS2 seems to be 
dispensable for the function of the NS1 protein in regulating the nuclear export of viral 
mRNA (168). The NS2 protein, which contains a nuclear export signal near the amino-
terminal end (amino acids 11-23) (149), mediates the nuclear export of viral RNPs. 
The NS1 gene of the strain A/FPV/Rostock/34 (H7N1) is only 69.7% identical to the NS1 of 
the strain A/Goose/Guangdong/1/96 (H5N1) at the nucleotide level, and only 69.3% at the 
AA level. In the RNA-binding domain (amino acids 1-73) of the NS1 protein of 
A/FPV/Rostock/34 (H7N1), there are seven continuous AA differences to NS1 protein of the 
strain of A/Goose/Guangdong/1/96 (H5N1). The differences are 21RFADQEMG28 to 
21LLSMRDMC28, and result in a change of hydrophilicity (Figure 23 and 24). There are eight 
AA different in the position 134 to 161 of the effector domain of NS1 protein between the 
strain A/FPV/Rostock/34 (H7N1) and the strain A/Goose/Guangdong/1/96 (H5N1), which 
also leads to a change of hydrophilicity (Figure 23 and 24). The conserved L at the position 
146 in the effector domain of NS1 protein of FPV, which is crucial for the function of both 
NS1 and HIV-1 Rev protein (137, 168) (HIV-1 Rev protein contains two functional domains 
(135) and facilitate the nucleocytoplasmic transport of unspliced and partially spliced viral 
mRNA (79, 136)), is changed to S in the according position of GDNS1FPV. The binding site 
for the CPSF (amino acid 184-188) among the two NS1 proteins of both viruses is completely 
conserved, but the binding site for the PABII between two NS1 proteins of both viruses is 
different (Figure 23). The NS2 gene of the strain A/FPV/Rostock/34 (H7N1) was 81.4% 
identical to the NS2 of the strain A/Goose/Guangdong/1/96 (H5N1) at the nucleotide level, 
and 82% at the amino acid level. Two amino acids (M14Q, G22E) were different in the NES 
of NS2 protein of the stain A/FPV/Rostock/34 (H7N1) compared to the NS2 protein of the 
strain A/Goose/Guangdong/1/96 (H5N1) (Figure 25). 
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FPVNS1     1 M D S N T V S S F Q V D C F L W H V R K R F A D Q E M G D A P F L D R L R R D Q  
GD1NS1     1 M D S N T I T S F Q V D C Y L W H I R K L L S M R D M C D A P F D D R L R R D Q  
 
 
FPVNS1    41 K S L R G R G S T L G L D I D T A T R V G K Q I V E R I L E D E S D E A L K M T  
GD1NS1    41 K A L K G R G S T L G L D L R V A T M E G K K I V E D I L K S E T N E N L K I A  
 
FPVNS1    81 I A S V P A T R Y L T D M T L E E M S R D W F M L M P K Q K V A G S L C I R M D  
GD1NS1    81 I A S S P A P R Y I T D M S I E E M S R E W Y M L M P R Q K I T G G L M V K M D  
 
 
FPVNS1   121 Q A I M G K N I I L K A N F S V I F D R L E T L I L L R A L T D E G A I V G E I  
GD1NS1   121 Q A I M D K R I I L K A N F S V L F D Q L E T L V S L R A F T E S G A I V A E I  
 
 
FPVNS1   161 S P L P S L P G H T D E D V K N A I G V L I G G L E W N D N T V R V S E T I Q R  
GD1NS1   161 S P I P S V P G H S T E D V K N A I G I L I G G L E W N D N S I R A S E N I Q R  
 
 
FPVNS1   201 F A W R S S N E N G G P P L P P K Q K R K M A R T I E S E I  
GD1NS1   201 F A W G I R D E N G G P S L P P K Q K R Y M A K R V E S E V  
 
 
Figure 23: Comparison of the NS1 protein of the strain A/FPV/Rostock/34 (H7N1) 
(FPVNS1) and A/Goose/Guangdong/1/96 (H5N1) (GD1NS1). Identical amino acids are 
marked by black color, and the position 19-38 of RNA-binding domain and the position 134-
161 of effector domain are outlined in blue rectangles. The two nuclear location signals are 
indicated by red rectangles. The binding sites for the CPSF and for the PABII are outlined in 
green rectangles. 
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Figure 24: Comparison of hydrophilicity and hydrophobicity of the NS1 protein of the 
strain A/FPV/Rostock/34 (H7N1) and A/Goose/Guangdong/1/96 (H5N1). This analysis 
was done by the Protean of DNASTAR software (DNASTAR, Inc. USA). This method 
predicts regional hydropathy of proteins from their amino acid sequences, using the approach 
of Kyte and Doolittle (1982). Hydropathy values are assigned for all amino acids and are then 
averaged. The average is plotted as shown. The value of nine residues is averaged in this 
analysis. If the value is more than 0, it means hydrophilicity. If the value is less than 0, it 
means hydrophobicity. The position 19-38 in the RNA-binding domain (bd) and the position 
134-161 in the effector domain (ed) are shown. The hydrophilicity is apparent different in the 
position 19-38 in the RNA-binding domains and also little different in the position 134-161 in 
the effector domains  of both NS1 proteins.  
 
GD1NS2    1 M D S N T I T S F Q D I L Q R M S K M Q L E S S S V D L N G M I T Q F E R L K I  
FPVNS2    1 M D S N T V S S F Q D I L M R M S K M Q L G S S S E D L N G M I T Q F E S L K L  
 
 
GD1NS2   41 Y R D S L G E S V M R M G D L H S L Q N R N A T W R N E L S Q K F E E I R W L I  
FPVNS2   41 Y R D S L G E A V M R M G D L H S L Q S R N G K W R E Q L S Q K F E E I R W L I  
 
 
GD1NS2   81 A E C R N I L T K T E N S F E Q I T F L Q A L Q L L L E V E S E I R T F S F Q L  
FPVNS2   81 E E V R H R L K I T E N S F E Q I T F M Q A L Q L P L E V E Q E I R T F S F Q L  
 
 
GD1NS2  121 I 
FPVNS2  121 I 
 
Figure 25: Comparison of the NS2 protein of the strain A/FPV/Rostock/34 (H7N1) 
(FPVNS2) and A/Goose/Guangdong/1/96 (H5N1) (GD1NS2). Identical amino acids are 
marked by black color, and the nuclear export signals (NES) is outlined with a blue rectangle.  
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2.   BDV 
2.1 Plasmids construction 
Pleschka et al. proved the existence of an additional "A" residue at the extreme 3' end of the 
single-strand genomic RNA of BDV (162) and that a terminal "U" residue is probably found 
at the 5' end. The result is very important because correct structures of the genome ends are 
most critical parameters for the development of reverse genetics techniques that permits the 
genetic manipulation of BDV. To generate a primary RNA transcript in vivo that can be 
replicated by the viral polymerase, I used the Pol I-system, because RNA polymerase I is an 
abundant nuclear enzyme which transcribes ribosomal RNA, that doesn't contain 5'-cap or 3'-
poly(A) structures. Moreover RNA polymerase I initiates and terminates transcription at 
defined promoter and terminator sequences. Therefore Pol I-transcripts resemble viral 
genomic RNAs and can be replicated by viral polymerases (146). As the Pol I normally does 
not readly incorporate an "U" as the first residue (normally A or G as first residue; I, Grummt 
personal communication), I have generated new Pol I expression constructs (using the pPOLI-
BDVcCAT2.1SP#10 and pPOLI-BDVcCAT2.2SP#11 as the parental plasmids constructed by 
S. Pleschka) that express a transcript, that start with a hammerhead ribozyme (HHR) sequence 
(suggested by M. Schwemmle and cooperation with our laboratory) beginning with an "A" 
residue (Figure 26). The hammerhead ribozyme should cleave the transcript in cis to generate 
a new 5’-end that starts with the genomic "U" residue. The correct 3’-end of the transcript is 
assured by a hepatitis delta virus (HDV) ribozyme that also cleaves the transcript in cis 
generating the correct 3'-end of the transcript (Figure 27).  This technique is used to generate 
Pol I-transcripts with correct 3’-ends in the Pol I-system for reverse genetics of influenza (60, 
161). I used three versions of the HHR and developed three different constructs including the 
three HHR versions, because I could not estimate which version would be functional. I used 
the parental plasmids: (1) pPOLI-BDVcCAT2.1SP#10 and (2) pPOLI-BDVcCAT2.2SP#11. 
They contain the human RNA polymerase I promoter and terminator, HDV ribozyme and a 
CAT reporter gene in positive orientation. Only three nucleotides were changed in the anti-
genomic BDV 3'NCR of the (2) pPOLI-BDVcCAT2.2SP#11 compared to the (1) pPOLI-
BDVcCAT2.1SP#10. I have constructed six new plasmids (Figure 27) with a HHR expressing 
a CAT reporter gene RNA (in positive orientation) flanked by the BDV-NCR. They were 
controlled by restriction enzyme digest (Figure 28) and sequenced to assure the correct 
sequences. The sequence results showed that the inserted HHR sequences were exact. In total 
6 kinds of constructs (pPolIHHRCAT2.1#1, #2, #3; pPolIHHRCAT2.2#1, #2, #3) for the 
expression of the CAT gene from a Pol I-transcript, that should resemble a BDV-like genomic 
RNA, were successfully constructed. 
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Figure 26: Hammerhead Ribozyme. The Pol I-transcript should begin with a 5' "A" of the   
hammerhead ribozyme. Bold "a" 1, 2 & 3 are three alternative 5' ends. Red "guc" is the 
cleavage site of the hammerhead sequence. Green is the native Borna virus 5' end sequence 
(in DNA code) which should be released by hammerhead after self cleavage.   
 
 
 
 
 
 
 
 
 
 
Figure 27: Schematic diagram of the RNA polymerase I transcription plasmid with 
HHR and HDV-Ribozyme. The transcription by RNA polymerase I will begin with the first 
"A" of hammerhead sequence. The hammerhead ribozyme should cleave the transcript in cis 
to generate a new 5’-end that starts with the genomic "U" residue. The correct 3’-end of the 
transcript is assured by a HDV ribozyme that also cleaves the transcript in cis generating the 
correct 3'-end of the transcript. There are two nucleotide changes (C38A, G44C) in anti-
genomic BDV 3' NCR of the vector pPOLI-BDVcCAT2.2SP#11 compared to the pPOLI-
BDVcCAT2.1SP#10, the other parts of two vectors are completely the same. There are three 
versions of HHR, the length of them is 53 nt, 50 nt and 46 nt respectively. So the plasmids 
were named pPolIHHRCAT2.1#1, #2, #3; pPolIHHRCAT2.2#1, #2, #3.  
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Figure 28: Restriction analysis of the new constructed plsmids. The new constructed 
plasmids was identified by restriction enzyme digest (PshAI). All digests show the expected 
bands. Lane 1: pPolIHHRCAT2.1#1 (1055 nt and 2887 nt); Lane 2: pPolIHHRCAT2.1#2 
(1052 nt and 2887 nt); Lane 3: pPolIHHRCAT2.1#3 (1048 nt and 2887 nt); Lane 4: 
pPolIHHRCAT2.2#1 (1055 nt and 2887 nt); Lane 5: pPolIHHRCAT2.2#2 (1052 nt and 2887 
nt); Lane 6: pPolIHHRCAT2.2#1 (1048 nt and 2887 nt).  
 
 
2.2 Ribozyme assay 
2.2.1 Plasmid construction 
In order to prove that both ribozymes of the new constructs are functional in vitro, four 
plasmids (pcDNA3.1Ribo1s-p, pcDNA3.1Ribo1p, pcDNA3.1Ribo2 and pcDNA3.1Ribo3) 
were constructed for a ribozyme assay (Figure 29). These four plasmids were identified by 
different restriction enzymes digest, the results obtained by this approach showed that these 
four plasmids were successfully constructed  (Figure 30). 
 
 
 
 
 
 
 
 
 
M          1          2          3         4           5         6          M 
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Figure 29: Schematic diagram of four different constructions for a ribozyme assay. 
These constructs differ only in the length of different HHR version except for 
pcDNA3.1Ribo1s-p. The part between the T7 promoter and HHR#1 is a little shorter in 
pcDNA3.1Ribo1s-p than in the other three constructs (pcDNA3.1Ribo1p, pcDNA3.1Ribo2 
and pcDNA3.1Ribo3). HHR#1, HHR#2 and HHR#1 are 53 nt, 50 nt and 46 nt respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30: Plasmids identification by different restriction enzymes. All digest show the 
expected bands. Lane 1: pcDNA3.1Ribo1p digested by SmaI (2108 nt and 4379 nt); Lane 2: 
pcDNA3.1Ribo1s-p digested by NdeI (1335 nt and 5091 nt); Lane 3: pcDNA3.1Ribo2 
digested by MscI (1737 nt and 4747 nt); Lane 4: pcDNA3.1Ribo3 digested by NdeI (1393 nt 
and 5091nt). 
 
 
2.2.2 Ribozyme assay 
Briefly, the four plamids were linearized by restriction enzyme digest (XbaI), then T7-
transcriptions were performed in vitro. The RNAs obtained by T7-transcription were assayed 
for ribozyme reaction with the appropriate concentration of MgCl2 at 37oC for 30 min. 
Subsequently, the RNA was analyzed by the denaturing acrylamide gel eletrophoresis, then 
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the gel was stained with a silver nitrate solution. The results showed that both ribozymes 
cleave the primary transcript and generate the expected bands. Approximately 100 nt bands 
were generated by HDV ribozyme cleavage in all four constructs (pcDNA3.1Ribo1s-p, 
pcDNA3.1Ribo1p, pcDNA3.1Ribo2 and pcDNA3.1Ribo3) and 187 nt (pcDNA3.1Ribo1s-p), 
248 nt (pcDNA3.1Ribo1p), 245 nt (pcDNA3.1Ribo2) and 241 nt (pcDNA3.1Ribo3) bands 
were obtained by HHR cleavage respectively (Figure 31). Other bands were generated (Figure 
32), when ribozymes did not cleave completely. This results indicated that three versions 
HHR and HDV ribozymes were functional in vitro.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31: Self-cleavage analysis of the hammerhead ribozyme and the hepatitis delta 
virus ribozyme in vitro. Reaction products were separated on 5% PAGE, denaturing 8 M 
urea gels. Lane 1: pcDNA3.1Ribo1s-p; Lane 2: pcDNA3.1Ribo1p; Lane 3: pcDNA3.1Ribo2; 
Lane 4: pcDNA3.1Ribo3. 
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Figure 32: Self-cleavage analysis of the hammer head ribozyme and the hepatitis de lta 
virus ribozyme in vitro. Reaction products were separated on 2.8% PAGE, denaturing 8 M 
urea gels. Lane 1: pcDNA3.1Ribo1s-p; Lane 2: pcDNA3.1Ribo1p; Lane 3: pcDNA3.1Ribo2; 
Lane 4: pcDNA3.1Ribo3. 
 
2.3 Establishment of a Vero cell line infected by BDV H1766  
In order to prove that my constructed "mini-genome" Pol I-transcripts for BDV were 
functional, I performed transfections (Pol I plasmids transfected into Vero cells and into BDV 
infected Vero cells) and RT-PCR was used to prove that BDV polymerase can recognize and 
use the primary RNA transcript (PolI-transcript) for replication and transcription (Figure 33). 
The RT-PCR results obtained in the first experiments showed that the transcription results of 
Vero cells and BDV infected Vero cells were the same (about 590 nt band) (Figure 34). 
The results indicated that the control Vero cells were contaminated with BDV. This was 
confirmed by IFA (Figure 35). I had to use new Vero cells as a control that were not 
contaminated by BDV. The new Vero cells I received proved not to be contaminated by BDV 
in IFA (Figure 36), but the new Vero cells and the BDV infected Vero cells were from 
different laboratories and were different in growth speed. It was very difficult to control the 
amount of cells in order to control the condition for transfection for both cell lines. So I had to 
establish new Vero cells infected by BDV (strain H1766). I tried to use BDV H1766 to infect 
Vero cells directly, but this approach failed. I had to use BDV H1766 to infect the primary rat 
embryo brain (REB) cells, and then co-culture the BDV infected REB cells together with the 
new Vero cells (Figure 37). After two passages, the REB cells were dead and the Vero cells 
were infected by BDV H1766. I have proved that the new Vero cells were almost completely 
infected by BDV H1766 through in situ immunhistochemical BDV-detection (Figure 38) and 
IFA (Figure 39).   
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B: Transcript+HHR (I + II) 
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Figure 33: Mechanism of RT-PCR detection of BDV-specific replication intermediates 
from transfected BDV-infected Vero cells. Primary transcription (antigenomic orientation) 
will be done by cellular RNA polymerase I, then the primary transcript  will be used by BDV 
polymerase and replicated and transcribed. The genomic orientated transcript can only be 
generated when BDV polymerase uses the antigenomic primary transcript to initiate 
replication and transcription. So RT-PCR can be used to detect BDV-specific replication.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34: RT-PCR detection of BDV-specific replication intermediates from 
transfected Vero cells (BDV-infected and non-infected). pPolI-HHR-CAT2.1#1 was 
transfected into the BDV-infected and non-infected vero cells, then RNA was extracted from 
the cells. RNA was digested by DNaseI, then half of digested RNA was used for RT with the 
specific primer (CAT29-52) and subsequent PCR with a pair of CAT-specific primers 
(CAT29-52 Fw, CAT612-589 Bw), another part was used for direct PCR. About 590 nt bands 
should be obtained. PCR products were analyzed on gels. Lane 2, 4: RT-PCR; Lane 3, 5: 
PCR. Lane 1: RT-PCR control. Lane 5: PCR control. 
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Figure 35: Detection BDV by indirect immunofluoresces assay. BDV-Vero and Vero cells 
were stained with a mouse monoclonal antibody against BDV nucleoprotein (Bo18, 1:100 
dilution). Goat anti-mouse IgG fluorescein isothiocyanate (1:100 dilution) was used as 
secondary antibody. The typical nuclear staining showed (green) in BDV-Vero cells (x40). 
Part of vero cells were specifically stained in the nucleus. This indicated that Vero cells were 
contaminated by BDV.    
 
 
 
 
 
 
 
 
 
 
 
 
Figure 36: Testing new Vero cells by IFA. Marburg-vero and BDV-Vero cells were stained 
with a mouse monoclonal antibody against BDV nucleoprotein Bo18 (1:100 dilution)  and 
goat ant i-mouse IgG fluorescein isothiocyanate (1:100 dilution). The nucleus of Marburg-
Vero cells were not stained compared to the BDV-Vero cells (x40).  
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Figure 37: Co-cultivation of BDV H1766 infected REB cells with the Marburg-Vero 
cells. It is very difficult to infect the passaged cell lines (Vero cell) directly by BDV. BDV 
infection spreads by contact between infected cells and noninfected cells. Primary REB cells 
can be easily infected with BDV, therefore BDV infected primary REB cells were 
cocultivated with Vero cells. After two  passages, the infected REB cells (arrow indicated) 
were dead.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 38: In situ immunhistochemical BDV-detection. Vero and BDV-Vero cells were 
stained with a mouse monoclonal antibody against BDV nucleoprotein (Bo18, 1:100 dilution)  
and biotin anti-mouse IgG (1:100 dilution). Subsequently the cells were incubated with 
Streptavidin/HR-Peroxidase-conjungated (1:1000 dilution), then incubated with 1 ml the 
substrate solution. The nucleus of BDV-Vero cells was stained brown, but not in Vero cells.  
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Figure 39: IFA of BDV H1766 infected Vero cells. BDV-Vero and Vero cells were stained 
with a mouse monoclonal antibody against BDV nucleoprotein (Bo18, 1:100 dilution). Goat 
anti-mouse IgG fluorescein isothiocyanate (1:100 dilution) was used as secondary antibody. 
The typical nuclear staining was seen (green) in BDV-Vero cells  compared to the control 
Vero cells.  
 
 
2.4 RT-PCR detection BDV-specific replication intermediates from transfected Vero 
cells (BDV-infected and non-infected) 
pPolI-HHR-CAT2.1#3 was transfected into BDV-infected and non-infected Vero cells, then 
RNA was prepared from cells. 4 µg RNA was treated with RQ1 (RNase-free DNase I), 1/3 of 
the total digested RNA was used to perform PCR with a pair of CAT-specific primers to test 
for plasmid contamination. As the PCR result was negative (no 590 nt band), which means 
that no plasmid DNA was left that could lead to false positive RT-PCR result, 1/3 of the total 
digested RNA was used to perform RT-PCR and direct PCR respectively. RT-PCR result 
shown that a specific band (about 590 nt) was only obtained from the RNA sample of BDV-
infected Vero cells compared to the control (Figure 40). The RT-PCR product was digested 
by EcoRI and the expected bands (about 185 nt and 400nt)  were obtained (Figure 41) and 
proved that the RT-PCR product is specific and correct. This results suggested that the correct 
3'- and 5'-ends of the minigenome were generated by splicing of the two ribozymes in vivo 
and the BDV polymerase can use the antigenomic mini- transcript for replication. 
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Figure 40: RT-PCR detection of BDV-specific replication intermediates from 
transfected Vero cells (BDV-infected and non-infected). pPolI-HHR-CAT2.1#3 was 
transfected into the BDV-infected and non-infected vero cells, then RNA was extracted from 
cells. RNA was digested by RQI, then RT-PCR and direct PCR was performed (specific 
primer (CAT29-52) for RT) with a pair of CAT-specific primers (CAT29-52Fw, CAT612-
589Bw). A 590 nt band should be obtained. PCR products were analyzed on a 1% gel. Lane 1, 
3: RNA from Vero cells; Lane 2, 4: RNA from BDV infected Vero cells. Lane 5: RT-PCR 
control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 41: Analysis of RT-PCR product by restriction enzyme. RT-PCR products were 
incubated with EcoRI as indicated and separated on an agarose gel. About 185 nt and 400nt 
band should be obtained after digestion. 
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2.5 RPA detection BDV-specific transcription products from transfected Vero cells 
(BDV-infected and non-infected) 
pPCRII-TOPO-RPA, which contains a T7 promoter, the HDV-Ribozyme, the 5'NCR and part 
of CAT gene, was used to generate a probe of genomic orientation and 441 bp in length. It 
will hybridize with the mRNA and the antigenomic RNA of the PolI-primary transcript 
generated by the BDV polymerase (Figure 42). 311 bp and a 249 bp long double-stranded 
RNA should be generated by the hybridization of RNA sample of BDV-infected Vero with 
the specific probe that is protected against RNase A/T1 digestion. The RPA result showed that 
about 311 bp and a 250 bp bands were protected by hybridization of the RNA sample from 
BDV-infected Vero by the specific probe (Figure 43). This result indicated that BDV 
polymerase can recognize and use the mini-genome for transcription and that the two 
ribozymes perform self-cleavage in vivo. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 42: Scheme of RPA detection of BDV-specific transcription products from 
transfected BDV-infected Vero cells. Primary transcription (antigenomic orientation) 
through the cellular RNA polymerase I, then the primary transcript can be used by BDV 
polymerase and replicated and transcribed. The genomic orientation transcript can only be 
generated when BDV polymerase uses the antigenomic primary transcript to initiate the  
replication and transcription. mRNA is generated with 5'-Cap and 3'-Poly(A) by BDV 
polymerase. When a genetic orientation specific RNA probe is synthesized and will hybridize 
with the mRNA and the primary transcriptional antigenomic orientation RNA, two different 
length of the double stranded RNAs will be protected after RNaseA/T1 digestion due to the 
3'-end difference among two antigenomic orientated RNAs (3'-end of mRNA with Poly(A) 
that can not hybridize with the probe). So RPA can be used to detect BDV-specific 
transcription.  
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Figure 43: Analysis of BDV-specific transcription from transfected Vero cells (BDV-
infected and non-infected) by RPA. RNA was hybridized with the according probes, then 
digested by the RnaseA/T1 and separated on 6% denaturing polyacrylamide gel. 
Electroblotting from polyacrylamide gel was performed. The protected bands were detected 
using BrightStarTM BioDetectTM kit (Ambion USA) according to the standard protocol. Lane 
1: RNA sample from the plasmid transfected BDV infected Vero cells; Lane 2: RNA sample 
from the plasmid transfected Vero cells; Lane 3 and 5: yeast RNA; Lane 4: mouse liver RNA 
(positive control provided by kit and hybridized with the positive probe; 245 nt RNA band 
was protected). Except for Lane 5 (RPA-probe), others were digested by RNaseA/T1.  
 
 
2.6 Luciferase activity assay 
pPolI-HHR-T7 (Figure 44) was transfected together with pCITC Luci (expressing luciferase 
reporter gene under the control T7 promoter) into Vero cells and BDV-infected cells 
separately. Two additional combinations of transfections (pCAGGS T7+ pCITC Luci; 
pcDNA3.1+ pCITC Luci) were performed as positive and negative control. If the BDV 
polymerase can use the "mini-genome” transcript generated by pPolI-HHR-T7 for replication 
and transcription, T7 polymerase will be expressed and will recognize the T7 promoter in the 
pCITC Luci resulting in the expression of luciferase. The luciferse activity assays showed that 
the activity of luciferase was induced by pPolI-HHR-T7 compared to the control (Figure 45). 
This result indicates that the "mini-genome” transcript generated by pPolI-HHR-T7 can be 
recognized by the BDV polymerase for replication and transcription, and proves that the 3'- 
and 5'-ends that I used are functional. 
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Figure 44. Schematic diagram of the pPol I-HHR-T7. The T7 polymerase gene and very 
short part of CAT gene (179 nt), flanked by the 3' and 5' noncoding regions of the BDV, was 
inserted between the Pol I promoter, HHR ribozyme and HDV-ribozyme, Pol I terminitor.  
 
Figure 45: The induction of the luciferase by the different combinations of transfections. 
Different plasmid combinations were transfected into Vero cells and BDV-infected Vero cells 
with a total of 5 µg DNA. Cell extracts were prepared at 48 h posttransfection in cell lysis 
buffer (Promega) and assayed for luciferase activity. For a comparison enzyme activity 
induced by the transfection of pCAGGS T7 and pCITC Luci in BDV-infected Vero cells was 
set to 100%. Average values determined in three independent experiments are shown.   
BpCAGGST7, BpPolI-HHR-T7 and BpcDNA3.1 mean that pCAGGS T7+ pCITC Luci, 
pPolI-HHR-T7+ pCITC Luci and pcDNA3.1+ pCITC Luci were transfected into BDV-
infected Vero cells respectively. VpCAGGST7, VpPolIHHRT7 and VpcDNA3.1 mean that  
pCAGGS T7+ pCITC Luci, pPolI-HHR-T7+ pCITC Luci and pcDNA3.1+ pCITC Luci were 
transfected into Vero cells respectively. 
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2.7   Luciferase acitivity assay and CAT assay by a plasmid-based reverse genetic system 
I could show that the Pol I expression construc t is functional in the BDV-dependent system 
(BDV-infected Vero cells). In order to prove whether this construct is also functional in a 
plasmid-based reverse genetic system, pPol I-HHR-CAT2.1#3 and pPolI-HHR-T7 with 
different plasmids (pCAGGS-L, pCAGGS-N and pCAGGS-P or pCITC Luci) for the 
expression of BDV-N, -P and –L were transfected into 293T cells respectively according to 
the method 2.6.2, then luciferase activity assay and CAT assay were performed. The results of 
these two assays showed that the activities of reporter genes (luciferase and CAT) were 
detected, and that the mini-genome expression depended on a delicate balance of the N- and 
P- expression plasmid as reported (157) (Figure 45 and 46). An N:P ratio of 5:1 resulted in a 
very low activity of luciferase (Figure 45), when the N:P ratio was 12.5:1, a higher activity of 
luciferase and CAT was detected, although the CAT activity is not very strong (Figure 45 and 
46). These results indicated that this Pol I expression construct is also functional in the 
plamid-based reverse genetic system.  
 
 
 Figure 45: The induction of the luciferase by the different combinations of 
transfections. 293T cells were transfected using lipofectamine 2000 with different plasmid 
combinations. At 60 h after tranfection, cell extracts were prepared in cell lysis buffer 
(Promega) and assayed for luciferase activity. For a comparison negative control values were 
subtracted. N:P=5:1 transfection combination is: pPolI-HHR-T7 (1µg), pCITC Luci (1µg), 
pCAGGS-N (1µg), pCAGGS-P (0.2µg) and pCAGGS-L (1µg); N:P=12.5:1 transfection 
combination is: pPolI-HHR-T7 (1µg), pCITC Luci (1µg), pCAGGS-N (1µg), pCAGGS-P 
(0.08µg) and pCAGGS-L (1µg); N:P=50:1 transfection combination is: pPolI-HHR-T7 (1µg), 
pCITC Luci (1µg), pCAGGS-N (1µg), pCAGGS-P (0.02µg) and pCAGGS-L (1µg); Negative 
control transfection is: pCAGGS (2µg), pPolI-HHR-T7 (1µg) and pCITC Luci (1µg). 
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Figure 46: CAT expression in 293T cells transfected with pPol I-HHR-CAT2.1#3 and 
the combinations of the pCAGGS-N, -P and -L. 293T cells were transfected, as described 
in figure 45. 60 h after tranfection, cell extracts were prepared and assayed for CAT activity. 
pSV2CAT (3µg) transfection as a positive control, pCAGGS (2µg) and pPol I-HHR-
CAT2.1#3 (1µg) transfection as a negative control. N:P=5 transfection combination is: pPolI-
HHR-CAT2.1#3 (1µg), pCAGGS-N (1µg), pCAGGS-P (0.2µg) and pCAGGS-L (1µg); 
N:P=12.5:1 transfection combination is: pPolI-HHR-CAT2.1#3 (1µg), pCAGGS-N (1µg), 
pCAGGS-P (0.08µg) and pCAGGS-L (1µg); N:P=50:1 transfection combination is: pPolI-
HHR-CAT2.1#3 (1µg), pCAGGS-N (1µg), pCAGGS-P (0.02µg) and pCAGGS-L (1µg). 
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Discussion 
 
1. AIV 
1.1 Establishing a reverse genetic system for avian influenza virus (AIV) 
A/Goose/Guangdong/1/96 (H5N1) 
Since the first reverse genetic system (helper virus-dependent system) was developed for 
influenza virus (55, 132) that allowed to genetically manipulate RNA segments of influenza 
virus, up to now new systems to rescue influenza infectious viruses entirely from cloned 
cDNAs have been established (60, 89, 145). The ability to generate infectious RNA viruses 
from cloned cDNAs has contributed greatly to our biological understanding of this pathogens 
and to improved methods of disease control (150). Scientists have done a lot of research on 
human influenza virus, but less on AIV. I chose AIV A/Goose/Guangdong/1/96 (H5N1) as a 
research target, because this virus shows high homology to the AIV of the outbreak in 
HongKong in 1997. The new and efficient system to generate recombinant influenza viruses 
from cDNA should be useful for mutagenesis studies and the production of vaccines. This 
study could be beneficial to seek the accurate reasons why this AIV was transmitted directly 
to humans. In this study I employed the Pol I-Pol II system to rescue the AIV 
A/Goose/Guangdong/1/96 (H5N1). In this plasmid-based expression system, viral cDNA is 
inserted between the RNA polymerase I (Pol I ) promoter and HDV ribozyme sequences. This 
entire Pol I transcription unit is flanked by an RNA polymerase II (Pol II) CMV promoter and 
terminator site. The orientation of the two transcription units allows the synthesis of negative-
sense viral RNA and positive-sense mRNA from one viral cDNA template. I have constructed 
eight plasmids (pBD-PB1, -PB2, -PA, -NP, -HA, -NA, -M, -NS) including the complete 
cDNAs of the eight segments of the strain A/Goose/Guangdong/1/96 (H5N1). These 
constructed plasmids were identified by restriction enzymes digestion (Figure 13) and were 
sequenced. At least five plasmids (pBD-PB1, -PB2, -PA, -NP and pBD-NS) were proved to 
be functional by direct (CAT-assay) and indirect (generation of a reassortant virus) method. 
The eight plasmids should be used directly to rescue the AIV A/Goose/Guangdong/1/96 
(H5N1). Although the strain of A/Goose/Guangdong/1/96 (H5N1) is different from the H5N1 
which broke out in Hongkong, the biological safety has to be considered to prevent any 
human infection, therefore I tried to rescue the reassortant virus using the genes of the strain 
A/FPV/Rostock/34 (H7N1) as a genetic background with only one gene of 
A/Goose/Guangdong/1/96 (H5N1), in order to test that every plasmid including the complete 
cDNAs of the strain avian A/Goose/Guangdong/1/96 (H5N1) virus is functional. The study to 
generate the infectious avian influenza virus from cloned cDNAs of the strain 
A/Goose/Guangdong/1/96 (H5N1) will be done in the National Avian Influenza Reference 
Laboratory of the Ministry of Agriculture, Harbin Veterinary Research Institute, Chinese 
Academy of Agricultural Science (CAAS), China. 
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1.2   Generation the reassorant avian influenza viruses 
In order to prove that the eight plasmids (including the genes of the AIV 
A/Goose/Guangdong/1/96 (H5N1)) are functional, I tried to rescue reassortant viruses using 
the genetic background of the avian influenza strain A/FPV/Rostock/34 (H7N1) with one 
gene of A/Goose/Guangdong/1/96(H5N1). I have substituted the PB1, PB2, PA, NP, HA, 
NA, M and NS gene of A/FPV/Rostock/34 (H7N1) by the according genes of the 
A/Goose/Guangdong/1/96 (H5N1) respectively to generate a reassortant virus, but only the 
wild-type A/FPV/Rostock/34 (FPV) virus and a reassortant virus (GD1NSFPV) which carries 
the A/Goose/Guangdong/1/96 (H5N1) NS gene and the other 7 genes of FPV were 
successfully rescued.  
It is known that transmission of influenza A viruses is restricted by host range, this means that 
a specific influenza A virus can not replicate efficiently in any hosts and cell lines, normally 
only in the specific host cells. Although influenza A viruses are occasionally transmitted from 
one animal species to another, for example the AIV (A/Hongkong/156/97(H5N1)) infected 
human beings directly in Hongkong (203). Normally avian influenza viruses replicate poorly 
in humans (11), while human viruses do not replicate efficiently in birds (86, 141, 244). But 
the two influenza virus strains (A/FPV/Rostock/34 (H7N1) and A/Goose/Guangdong/1/96 
(H5N1)) were isolated from birds, therefore there should be no species barriers between them. 
Studies have shown that the ion channel activity of the influenza virus M2 protein stabilizes 
the native form of fowl plaque virus (FPV) hemagglutinin during intracellular transport (34, 
213, 216). These results indicated cooperation between the HA and M2 proteins, which is 
very important for the generation a new reassortant influenza virus between FPV and other 
strains. In early stud ies of the rescue of temperature-sensitive reassortant virus, the HA gene 
of the A/FPV/Rostock/34 (H7N1) did not segregate with the human matrix (M) gene (199). 
The sequence results showed that there are only two AA differences in M1 protein of 
A/Goose/Guangdong/1/96 (H5N1) compared to the known AA sequences of M1. Maybe the 
M1/M2 protein of the A/Goose/Guangdong/1/96 (H5N1) can not cooperate with the HA 
protein of A/FPV/Rostock/34 (H7N1), it is perhaps the reason why I did not rescue a 
ressortant virus containing the A/Goose/Guangdong/1/96 (H5N1) M gene and the other 7 
genes of FPV. 
I was also unable to generate ressortant viruses possessing only the H5N1 virus HA or NA in 
the background of the FPV genes in my study. Studies have suggested that a balance of HA 
and NA activities is important for efficient growth of influenza virus (4, 77, 84, 184, 231). 
The lack of balanced activities between HA and NA from both viruses might well explain my 
failure to generate the desired reassortant viruses. A reassortant virus possessing the HA and 
the NA genes or the HA and the M genes from the H5N1 virus can be perhaps produced, I 
will try to do this in future work.  
The NP protein is thought to be the major determinant of host range and species specificity 
(198). The rescue experiments of temperature sensitive (ts) mutants of the A/FPV/Rostock/34 
(H7N1) by Scholtissek and his colleagues provide the direct evidence for the active 
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partic ipation of NP in determining host range. FPV reassortants with a human influenza viral 
NP were no longer capable of forming plaques on the chicken embryo cells and had lost their 
pathogenicity for chickens (197). The NP gene of FPV could be replaced by that of the 
different avian influenza strains through double infection, moreover the rescue frequency of 
the FPV-NP mutants is very high (198). This indicated that the NP gene from the avian 
influenza strains should be able to replace the NP gene of FPV. The NP gene of the strain 
A/FPV/Rostock/34 (H7N1) is 90.2% identical to the NP of the strain 
A/Goose/Guangdong/1/96 (H5N1) at the nucleotide level, and 98% at the amino acid level. 
Why a reassortant virus containing the NP gene of the A/Goose/Guangdong/1/96 (H5N1) was 
not rescued in my study, it is not clear. Maybe the reasons are caused by different methods 
(double infection or reverse genetic based on the plasmids), or the NP gene of the 
A/Goose/Guangdong/1/96 (H5N1) does not cooperate with the other genes of the FPV. Why a 
reassortant virus containing the PB1 or PB2 or PA gene of the A/Goose/Guangdong/1/96 
(H5N1) was not rescued in this my study, remains unclear.  
 
1.3 Activation of Raf/MEK/ERK cascade by both the wild type FPV and reassortant 
GD1NSFPV viruses 
Scientists have done a lot of research about DNA viruses inducing signaling through MAPK 
pathways in infected host cells, therefore much is known about how DNA viruses interact 
with host cell (14, 22, 180). Although interaction of RNA viruses with the Raf/MEK/ERK 
signaling pathway has been reported, little information is know compared to the DNA viruses. 
For example, Planz et al. proved that the signaling through MEK is essential for BDV spread, 
but the molecular mechnism of how BDV interacts with the cellular Raf/MEK/ERK signaling 
pathway remians to be elucidated (160).  
This cascade is also activated by influenza virus, and signaling through the mitogen cascade 
seems to be essential for RNP export from the nucleus and accordingly for virus titer (163). 
The question was whether there are differences in the activation of the mitogentic 
Raf/MEK/ERK cascade between both the wild type FPV and reassortant GD1NSFPV, 
because the reassortant GD1NSFPV grows to higher titer compared to the wild type FPV. The 
results showed that both viruses induce MAPK-signaling, but there are no big differences in 
the activation of the Raf/MEK/ERK cascade induced by both viruses. According to this result, 
it can be speculated that the activation of the Raf/MEK/ERK cascade is not a determinanting 
factor which results in the different titer of both viruses. 
 
1.4 Character of the reassortant GD1NSFPV and the role of the NS gene for viral 
replication 
The reassortant GD1NSFPV virus that differs from the wild-type FPV only by the NS-
segment grows to significantly higher titers and forms bigger plaques than the wild-type FPV. 
Furthermore the induction of the IFN promoter dependent reporter by the wild-type FPV was 
much higher (about three folds) than by the reassortant GD1NSFPV (luciferase gene is 
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controlled by IFN-ß promoter) (Figure 21). The titer formed by the reassortant GD1NSFPV 
virus is comparable to another FPV-type influenza virus (H7N7), which is used in the 
laboratory and grows to the same high titers. It can be speculated that the pathogenicity of the 
GD1NSFPV is highly enhanced compared to the wild-type FPV (H7N1). The differences 
between the wild-type FPV (H7N1) and the reassortant GD1NSFPV are subjected to the NS 
gene. 
The NS gene of influenza A virus encodes both the NS1 and the NS2 (NEP) protein. NS1 is a 
nonstructural protein and is expressed to high levels in virus-infected cells. The NS1 protein 
has been shown to have many functionalities, such as inhibition of the host mRNA 
polyadenylation (142) and the pre-mRNA splicing (61, 128, 249), inhibition of the nuclear 
export of polyadenylated host mRNA (32, 170), stimulation of the translation of the viral 
mRNA (3, 49, 53, 54), and modulation of viral RNA transcription and replication (138, 202). 
Another important function is to bind to dsRNA (80). Some studies suggested that binding of 
dsRNA by the NS1 protein prevents the activation of the double-stranded RNA activated 
protein kinase (PKR) (15, 81, 129, 219). PKR, the 68 kDa double-strand-RNA dependent 
kinase, is activated by dsRNA or by interaction with specific proteins (45, 154, 155, 159, 248) 
and is highly upregulated in response to the virus-induced cytokine IFN (187). Activated PKR 
phosphorylates the a-subunit of the eukaryotic translation initiation fator elF2, resulting in the 
inhibition of protein synthesis and hence virus replication (185). These functions of the NS1 
protein are very useful for efficient viral replication and the "shut off" of the host cell protein 
expression.  
Garcia-Sastre et al. generated an infectious recombinant influenza A/PR/8/34 virus lacking 
the NS1 gene (delNS1). They deleted the NS1 open reading frame except for the first 10 
amino acids, which are shared with the viral NS2 protein (65). This virus only replicates 
efficiently in interferon-deficient systems, this findings supports the suggestion that the NS1 
protein is a virally encoded inhibitor of the IFN-mediated antiviral responses, such as the 
activation of PKR. In my study the induction of the IFN-promoter dependent reporter gene by 
the wild-type FPV was much higher than by the reassortant GD1NSFPV. This results 
suggests that the NS1 protein of the GD1NSFPV virus is more efficient to counteract IFN-ß 
and interferon-mediated cellular response to virus-infection than that of the wild-type FPV.  
The IFN system is a major component of the host innate immune response to viral infections. 
IFN is synthesized in response to the viral infection due to the activation of several 
transcription factors, including IFN regulatory factor (IRF3 and IRF7), AP1 and NF-kB (101, 
188, 189, 223, 239, 240, 253). Since dsRNA also induces the activation of these factors, it is 
assumed that viral dsRNA intermediates generated during viral replication are at least 
partially responsible for the induction of interferon secretion. Activation of the synthesis of 
IFN during the viral infection results in the transcriptional activation of many host genes 
(about 250) involved in antiviral defense mechanisms. Because of the importance of IFN-a/b 
in antiviral host responses, many viruses have evolved different strategies to subvert the IFN 
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system. For example, multiple IFN-antagonist actives have been showed in vaccinia virus, 
adenovirus and hepatitis c virus (12, 18, 47, 62, 63, 106, 121, 221, 222). Several negative-
strand RNA viruses have been reported to encode inhibitors of the IFN signaling pathway, 
such as the V proteins of the paramyxoviruses (SV5 and PIV2) (51, 254), the VP35 protein of 
the Ebola virus (10), the NS1 and NS2 proteins of bovine respiratory syncytial virus (190), the 
C proteins of Sendai virus (66, 67, 74, 112), the P proteins of the Borna disease virus (228), 
the V proteins of Newcastle disease virus and the V, W, and C protein of the Nipah virus 
(153). For influenza virus, the NS1 protein, which has RNA-binding activity (80), prevents 
production of IFN by inhibiting the activation of the transcription factors IRF3 and AP1 and 
NF-kB and blocking the activation of the IFN induced antiviral protein PKR and the (2'-5') 
oligoadenylate synthetase (OAS) (15, 65, 131, 217, 236). 
Pervious studies have proved that the NS1 protein of influenza A virus possesses two 
important functional domains: an RNA-binding domain near the amino-terminal end (amino 
acids 1-73) and an effector domain in the carboxyl half the molecule (amino acids 74-231) 
(168, 169). Furthermore the RNA-binding domain of the NS1 protein is conserved among 
influenza A and B viruses (234). This suggests that this domain, which specifically binds to 
the RNA poly(A), U6 snRNA and double-stranded (ds) RNA, is important for the replication 
of these two types of influenza viruses. In contrast, the NS1 protein of the influenza B virus 
lacks an effector domain that functions like that of the NS1 protein of influenza A virus. The 
effector domain of NS1 protein of influenza A virus is required for the inhibition of the 
nuclear export of poly(A)-containing cellular mRNA and the inhibition of pre-mRNA splicing 
(234) by binding and inhibiting the function of two cellular proteins. These two proteins are 
required for the 3'-end processing of the cellular pre-mRNAs: the 30 kDa subunit of the 
cleavage and polyadenylation specificity factor (CPSF) and the poly(A)-binding protein II 
(PABII) (32, 123, 142). CPSF factor binds to the AAUAAA poly(A) signal in cellular pre-
mRNA and is required for cleavage at the 3' site at which poly(A) addition occurs (7, 36). 
When the CPSF factor is inhibited, cellular pre-mRNA are not cleaved. The PABII protein is 
required for the processive elongation of poly(A) chains catalyzed by the cellular poly(A) 
polymerase (7, 232). When the effector domain of NS1 protein targets the PABII protein, the 
elongation of the 3'-short poly(A)of the cleaved pre-mRNAs is blocked as a consequence of 
this interaction. Thus the NS1 protein effectively blocks the 3'-end processing of cellular pre-
mRNAs in influenza virus infected cells (32). The polyadenylation of viral mRNAs is not 
affected, as these RNAs receive their poly(A) tail by "stuttering" of the RDRP at the specific 
poly(A) signal in the viral RNA.   
The RNA binding/dimerization domain in the NS1 protein of influenza A virus (amino acids 
1-73) exhibits a dimeric six-helical folding (33, 126). Wang et al. have proved that the 
dimeric structure of the NS1 protein of influenza A virus is essential for RNA binding, 
because any alanine replacement (D12, R19, D29, R35, and R46 are required for the 
maintenance of the dimer structure) that cause disruption of the dimer results in the loss of 
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RNA-binding activity (235) Interestingly, R38 was found to be the only AA which is 
absolutely required for RNA binding but not for protein dimerization. This finding indicated 
that R38 probably interacts directly with the RNA target. The lysine at the position 41 in helix 
2 makes an additional strong contribution to the affinity of RNA binding (235). 
The binding domain and effector domain of NS1 protein are important for the character of 
influenza virus, so I compared the amino acids sequences of the NS1 protein between the 
wild-type FPV and GD1NSFPV. The results showed that the NS1 protein of the strain 
A/FPV/Rostock/34 (H7N1) was only 69.3% identical to the NS1 of the strain 
A/Goose/Guangdong/1/96 (H5N1). Specifically, the continuous difference (FPV 
21RFADQEMG28 ; GD1NSFPV 21LLSMRDMC28) in the RNA-binding domain of NS1 
protein of both viruses resulted in the change of hydrophilicity of NS1 protein (Figure 24). 
Maybe this change leads to a structural change of the NS1 protein, which influences the 
function of NS1 protein and results in the difference of both viruses. R38 and K41 in RNA-
binding domains of both NS1 protein, which have been proved to be very important for the 
RNA binding activity (235), are conserved. The position R44 in the RNA-binding domain of 
NS1 protein of FPV is K44 in the NS1 protein of the GD1NSFPV, R44 and R37 are not 
required for RNA binding (235). The other differences among the RNA-binding domain of 
the NS1 protein of both viruses might be responsible for the RNA binding activity, because 
only 67.1% AA are identical in the RNA-binding domain of the NS1 protein of both viruses.  
The NS1 effector domain contains a 10 AA  (amino acids 138-147) sequence which is similar 
to a consensus sequence found in the effector domains of HIV-1 Rev proteins (168). 
Particularly, the two Ls which are located at positions 7 and 9 of this sequence are crucial for 
the function of both the NS1 and HIV-1 Rev protein (137, 168). HIV-1 Rev protein interacts 
with host nuclear targets to regulate the nuclear export of cellular mRNA and viral mRNA. 
There are eight AA differences in the position 134 to 161 in the effector domain of NS1 
protein of the strain A/FPV/Rostock/34 (H7N1) compared to the NS1 protein of the strain 
A/Goose/Guangdong/1/96 (H5N1), and this also results in a change of hydrophilicity (Figure 
23 and 24). The L at the position 9 of the conserved 10 AA sequence in the effector domain of 
NS1 protein of FPV (L146 in the effector domain) is changed to S in the according position of 
GDNS1FPV. It is not known what effect is caused by this change for the NS1 protein function 
of GDNS1FPV compared to that of FPV.  
The binding sites for the cellular proteins CPSF and PAB II have been identified and are near 
the carboxy end of the NS1 protein: the CPSF binding site is centered around amino acid 186 
and the PAB II binding site is located in the 223-237 amino acid region (123). A recombinant 
influenza A/Udorn/72 virus has been generated encoding an NS1 protein that has an altered 
amino acid sequence centered around amino acid 186 (184GLEWN188®184RFLRY188), and as 
a result it does not bind the 30 kDa subunit of CPSF (147). This recombinant virus is highly 
attenuated, suggesting this binding site in the NS1 protein is required for efficient virus 
replication (147).  Comparing the binding site of the 30 kDa CPSF in the NS1 protein of 
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influenza A/Udorn /72 virus with that of FPV and GDNS1FPV, I found that the binding sites 
of the 30 kDa CPSF of the three influenza viruses are completely conserved (184GLEWN188), 
suggesting that this binding site is crucial for efficient viral replication. The binding site for 
PAB II protein in the NS1 protein of both FPV and GDNS1FPV viruses is different (FPV 
223MARTIESE230; GDNS1FPV 223MARTIESE230), it is not known whether these differences 
in the NS1 protein of both viruses effects their abilities to bind to PABII resulting in different 
growth. 
The NS1 protein would be able to sequester cellular pre-mRNAs and mRNAs in the nucleus 
due to the ability to inhibit pre-mRNA splicing and the nuclear export of the poly(A)-
containing mRNA. Consequently, more of cellular capped RNAs would be accessible to the 
viral cap-dependent endonuclease (PB2) in the nucleus for the production of the capped RNA 
primers that are needed for viral mRNA synthesis (115). The change in hydrophilicity might 
be important for the structure and abilities of the RNA binding domain and the effector 
domain, and could result in a functional change of the NS1 protein. Thus, the NS1 protein of 
GDNS1FPV might be more efficient to inhibit the cellular pre-mRNA splicing and the 
nuclear export of the poly(A)-containing mRNA than that of FPV virus, and leads to 
enhanced replication. 
The influenza virus NS2 protein mediates the nuclear export of the viral RNPs and has been 
proposed to act as an adapter molecule between the nuclear export machinery and the viral 
RNP complex (149). Nuclear export is controlled by export receptors (for example the highly 
conserved chromosome region maintenance 1 protein (CRM1)) that mediates the nuclear 
export of nuclear export signal (NES) containing substrates. A functional Leucine-rich NES 
was mapped in the N-terminal region of the NS2 protein (Figure 25), because it interacts with 
nucleoprorins in the yeast two-hybrid system, and can functionally replace the effector 
domain of the human immunodefciency virus type 1 Rev protein (149) that is presumed to 
interact with host nuclear protein to regulate the nuclear export of viral pre-mRNAs (135). 
Neumann et al. demonstrated that NS2 interacts with the cellular export factor hCRM1, but 
the NS2-NES is not required for the interaction with hCRM1 (143). But replacement of the 
putative NS2-NES by alanine (M16A, M19A, L21A) resulted in abolishing the nuclear export 
of NP and no virus could be rescued in a plasmid transfection sys tem (143), suggesting that 
the NES function is crucial for viral replication. In addition, the C terminus of NS2 has been 
shown to interact with M1 both in vitro and in vivo (237, 252). According to these 
observations, it has been proposed that NS2 mediates the export of vRNPs by acting as an 
adapter protein between the nuclear export machinery and the M1-vRNP complex (143, 149, 
151). A recent report shows that the structure of NS2 is characterized by a high degree of 
plasticity, suggesting that NS2 may indeed exist in multiple conformations in vivo (127) to 
mediate the nuclear export of the viral RNPs (238). 
The NS2 gene of the strain A/FPV/Rostock/34 (H7N1) is only 81.4% identical to the NS2 of 
the strain A/Goose/Guangdong/1/96 (H5N1) at the nucleotide level, and 82% at the amino 
acid level. Two amino acids (M14Q, G22E) were different in the NES of NS2 protein (amino 
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acids 11-24) of the strain A/FPV/Rostock/34 (H7N1) compared to the NS2 protein of the 
strain A/Goose/Guangdong/1/96 (H5N1). The amino acids M16, M19, L21 in the NES of the 
NS2 protein, which are crucial for viral replication and for NP nucleocytoplasmic transport, 
were not changed in both viruses. The "conserved" M at the position 14 in the NES of the 
NS2 protein of FPV was changed to Q in the NES of the strain A/Goose/Guangdong/1/96 
(H5N1), it is not known whether this change affects the function of the NES. There are many 
other differences between both NS2 proteins except for the NES. It remains to be determined 
whether they affect the structure or the functionality of NS2 protein, and whether the NS2 
protein of the GDNS1FPV mediates much more efficiently the nuclear export of the viral 
RNPs than that of FPV, resulting in higher titer. 
In general, the reassortant GDNS1FPV grows to significantly higher titers and forms larger 
plaques than the wild-type FPV, differing only in the NS-segment. Additionally, this 
reassortant virus inhibits more efficiently the IFN activation than the wild type. It can be 
speculated that the NS gene must contribute to the enhanced pathogenicity of the reassortant 
virus compared to the wild-type FPV. Animal (chicken) experiments will be done to 
investigate the pathogenic difference of both viruses in China. 
 
2. BDV 
2.1 Reverse genetics systems for negative-strand RNA virus  
Negative-strand RNA viruses are different from positive-strand RNA viruses, because the 
genomic RNA of negative-strand RNA viruses is not infectious, and infectious virus particle 
must deliver their own RNA-dependent RNA polymerase (RDRP) into the infected cell to 
initiate the first round of virus specific mRNA synthesis. Thus generating negative-strand 
RNA viruses from cDNAs poses a greater challenge, specially for the segmented, negative-
stranded RNA viruses, as one must produce a separate vRNA for each gene segment. 1990, a 
breakthrough in reverse genetics technology in the negative-stranded RNA field was 
achieved, when Palese and colleagues established the first system for modifying negative-
stranded RNA viruses (influenza virus) by reconstituting the biolo gical activity RNPs in vitro 
(55, 132) Nevertheless this system has not been successful in the rescue of nonsegmented, 
negative-stranded (NNS) RNA viruses, as reproducible reconstitution of infectious RNPs  
containing full length genomes, all of which are greater than 11 kb in length, could not been 
achieved (177). 
An effective DNA transfection systems have been developed for cytoplasmatic replicating 
viruses like Rabies virus by Schnell et al in 1994 (196). Plasmids encoding the viral 
nucleocapsid protein (N) and the polymerase proteins (L and P) under the control of T7 
polymerase promoters were transfected into cells previously infected with recombinant 
vaccinia virus expressing the T7 polymerase protein. In addition to these plasmids, a plasmid 
encoding a full- length antigenomic viral RNA under the control of a T7 promoter and a 
hepatitis delta ribozyme was co-transfected into the cells. After transcription of RNAs from 
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the T7 promoters and translation of the encoded proteins, nucleocapsid proteins assemble with 
the antigenomic RNAs and polymerase proteins, then replicate these RNPs to form new RNPs 
containing genomic RNAs. After transcription of mRNA from the genomic RNP and 
translation, infectious virus was assembled. Subsequently, Vesicular stomatitis virus (VSV) 
(119, 247), Measles virus (171), Respiratory syncytial virus (RSV) (37) Sendai virus (68, 
103), Bunyamwera virus (19), Rinderpest (9) Human parainfluenza virus type 3 (HPIV-3) 
(88) and Simian virus 5 (SV5) (85), which are all cytoplasmatic replicating viruses, were 
successfully recovered from the cDNAs by almost the same strategy. 
Following the approach outlined by Schnell et al (196), Bridgen & Elliott firstly generated a 
segmented negative-stranded RNA virus (Bunyamwera virus belongs to family Bunyaviridae) 
in 1996 (19), demonstrating the feasibility of artificially producing more than one vRNA. 
In 1996, a plasmid-based system for expression of influenza RNPs was reported (161). Here 
an improved RNA polymerase I system was used for the intracellular synthesis of influenza 
virus RNA as described by Neumann et al (146). In 1999, a completely plasmid-based system 
was developed to generate an infectious influenza particle from cDNAs by Neumann et al. 
and Fodor et al. (60, 145). Thogoto virus, another member of the order Orthomyxoviridae 
with six segments of negative-sense RNA, was generated from plasmids by T7 RNA 
polymerase system (230). 
These reverse genetics systems allow to manipulate the viral genome of negative-stranded 
RNA viruses without technical limitation. It has profound implications on the study of the 
viral life cycle, functional regulation of viral proteins and molecular mechanisms of viral 
pathogenicity. Finally reverse genetics has opened the way to develop live attenuated virus 
vaccines and vaccine vectors.  
 
2.2 Reverse genetic system for BDV 
BDV is a nonsegmented negative-stranded (NNS) RNA virus that replicates it's about 8900 nt 
genome in the nucleus of infected cells as influenza viruses. In contrast to other NNS viruses, 
up to now reverse genetics system for BDV developed very slowly. There are many different 
reasons that hindered the establishment of a reverse genetic system for BDV. The genetic 
information about BDV was very limited, and the complete genome sequence of only two 
closely related BDV strains, named He/80 and V, were available until 2001 (21, 43). The 
genomes of these two strains show 95% sequence identity, and the L protein of the He/80 was 
reported to lack 24 amino acids at the C terminus, and the last 3 nt at the 5'- end differed 
completely from that of the strain V. Since genome ends are of critical importance for 
efficient replication and transcription of negative-strand RNA viruses (38), correct 5'- and 3'-
ends of BDV are very crucial for developing a reverse genetic system for BDV. In 2001, 
Pleschka et al. (162) determined the complete nucleotide sequences of two other strains 
(H1766 and No/98) of BDV and compared them to the reference strains V and He/80. They 
showed conservation of coding and terminal sequences in these four different isolates of 
BDV. Specially they found an additional A residue at the extreme 3' end of the single-
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stranded RNA genome in all four BDV strains. If the 3'-end of the BDV genome is indeed 
occupied by an A residue, the BDV polymerase has to initiate replication with UTP. 
Compared to the polymerases of other viruses from the order Mononegavirales, they all seem 
to initiate transcription by employing either ATP or GTP (38). This constellation of BDV 
would therefore represent a unique case among nonsegmented negative-stranded RNA 
viruses.  
Additionally, the polymerase of BDV seems to have a very low activity. Also BDV causes a 
very slow and persisting infection. This means that perhaps its genome replication requires a 
very exact and tuned system.  
A T7 polymerase system was reported by Schneider et al. (195) to express the reporter CAT 
gene by reconstituting the BDV polymerase complex in vivo. In this approach, co-expression 
in BSR-T7 cells of BDV-L, N and P (expression L, N and p plasmids were controlled by T7 
promoter) together with a negative-sense mini-genome RNA containing a CAT gene was 
sufficient to induce L-dependent synthesis of CAT protein. Because this virus replicates its 
genome in the nucleus of infected cell as influenza virus, the T7 polymerase, that works in the 
cytoplasm, might not be successful to rescue BDV by a T7 polymerase system. A T7 
generated minigenome that was replicated and transcribed by transiently expressed influenza 
virus proteins (RNPs) was not packaged into a helpervirus after infection of the new cells with 
the supernatant of the transfected cells. In contrast a Pol I generated minigenome was. 
(Pleschka, unpublished data).  
Recently, a Pol I reverse genetics system for BDV was developed (157). A BDV RNA mini-
genome was synthesized intracellularly from a plasmid driven by RNA polymerase I. Co-
transfection with plasmids expressing the BDV-L, N and P under the control of RNA 
polymerase II allowed BDV mini-genome replication and expression. It is noted that both 
systems used an artifical 5'NCR beginning with the "G" residue and that in this Pol I system a 
3'NCR encompassing the transcription initiation signal of the BDV N protein was used. In my 
study, I used the original BDV NCR (5' NCR is complementary with 3' NCR) for my Pol I 
mini-genome construct, and HHR and HDV ribozymes were used to generate a correct 5'- and 
3'-end respectively. I tried to establish a reverse genetic system for BDV analogue to the 
successful system for influenza viruses. 
 
2.3 New construct for generating a "mini-transcript" of BDV 
Pleschka et al. proved the existence of an additional "U" residue at the extreme 5' end of the 
single-strand anti-genomic RNA of BDV (162). Also other sequence specificities in the 
noncoding regions that could be important for replication and transcription. Furthermore a 
consensus sequence of the polymerase gene was established. The results are very important 
because correct structures of the genome ends and of the polymerase gene are most critical 
parameters for the development of reverse genetics techniques that permits the genetic 
manipulation of BDV. To generate a primary RNA transcript in vivo that can be replicated by 
the viral polymerase, I used the Pol I-system, because RNA polymerase I is an abundant 
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nuclear enzyme which transcribes ribosomal RNA, that doesn't contain 5'-cap or 3'-poly(A) 
structures. Moreover RNA polymerase I initiates and terminates transcription at defined 
promoter and terminator sequences. Therefore Pol I-transcripts resemble viral genomic RNAs 
and can be replicated by viral polymerases (146). As the Pol I normally does not incorporate 
an "U" as the first residue (normally A or G as first residue; I, Grummt personal 
communication), I have generated new Pol I expression constructs that express a transcript, 
that starts with a hammerhead ribozyme (HHR) sequence beginning with an "A" residue. The  
hammerhead ribozyme should cleave the transcript in cis to generate a new 5’-end that starts 
with the genomic "U" residue. The correct 3’-end of the transcript is assured by a HDV 
ribozyme that also cleaves the transcript in cis generating the correct 3'-end of the transcript. 
This technique is used to generate Pol I-transcripts with correct 3’-ends in the Pol I-system for 
reverse genetics of influenza (60, 161).  
I constructed new plasmids (pPolI-HHR-CAT2.1#1, #2, #3) with HHR expressing a CAT 
reporter gene RNA and tried to analyze whether these constructs can be recognized and 
transcribed by BDV polymerase. The ribozyme assay result showed that the three versions of 
HHR together with HDV ribozymes are functional and generate the correct 5'- and 3'-end in 
vitro. So pPolI-HHR-CAT2.1#3 (including HHR version #3) was used to transfect Vero and 
BDV-infected Vero cells for in vivo assays (RT-PCR and RPA assay). After transcription, the 
HHR sequence is folded in its secondary structure (see Figure 26) where part of it anneals to 
the newly generated 5' end sequence before the HHR cleaves itself off. As the remaining 
HHR sequence will leave the newly generated 5' end, it seems to be easy when the stretch of 
annealed HHR is short. I choose the HHR version #3 with the shorter stretch of homology to 
the new 5' end, this way the correct 5' end should be accessible for the BDV-RDRP. The RT-
PCR results demonstrated that an replication intermediate of genomic orientation was 
generated from pPolI-HHR-CAT2.1#3 primary transcript (antigenomic orientation). This 
"mini-genome" can be recognized and replicated by the BDV polymerase, because the 
replication intermediate (shown by RT-PCR) can only be generated when the BDV 
polymerase uses the primary transcript to initiate replication. Furthermore the primary 
transcript and the according mRNA was detected in a RPA assay. These results indicate that 
primary transcript can be replicated and transcribed, and that the BDV 5'- and 3'- end NCR 
sequences that I have used are functional. 
On the other hand the transcription termination sites of BDV was proposed to be the poly(U) 
sites of the BDV genome (21, 43), Schneeman et al. (191) confirmed that there are four 
transcription termination sites of BDV genome and each termination site consists of 6 or 7 U 
residues as known in other viruses of Mononegavirales. It seems likely that polyadenylation 
for BDV also occurs by polymerase stuttering on these U residues like for influenza virus. 
The RPA results showed that a short band (249 nt) “mRNA” was detected, confirming that 
the polyadenylation signal is indeed used in the trancription termination of the BDV genome, 
because the probe can not hybrized completely with the mRNA resulting in partial digest by 
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RNAase. In contrast the probe hybridizes completely with the primary transcript resulting in a 
longer fully protected probe (311 nt). 
To generate an amplified and highly sensitive reporter system, a Pol I-plasmid expressing the 
T7 polymerase gene flanked by the BDV 3' and 5' NCR and the ribozymes sequences was 
constructed. This plasmid was transfected together with plasmids expressing luciferase 
reporter gene under the control of the T7 promoter into Vero cells and BDV infected Vero 
cells respectively, to prove that this "mini-genome" can be recognized and transcribed by the 
BDV polymerase. The luciferase assay results indicated that the polymerase of BDV can 
indeed use the "mini-transcript" generated by pPolI-HHR-T7 for replication and transcription, 
although the relative luciferase activity is not very high. 
In the plasmid-based reverse genetic system, the Pol I expression construct has also shown to 
be functional by CAT and luciferse activity assays. These results furthermore prove that the 
functional 5’-NCR and 3’NCR can be generated by the Pol I expression construct of the 
reported system, although the activity of CAT and luciferase is not as strong compared to the 
data reported. Maybe the following reasons can present a good explanation. Firstly, this is the 
first experiment, a strong activity of the reporter gene should be detected, if the experimental 
condition is further optimized. Secondly, different NCR ends were used in my Pol I construct 
compared to the two reported systems. G of 5’NCR and A of 3’NCR were used in the mini-
genome constructs, this means that the last nucleotide is not homologous and overhanging 
ends will be formed, which is different from the orignal ends in my construct according the 
expected sequences. The reported Pol I and T7 systems can work very well in vitro, maybe 
infectious BDV can be rescued by the reported Pol I system, but it remians to be determined 
whether it can represent the true viral condition in vivo. Moreover, different virus strains and 
cell lines were used in the reported Pol I system compared to my system. The He/80 strain 
was used to determine the 5’- and 3’-NCR ends in the reported Pol I system, but my construct 
is according to the strain BDV H1766. 
In general, the new construct for generating a "mini-genome" of BDV is functional not only 
in the helper virus dependent system, but also in the plasmid-based reverse genetics system. 
This study might be the basis for establishing a reverse genetic system for the rescue of BDV 
in the future, that will play an role in understanding the character of the BDV.  
 
 
3 Perspectives 
 
3.1      AIV 
Five Pol I expression plasmids for a reverse genetic system have been proved to be functional, 
and the sequences of other three genes should be correct, because there are very little 
differences compared to the sequences from the genebank and the original sequences. I will 
therefore try to rescue an infectious avian influenza virus A/Goose/Guangdong/1/96 (H5N1) 
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using these eight plasmids under safe conditions (P3 laboratory) in China, and establish a 
reverse genetic system for this strain. Some mutation studies will be performed by this reverse 
genetic system, in order to learn more about the molecular biology of this virus.  
The HA is very important for the pathogenicity of influenza A viruses. But the reassortant 
GDNS1FPV differs from the wild type FPV only by the NS-segment. I will compare the 
pathogenicity of these three viruses (wild type FPV; reassortant GDNS1FPV and 
A/Goose/Guangdong/1/96 (H5N1)) by tissue cultures and animal experiments. These 
experiments will be very useful to learn more about pathogenicity of avian influenza viruses. 
Moreover, as the reassortant GDNS1FPV inhibits more efficiently the IFN activation than the 
wild type FPV, a series of mutation experiments will be done to investigate which domain is 
responsible for this function. This will benefit the development of the live attenuated 
influenza vaccine in the future. 
In nature, it is possible that both highly pathogenic avian influenza viruses can infect the same 
host and lead to a new reassortant virus  that might be much more pathogenic than the parental 
viruses. Therefore it is necessary to try to rescue the other ressortant viruses by different 
plasmid combinations as mentioned in the discussion, in order to study how the highly 
pathogenic H5 and H7 avian influenza viruses recombine in nature. 
 
3.2 BDV 
Compared to the reported two reverse genetic systems (T7 and Pol I), I used the original BDV 
NCR for the mini-genome construct in my system. Moreover I have shown that this Pol I 
construct is functional not only in the helper virus dependent system but also in the plasmid-
based reverse genetic system. Artificial NCR ends were created (G of 5'NCR and A of 
3'NCR) in the reported two systems, this means that overhanging ends will be formed. This is 
until now not the case for other NNS viruses and it can not be estimated what effect such ends 
would have for viral replication. Maybe the infectious BDV can be rescued by the reported 
Pol I system, but it remains to be investigated that it represents the true cond ition of BDV in 
vivo (animals).  
The optimal condition for my Pol I system will be investigated, in order to study the 5'NCR 
and 3' NCR functions by mutations in the future and to rescue infectious BDV by this system. 
I hope my system will be useful to understand more molecular biology of BDV.  
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Abbreviations  
 
AA  amino acids 
APS  Ammonium persulfate 
AI  Avian influenza 
AIV  Avian influenza virus 
BD  Borna disease 
BDV  Borna disease virus 
bp  base pairs 
BSA  bovine serum albumin 
oC  centigrade 
cm  centimeter 
CAT  chloramphenicol acetyltransferase 
CMV  cytomegalovirus 
CPSF  cleavage and polyadenylation specificity factor 
CTP  cytidine triphosphate 
ddH2O deionized distilled water 
DMEM Dulbecco's Modified Eagle's medium 
DNA  deoxyribonucleic acid 
DNase  deoxyribonuclease 
dNTP  deoxynucleoside triphosphate 
DTT  dithiothreitol 
EDTA  ethylenediamine tetraacetic acid 
eIF2  eukaryotic translation initiation factor 2 
ERK  extracellular signal regulated kinase 
et al.  et alii (=and others) 
FCS  fetal calf serum 
FPV  fowl plague virus 
g  gram 
GFP  green fluorescent protein 
GTP  guanosine triphosphate 
GP  glycoprotein, BDV 
h  hour(s) 
HA  hemagglutinin  
HEPES N-2-hydroxyethylpiperazine 
HDV  Hepatitis delta virus  
His  histamine 
HPAIV highly pathogenic avian influenza virus  
IFA  indirect immunofluoresces assay 
IFN  interferon 
IRF3  IFN regulatory factor 3 
kb  kilobasepairs 
kDa  kilodalton 
L   RNA-dependent RNA.polymerase, BDV 
LPAIV lowly pathogenic avian influenza virus 
M  molar 
M  matrixprotein, BDV 
M1  matrixprotein, Influenza 
M2  ion channel protein, Influenza 
MAPK mitogen-activated protein kinase 
MEK  MAPK kinase/ERK kinase 
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mg  milligram 
min  minute(s) 
ml  milliliter 
mM  millimolar 
MOI  multiplicity of infection 
mRNA messenger RNA 
N  nucleoprotein, BDV 
NA  neuraminidase 
NCR  noncoding region(s) 
NEP/NS2 nuclear export factor 
NES  nuclear export signal 
NLS  nuclear location signal 
NP  nucleoprotein 
NPC  nuclear pore complex 
NS1  nonstructural protein 
ng  nanogram 
nt  nucleotide(s) 
NTP  ribonucleoside triphosphate 
OD  optical density 
P  phosphoprotein, BDV 
p10/x  10 kilo Dalton protein, BDV  
PA  subunit of RDRP, influenza  
PABII  poly(A)-binding protein II 
PAGE  polyacrylamide gel eletrophoresis 
PB1  subunit of RDRP, influenza  
PB2  subunit of RDRP, influenza  
PBS  phosphate buffered saline 
PCR  polymerase cha in reaction 
PFU  plaque forming unit(s) 
PKR  dsRNA activated protein kinase 
pmol  picomolar 
PolyA  polyadenylic acid 
Pol I  RNA polymerase I 
RDRP  RNA-dependent RNA-polymerase 
RNA  ribonucleic acid 
RNase  ribonuclease 
RNasin RNase inhibitor 
RNPs  ribonucleoproteins 
RPA  RNase protection assay 
RT  reverse transcription 
s  second(s) 
SDS  sodium dodecyl sulfate 
TEMED N,N,N',N'-tetramethylethylenediamine 
Tris  tris-hydroxymethylaminomethane 
ts  temperature sensitive  
Tween 20 polyoxyethylenesorbiten monolaurate 
U  unit(s) 
U  uridine 
UTP  uridine triphosphate 
UV  ultraviolet 
V  volt 
Appendices 
  
114  
vol  volume 
vRNA  viral RNA 
v/v  volume percentage 
w/v  weight percentage 
µg  microgram 
µl  microliter 
µM  micromolar 
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